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Glioblastoma multiforme (GBM) is the most common deadly and aggressive malignant brain tumour 
of the central nervous system in humans. The relentless progression of this disease is due to the 
infiltration of the cells from the primary tumour site into distant regions of the brain, which renders 
complete resection of the tumour impossible leading to tumour recurrence. Current methods of 
treatment including surgical removal, chemotherapy combined to radiotherapy are mainly 
unsuccessful because of the highly invading and resistant nature of these glial tumours. Therefore, 
there is an urgent need to develop new methods and understand the complex behaviour and 
microenvironment of glioblastoma tumours. The key challenge in successful glioblastoma treatment 
lies in destroying the cancer cells that invade the brain tissue and exist in the brain parenchyma after 
the removal of the primary tumour bed.  
To date, strategies that have been used, suffer from several disadvantages, including the absence of 
molecules that naturally exist in the brain extracellular matrix and most importantly they lack from 
effective chemoattractants. Consequently, residual invasive tumour cells remain in the margins of 
the resection cavity, leading to inevitable tumour recurrence. Therefore, this thesis aims to shed light 
on and tackle the majority of different limitations of the conventional methods of GBM treatment. 
In order to address these challenges, we here investigated the use of 3D scaffolds such as hydrogels 
for attracting and trapping glioma cells. Particular attention was given to those based on 
polysaccharides such as hyaluronic acid (HA) and methylcellulose (MC). HA is one of the main 
components of the brain extracellular matrix and is implicated in tumour cell behavior, creating a 
microenvironment favourable for migration, proliferation and invasiveness of malignant cells.  HA-
based hydrogels were prepared by chemical crosslinking of HA with Adipic Acid Dihydrazide 
(ADH) or Bovine Serum Albumin (BSA) as crosslinkers using EDC/sulfo-NHS chemistry.  In this 
work, the fabricated hydrogels were loaded with a chemokine at a concentration gradient in order to 
achieve the migration of glioma cells to the hydrogel matrix and with a chemotherapeutic drug in 
order to induce cell death. The chemokine that was used is the vasoactive peptide urotensin II (UII) 
which at a gradient concentration has demonstrated chemoattracting migratory effects on glioma 
cells. Herein, the chemoattraction was tested on hydrogels loaded with this chemokine peptide.  
Moreover, the physicochemical and mechanical properties of the fabricated hydrogels were mainly 
characterised by swelling studies, Scanning Electron Microscopy, enzymatic degradation 
experiments, Differential Scanning Calorimetry, Infrared Spectroscopy and oscillatory rheology. In 
overall, hydrogels presented favourable physicochemical features and mechanical properties that can 
mimic those of the native brain tissue. Preliminary biological results showed that glioma cells could 
invade and migrate in response to the loaded chemoattractant UII in the matrix.  
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Chapter 1: Introduction 
1.1 Background 
Over the past two decades the number of people diagnosed with cancer worldwide has increased 
dramatically. In many countries, cancer ranks the second most common cause of death following 
cardiovascular diseases and it remains as a major health problem around the world [1], [2]. There are 
different types of cancer, the most common types include lung, breast, prostate, colorectal, bladder 
cancer, melanoma and leukaemia. Brain tumours are less common, but there is evidence that 
the incidence of these tumours has been rising since the last years. Approximately 19 in 0.1 million 
individuals are diagnosed with central nervous system (CNS) tumours and primary brain tumours 
every year worldwide [2]. Indeed, brain cancer treatment presents several challenges due to the 
unique sanctuary situation of the brain and there is an urgent need for the development of new 
therapeutic strategies. Chemotherapy is the most efficient standard treatment for cancer in general, 
and can be also used in brain cancer treatment combined with radiotherapy. However, conventional 
methods of treatment are mainly unsuccessful, giving rise to alternative strategies that potentially 
overcome the limitations of the traditional ones and they will be further discussed below. 
1.2 Brain tumours 
A brain tumour is an intracranial mass produced by the uncontrolled growth of cells either normally 
found in the brain or spread from primary tumours located in other tissues of the body. Brain tumours 
are considered one of the worst diseases as they have a direct impact on patient’s life from a 
psychological, physical and neurological aspect [3].  
These tumours can be classified by the biological behaviour as benign or malignant. In both cases, 
there is an abnormal aggregation and proliferation of cells. Benign tumours originate from cells 
within or surrounding the brain and are less likely to spread to other parts of the brain. On the other 
hand, malignant tumours are the most aggressive type of brain tumours, tending to invade the 
surrounding brain tissue and are considered to be life threatening. Brain tumours can be classified by 
the location of origin as primary or secondary tumours. Primary tumours arise in the brain, rather 
than spreading from another part of the body while secondary spread to the brain through a metastatic 
process. Metastasis is the most common cause of brain cancer while tumours originating in situ from 
nerve cells are less common [4]. There are more than 100 types of primary CNS tumours [5]. Figure 
1.1 summarises the different types of brain tumours and their location. The most common types are 
gliomas and meningiomas. Acoustic neuroma, lymphoma, medulloblastoma and hemangioblastoma 




Figure 1.1: Illustration of the most common locations of different types of brain tumours in adults. Adapted 
from reference [5]. 
CNS tumours are the 9th most common cancers in the United Kingdom and are accounting for 
approximately 2 % of all cancer cases in adults [6]. In adults, the majority of brain tumours are 
supratentorial with high-grade gliomas and meningiomas to predominate. Brain tumours can develop 
at any age but are most common in people aged between 50 and 70. The period 2013-2015, on 
average each year approximately 24 % of new cases observed in people aged 75 and over and the 
incidence rates were similar between both genders. Figure 1.2 presents the average number of brain 
cancer cases per year in the United Kingdom and the different rates between both genders. It can be 
concluded that the highest incidence is observed at the age of 70 for male and female population and 
there is an increasing number of patients diagnosed with brain tumours per year. 
 
Figure 1.2: Average number of new cases diagnosed with brain cancer per year in the United Kingdom and 
age incidence rates. Adapted from Cancer Research UK [6]. 
On the other hand, brain tumours are the second most common cancer in children, accounting for 
almost 26 % of all childhood cancers [7]. In the United Kingdom approximately 400 children are 
3 
 
diagnosed with brain tumour each year and boys are affected slightly more than girls as demonstrated 
in Figure 1.3. These brain cancer pediatric patients generally have a better outcome than adults but 
they are frequently unwell for months prior to diagnosis and a prolonged period between the 
appearance of symptoms and diagnosis is associated with increased morbidity [8]. In addition, 
treatments in children would potentially impact normal brain development [9]. 
 
Figure 1.3: Average number of new cases diagnosed with cancer per year, children (0-14 years old) in the 
United Kingdom. Adapted from Cancer Research UK [10].                  
1.3 Classification of brain tumours 
The German pathologist Rudolf Virchow was the first in 1860 to introduce the term ʺgliomaʺ, 
distinguishing this class of tumours from other brain primary tumours. With the progression of 
cytological and histological techniques, a more refined classification was published by the WHO in 
1979, and revised by the same organisation in 1993, 2000 and 2007 [11] and more recently in 2016 
[12]. Malignant or high-grade gliomas are the most common type of primary brain tumours that arise 
from glial cells, accounting for 80 % of patients and an annual incidence of 5.81 per 100.000 
population [13]. There are several types of gliomas including brain stem gliomas, optic nerve 
gliomas, astrocytomas, oligodendrogliomas, ependydomas or glioblastomas as shown in Figure 1.1. 
Based on histological criteria, WHO 2007 has identified more specifically the growing malignancy 
of astrocytoma into 4 grades (I-IV) and of oligodendroglioma in 2 grades (II-III). Among malignant 
gliomas, grade IV astrocytomas or glioblastomas are the most common and deadly primary brain 
tumours. Grade I or pilocytic astrocytoma is delimited, benign and is most often treated by resection. 
Malignant grade II glioma or diffuse astrocytoma, exhibits a high degree of differentiation and 
moderate cell density, and is classically called ʺlow grade gliomaʺ but can be infiltrative often 
progressing to higher grades [14]. The anaplastic astrocytoma or grade III consists of undifferentiated 




IV or glioblastoma multiforme (GBM) is a very aggressive tumour that can be developed de novo 
(primary GBM) or evolve from lower grades (secondary GBM) [15]. 
 
1.4 Glioblastoma multiforme 
1.4.1 General information   
The most common type of gliomas is GBM and it is the most aggressive malignant primary brain 
tumour, accounting for approximately 50 % of all brain tumours as shown in Figure 1.4 [16], [17]. 
The most frequent anatomic location of GBMs is the cerebral hemispheres, with 95 % of these 
tumours arise in supratentorial region, whereas only few of them occur in the cerebellum, brainstem 
and spinal cord [18]. GBM is characterised by high infiltration along white matter tracts [19] and 
blood vessels [20], high heterogeneity [21], significant mitotic activity, high tortuous vascularisation, 
necrotic areas, chemoresistance and high recurrence rates [22]. The average survival period is around 
15 months following standard Stupp protocol e.g. radio and chemotherapy [23]. According to the 
histomolecular classification published by WHO 2016 three major diagnostic subtypes of GBM 
based on the status of Isocitrate Dehydrogenase (IDH) are individualised in 3 groups: (i) IDH mutant, 
(ii) IDH-wildtype and (iii) IDH not otherwise specified. This classification would facilitate clinical, 
experimental and epidemiological studies dedicated to improvements in the development of 




Figure 1.4: Distribution of all primary central nervous system gliomas. Astrocytomas account for 75 % of all 
gliomas. Adapted from Central Brain Tumor Registry of the United States [16].  
 
All other gliomas, 11.1% 
Other brain tumours, 5.8% 
Oligodendrogliomas, 8.4% 
Pilocytic astrocytoma 
(WHO I), 5.8% 
Diffuse astrocytoma 
(WHO II), 1.5% 
Anaplastic astrocytoma 
(WHO III), 7.5% 
All other 
astrocytomas, 8.7% 




1.4.2 Incidence of GBM 
GBM typically affects adult population ranging in age from 50 to 70 years and is mainly located in 
the cerebral hemispheres. It has an incidence of 2 to 3 per 100.000 adults per year and they tend to 
affect more men than women [24]. While GBMs are primarily an adult-age tumour, pediatric GBMs 
are also classified as high-grade gliomas. Pediatric GBMs account for 3 % of childhood primary 
brain tumours and are rarely diagnosed among children and adolescents. The incidence of these 
tumours is 4.84 cases per 100.000 children per year. Anatomically, the majority of these tumours are 
located in the brain stem [25]. 
1.4.3 Risk factors 
For the majority of gliomas, no underlying carcinogenetic causes have been identified, however, 
scientists have found that mutations in the genes of different chromosomes might play role in the 
development of these tumours. There is convincing evidence that specific inherited genes can 
significantly affect the risk of developing brain tumours in 5-10 % of glioma cases [26]. More 
specifically, some gliomas can be associated with genetically  inherited syndromes, such as Neuro-
fibromatosis [27], Li-Fraumeni [28], Von Hippel-Lindau, Turcot and Tuberous Sclerosis [29]. 
Furthermore, exposure to therapeutic radiation may be responsible for the onset of GBM [30]. 
Specifically, several studies have demonstrated that children who received prophylactic CNS 
irradiation, a cumulative dose of 2.500 cGy for acute lymphnoblastic leukaemia, were susceptible to 
be diagnosed with brain tumours [31]. Other environmental risk factors include exposure to smoking, 
pesticides, petroleum refining and employment in synthetic rubber manufacturing [30]. Additional 
factors such as severe head injury, dietary habits, exposure to electromagnetic fields and diagnostic 
irradiation are suspected to lead to GBM but it is not confirmed [32].  
1.4.4 Clinical presentation, diagnosis and prognosis 
Depending on the localisation and the increasing intracranial pressure, as a sult of the clinical stage 
of the disease, the most common symptoms of GBM include headaches, seizures, memory loss and 
changes in mental status [33]. More specifically, for patients who present hearing and visual 
problems, it is indicated that the tumour is located in the temporal lobe region. In contrast, 20-40 % 
of the patients diagnosed with impairing cognitive functions, the location of the tumour is in the 
frontal lobe [34]. Gadolinium-enhanced magnetic resonance imaging (MRI) and computed 
tomography (CT) are routinely used to visualise brain tumours as shown in Figure 1.5 [35]. 
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Figure 1.5: MRI and CT imaging are commonly used in the detection of brain tumours. To the left is MRI of 
a brain tumour, to the right is a CT scan of a brain tumour. Adapted from Nelson et al [35]. 
MRI plays a crucial role in the detection of the location of the tumour and diagnosis of GBM. In 
addition, a definite diagnosis of GBM on MRI or CT requires a stereotactic biopsy for tumours 
localised in essential functional zones, or craniotomy with tumour resection for histological and 
molecular characterisations. A meta-analysis published in 2016 in which the Stupp protocol 
(fractional radiotherapy combined with chemotherapy with temolozomide and then chemotherapy 
alone) indicated that the overall survival of 1 year and 2 years of follow-up was significantly 
improved in the case of ʺcompleteʺ excision [γ6]. Currently, the prognosis of patients with GBM 
remains poor as the median survival rate is 12-15 months from the time of diagnosis rendering this 
disease incurable [37]. The poor prognosis is mainly related to the tumour location, the high 
heterogeneity of GBM and infiltration of glioma cells in the health brain parenchyma, likely leading 
to recurrence. 
1.5 Challenges in the treatment of GBM 
Generally, gliomas show a high proliferation rate, phenotypic variations, variability in tumour 
histopathology and diffusely infiltrate adjacent brain tissue [38], rending GBM a very challenging 
cancer to treat. Several features unique to GBM limit the assessment of tumour response and the 
reliable delivery of cytotoxic agents to the tumour, are highlighted in Figure 1.6. GBM cells widely 
diffuse into the brain parenchyma and cannot be detected by conventional brain imaging techniques. 
Moreover, it has been reported that i) GBM invasion occurs through white matter tracts and blood 
vessels responsible for incomplete surgical resection, increasing tumour recurrence, ii) GBMs were 
found to be highly angiogenic, crucial step to their growth and resistance to therapy [39], iii) the 
anatomic location of GBM in the brain usually hinders a complete surgical removal of the tumour 
without damaging the surrounding functional tissue close to the vicinity of the tumour [40], iv) the 
presence of the blood-brain barrier (BBB) limits the number of cytotoxic drugs that can effectively 
reach the tumour site at therapeutic concentrations [41] and v) the unique brain microenvironment 
drives GBM progression indicating craving for the brain microenvironment [42]. In overall, despite 
therapeutics strategies, GBM still remains as one of the most deadly cancers. 
7 
 







Figure 1.6: Features unique to GBM that provide a challenge for the current treatment options and contribute 
to its fatal outcome.  
One of the recognised challenges for the current GBM treatment strategies, is the ability to penetrate 
the BBB and at the same time, to minimise the systemic toxicity in order to overcome the tumour 
resistance. Furthermore, one of the hallmarks of GBM is its heterogeneity at all levels, from the 
histological to molecular and clinical level [43], [44]. GBMs display a highly phenotypic 
heterogeneity because they are composed of cells that express markers of differentiated and 
undifferentiated cells [45]. Patel et al studied the intratumoural heterogeneity in primary GBMs and 
they demonstrated that spheroids and differentiated clusters represent two morphologically distinct 
types of cells within a single tumour [46]. In addition, this intratumoural heterogeneity in GBM 
contributes to variability in responses and resistance to conventional methods of treatment [47]. 
Moreover, a subpopulation of GBM cells has been found to demonstrate stem like properties such as 
expression of stem cell markers or long-term self-renewal which can be responsible for the resistance 
to chemotherapy or radiotherapy. Imaging plays a central role in diagnosis, MRI and CT consist the 
conventional diagnostic methods to visualise brain tumours, but these techniques suffer from 
significant limitations. Firstly, conventional MRI hardly distinguishes low grade from high grade 
gliomas requiring histological analysis and biopsies for a secure diagnosis [48]. Secondly, high grade 
tumours, intracranial metastasis and inflammation induce disruptions in BBB leading to contrast 
enhancement on MRI. Finally, the extent of GBM and the margins of the malignant tumour are not 
always detectable by the conventional neuroimaging techniques as tumour cells can be only detected 
in close proximity to the tumour bed.  
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1.6 Brain microenvironment and blood-brain barrier 
The brain microenvironment is a critical regulator of the cancer progression in primary and metastatic 
brain tumours [49]. GBM cells interact with their microenvironment for invasion, as these cells hav 
the ability to move along the myelinated axons in white matter, spreading into healthy brain regions 
[50]. It is widely accepted that the BBB is the most important factor in GBM recurrence as it prevents 
the effective systemic administration of the chemotherapeutic drugs to the tumour site. The BBB is 
a highly selective semipermeable membrane which separates the blood vessels in the brain and the 
spinal cord by monitoring the circulation of blood and extracellular fluid in the CNS [51]. It is mainly 
comprised of cellular and molecular factors, endothelial cells, pericytes, astrocytes and extracellular 
matrix (ECM) as shown in Figure 1.7. The main role of BBB is to block the passage of toxic 
molecules from the systemic blood circulation to the brain and this can be achieved by the specific 
defense mechanisms (transport barrier, immunologic and enzymatic barrier) [52]. In addition, 
another important role of BBB is to transport nutrients and other necessary molecules to the brain 
tissues, however, only small hydrophobic molecules can cross the unique morphology of BBB [53]. 
The barrier’s function is mainly endorsed by the endothelial cells and is highly impenetrable to 
hydrophobic molecules larger than 200 kDa including the majority of the common chemotherapeutic 
agents. On the other hand, only lipophilic molecules with molecular weight lower than 400-500 Da 
can effectively cross the BBB which are used for the treatment of neurological diseases such as 
epilepsy, chronic pain and depression [54].  
 
Figure 1.7: Structure of the blood-brain barrier. It is a complex network which is impermeable to large 
macromolecules, excessive CNS fluids and other blood components. Adapted from Sarkar et al [55]. 
Furthermore, the structure and function of the BBB can be affected from the intensity of the tumour 
growth which results in the formation of the blood brain tumour barrier (BBTB). This barrier is 
formed by disruption of the tumour membrane, albeit it resembles the intact structure of the BBB. 
The abnormalities caused by the vascularisation of GBM decrease the permeability of the brain 
barrier, thus acting as an obstacle for the effective delivery of the majority of the antitumour agents.   
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1.7 Conventional methods of treatment  
1.7.1 Surgical resection 
The treatment of GBM currently presents several challenges due its location, aggressiveness and 
highly infiltrative nature. GBM remains an incurable cancer despite the intense clinical research 
including improvements in surgery, use of combined chemoradiation and the advent of novel 
methods of treatment. The surgical resection and the extent of the excision are critical factors for the 
determination of tumour diagnosis and patient prognosis. Current technologies used for glioma 
resection include laser interstitial thermal therapy, awake craniotomy, fluorescence guided surgery 
and intraoperative mass spectrometry [56]. In addition, it has been observed that longer survival rates 
occur in patients who have undertaken aggressive resection surgery, almost 98 % of tumour volume 
resected with a mean initial tumour volume being 33-39 cm3 without causing neurologic deficits 
[57], [58]. The current scheme of treatment for newly diagnosed GBM patients consists of maximum 
tumour resection plus daily administration of temozolomide (TMZ) at a dose of 75 mg/m2 and 60 Gy 
of radiotherapy (2 Gy daily) for 4-6 weeks, followed by a TMZ maintenance dose of 150-200 mg/m2 
for 5 days every β8 days for 6 cycles [59]. Although, extensive and ʺcompleteʺ surgical resection of 
GBM represents the most effective way to increase survival rates of GBM patients, it is difficult due 
to the location and infiltration of the tumours. Broadening the resection area could lead to 
neurological deficit and loss of the functional brain tissue. Particularly, most of the tumours are 
located in sensitive areas of the brain, including areas that control the speech, motor function and 
senses [60]. The high degree of invasiveness renders radical removal of the primary tumour 
challenging as the infiltrating tumour cells remain within the surrounding brain, leading to recurrence 
of the tumour [61]. To conclude, surgery suffers from critical limitations that contribute to 
recurrences. Residual cancer cells that have not been removed and remain in the periphery of the 
tumour site and the existence of brain tumour initiating cells can increase the risk for tumour 
recurrence. In addition, the natural wound healing process initiated at the surgical site with the 
presence of growth factors can enhance the proliferation or migration of tumour cells [62]. 
1.7.2 Chemotherapy 
Chemotherapy also plays a significant role in the treatment of the disease and is commonly 
administered to patients. Several chemotherapeutic agents have been tested for their effectiveness in 
the treatment of GBM in order to improve the survival rates of patients, are summarised in Figure 
1.8. Among them, alkylating agents such as carmustine (BCNU), lomustine (CCNU) and 
temozolomide (TMZ) have indicated some advantages and been used in clinical trials for the 
treatment of GBM [63]. However, it has been reported that BCNU and CCNU result in early 
development of resistance and their use is associated with many side effects such as nausea, 
myelosuppression and pulmonary fibrosis [64]. Doxorubicin (DOX) is not commonly used in 
gliomas due to its low bioavailability in the brain, however, new delivery strategies focus on low 
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doses of this drug, especially as part of a drug cocktail [65]. Currently, TMZ is the preferred FDA 
approved chemotherapeutic drug in the treatment of GBM due to its lipophilic nature which enables 
it to penetrate the BBB and is currently used in combination with radiotherapy as recommended by 
the Stupp protocol. More specifically, TMZ acts by methylating adenine and guanine residues to 
form the methylated bases N3-methyladenine, N7-methylguanine and O6-methylguanine which 
causes the cytotoxicity of TMZ. However, TMZ is administered at high doses and its prolonged 
systemic administration has been associated with several side effects such as nausea, headaches, 
vomiting [66] and bone marrow suppression. In addition, at least 50 % of TMZ treated patients do 
not respond to the treatment. This resistance mainly arises from the overexpression of O6-
methylguanine methyltransferase (MGMT) which is an enzyme involved in DNA repair processes 
[67]. Several ongoing studies focus on the identification of the factors including the expression level 
of DNA alkylating proteins, DNA repair enzymes and gene mutations which contribute to TMZ 
resistance will be discussed in Chapter 4. 
 
Figure 1.8: Chemical structures of traditional chemotherapeutic agents used in the treatment of GBM. 
The use of chemotherapeutic agents in the treatment of GBM presents several important limitations. 
Firstly, systemic delivery of the drugs at the site of the tumour is ineffective due to the presence of 
BBB and the repeated administration of high doses of the drugs is necessary which leads in severe 
side effects. Secondly, malignant gliomas are often resistant to alkylating agents and this results in 
the formation of recurrences close to the resection borders, rendering GBM treatment challenging 
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[68]. For the aforementioned limitations of the current chemotherapeutic approach, there is an urgent 
need to develop more efficient local drug delivery strategies that will enable the targeted drug release 
to the tumour site over a sustained period of time.  
1.7.3 Radiotherapy     
Surgical treatment is followed by radiotherapy in order to kill the remaining tumour cells and it aims 
to improve the life expectancy of the patients diagnosed with high grade glioma [69]. Since 1940s, 
clinicians have routinely incorporated radiotherapy into the treatment of brain tumours. Walker et l 
investigated a dose-effect correlation in radiotherapy and the response of GBM [70]. They found that 
doses of 50-60 Gy were associated with improved survival rates and patients who were subjected to 
this dose of radiation, demonstrated 2.3 times longer survival compared with those with no 
radiotherapy. Currently, the radiotherapy scheme consists of administration of approximately 60 Gy 
of radiation in 1.8 to 2.0 Gy daily doses 5 times per week for 6 weeks and it is delivered to the 
surrounding area of the original tumour. The extent of the treatment is controversial since it is 
difficult to define the margins of the tumour with the conventional imaging techniques such as MRI 
and CT. Alternative advances of radiotherapy include intensity-modulated radiotherapy, image-
guided radiotherapy, image-guided radiotherapy and use of radiation sensitisers [71]. The efficacy 
of radiation regimen can be improved by using radiosensitisers, which are mainly chemotherapeutic 
agents. Despite the efforts to provide higher local doses of radiation and improve the efficacy of 
radiotherapy, GBM recurrences occur. Moreover, increasing the intensity of radiation could lead to 
adverse side effects including radionecrosis, radiation-induced oedema and damage to healthy 
surrounding brain tissue. Another limitation of this treatment regimen is that tumour margins cannot 
be accurately detected and identified by MRI, rendering difficult to be reached by radiation. 
Radiation oncology should focus on the development and improvement of delivery and dose of 
radiotherapy in order to minimise the toxicity associated with this treatment.                                        
Over the past decades, scientific community has made a lot of efforts to prolong patients’ life 
expectancy and increase the long-term benefits of GBM treatment. However, conventional methods 
of treatment including surgical resection, radiotherapy and concomitant chemotherapy suffer from 
crucial limitations highlighted in Figure 1.9. Alternative therapeutic strategies should be developed 








                                                  
                                                                                                                       
                                                        
 
         
 
   
 
Figure 1.9: Schematic representation of critical limitations of conventional methods of GBM treatment. 
1.8 New strategies for GBM treatment 
1.8.1 Targeted delivery of genetic therapeutics to the brain 
Standard treatment of GBM includes surgical resection of the tumour mass followed by radiation in 
the vicinity of the resection cavity and concomitant administration of TMZ. Despite this multi-
therapeutic approach, tumour recurrence occurs. The majority of gliomas, almost 95 % reoccur in 
close proximity (1-2 cm) to the initial tumour bed within 5 to 8 months after the treatment [72]. Most 
of the current local delivery systems depend on drug diffusion into brain parenchyma which only 
covers few millimeters around the delivery site. Unfortunately, the clinical end point for GBM is 
restricted to stabilise the disease, to slightly prolong patient’s life and to improve the quality of life 
during the last stages of the disease. Therefore, the development of effective therapeutic treatment 
for GBM is necessary and requires multidisciplinary approaches that can overcome the complexity 
of these malignant tumours. During the last decades, great efforts have been made to develop 
innovative methods of GBM treatment including BBB opening or effux pump inhibition, convection-
enhanced delivery (CED), immunotherapy strategies including use of monoclonal antibodies and 
vaccines, pharmaceutical formulations for local drug delivery such as wafers, liposomes, 
nanoparticles and hydrogels as shown in Figure 1.10. 
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Figure 1.10: Schematic representation of novel strategies for the treatment of GBM. Strategies of targeted 
delivery of therapeutics are represented in light blue background, while strategies for local delivery of 
chemotherapeutics are depicted in dark blue background.  
1.8.2 Immunotherapy strategies and targeted therapies  
Recently, immunotherapy seems to be a novel promising approach for GBM treatment and brings 
new hopes for GBM patients [73], [74]. The principal targets of immunotherapy include the 
improvement of the immune response and the targeting of specific antigens. The brain hosts several 
immune cells such as microglia which are concentrated in brain’s gray matter and migrate to 
inflammatory sites in the CNS, secreting cytokines and chemokines [75]. Interestingly, brain was 
considered to be an immune privileged site due to the presence of the BBB and the absence of a usual 
lymphatic system. However, there are significant limitations of this treatment strategy and GBM 
patients demonstrate low immune responses. Firstly, immune cells can migrate into the brain 
parenchyma by chemotaxis, where interferons and integrins play an important role in GBM cell 
migration and invasion. Secondly, in the microenvironment of GBM, hypoxia triggers the secretion 
of immunosuppressive factors that inhibits the cytotoxic T cell activity [76]. A high level of vascular 
endothelial growth factor (VEGF) expression can contribute to increased permeability of BBB, 
enhancing the interaction between tumour cells and the immune system. Therefore, current 
approaches to immunotherapy focus on targeted therapies such as the use of monoclonal antibodies 
and vaccines. 
Over recent years, several studies investigated the administration of immune cells or antibodies 
targeted against tumour antigens to patients. It is well known that GBM cells are highly vascularised 
and they enhance the secretion of proangiogenic factors such as VEGF, which role is critical in 
angiogenesis and the vascular permeability of the BBB. These proangiogenic factors bind with their 
corresponding receptors which contributes to the development of angiogenesis, lymphangiogenesis 
and increased vascular permeability of the BBB. In 2009, FDA approved the use of the monoclonal 
antibody bevacizumab for the treatment of adult patients diagnosed with GBM [77]. More 
specifically, bevacizumab selectively binds to the different forms of the VEGF and prevents the 
interaction of VEGF with target receptors VEGFR-1 and VEFGR-2 on the surface of endothelial 
cells [78]. The role of bevacizumab by neutralising the biological activity of VEGF contributes to 
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the reduction of tumour angiogenesis and inhibition of the tumour growth. Despite many clinical 
trials for the treatment of GBM, recent studies to evaluate the use of bevacizumab combined with 
the standard therapy, demonstrated no increase of GBM survival rates and patients did not present 
benefits from the bevacizumab treatment. On the other hand, severe side effects were reported such 
as hemorrhage, deep vein thrombosis and gastrointestinal problems [79]. To date, there is lack of 
information on the optimal conditions of using bevacizumab for the treatment of GBM in terms of 
dosage, the duration of the treatment and lack of biomarkers to identify the benefits from this targeted 
therapy. 
Moreover, the rapid development of immune targeted therapeutic strategies contributed to the 
investigation of anticancer vaccines. Advantages of the vaccination strategy involve the targeted 
delivery of tumour associated antigens directly to the tumour site [80]. Currently, vaccine therapies 
for GBM have been successfully investigated in clinical trials, with promising results so far 
highlighting their potential for future therapeutic integration. There are different types of vaccines 
for GBM treatment including peptide vaccines, heat shock protein (HSP) and dendritic cell vaccines 
[81]. Among the immunotherapies studied for the treatment of GBM, there are several therapeutic 
vaccines including the peptide vaccine, Rindopepimut [82]. The main component is a peptide 
corresponding to a mutated form of EGFR, EGFRVIII (expressed solely by 20 to 30 % of GBM). 
Initial results from a randomised trial presented no improvement in median overall survival and 
progression-free survival in EGFRVIII-expressing GBM patients who received + TMZ + vaccine 
compared to patients who received only TMZ (ACT IV trial) [83].  
Main limitations of these type of vaccines include the alteration of second- or third-line therapeutic 
approach in case of tumour recurrence and the restriction of targeting specific antigens, while GBM 
cells are highly heterogeneous and this results in inadequate tumour control. Furthermore, 
immunotherapy is usually combined with chemoradiation which causes adverse side effects and it 
renders immunotherapy regimen challenging and sometimes difficult to be integrated into the GBM 
treatment.  
1.8.3 Gene delivery 
Strategies for gene therapy of gliomas have been in development for the last 2 decades focusing on 
the delivery of genetic therapeutics with the aim to induce apoptosis of tumour cells or activating the 
immune response against them. More specifically, the gene therapeutic strategies for the treatment 
of GBM include the delivery of cytokine genes or suicide genes to trigger immune cells and convert 
prodrugs into active cytotoxic compounds in the tumour site leading to apoptosis. In addition, gene 
treatment involves the delivery of specific viruses in order to induce intracellular toxicity to the 
tumour cells or destroy them during the replication process [84]. In 1991, Ezzedine et al studied the 
selectivity and efficacy of the Herpes simplex virus thymidine kinase (HSV-TK) on the apoptosis of 
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glioma cells upon the administration of the prodrug ganciclovir (GCV) [85]. The enzymatic process 
induced by the GCV leads to death of the tumour cells that express the HSV-TK enzyme. Another 
widely studied gene is the bacterial enzyme Cytosine Deaminase (CDA), which converts the prodrug 
5-fluorocytosine to the toxic compound 5-fluorouracil (5-FU). Combination of CDA with 
radiotherapy has shown significant results by killing tumour cells and delaying tumour growth in 
xenograft models of glioma [86]. Moreover, latest studies focus on the viral delivery of p53 gene 
which is one of the most frequently mutated genes in glioma cells in order to prevent the tumour 
growth [87]. However, gene therapy still faces considerable challenges for successful long-term 
therapeutic benefits for GBM patients. Firstly, poor rate of delivery and diffusion of genes to the 
tumour cells renders GBM treatment challenging. Secondly, lack of clinical effectiveness which can 
be mainly assigned to the poor distribution of the genes into the tumour. Interestingly, in a recent 
clinical study using retrovirus-producing cells to deliver HSV-TK gene therapy in GBM patients, 
researchers did not observe any improvements in the overall survival [88]. Moreover, gene infected 
cells could present potential resistance to the prodrugs, requiring combination of gene therapy with 
the conventional chemoradiotherapy regimen in order to overcome this obstacle.     
1.8.4 Alternative magnetic field treatment 
A treatment based on the application f very low intensity alternating fields, named TTfields 
(Tumour Treating Fields) is currently being studied using the NovoTTF-100A and involves wearing 
a helmet consisting of 4 electrodes on the patient's skull, producing a magnetic field treatment [89]. 
This device should be worn as long as possible per day, every day. In vitro, these fields lead to tumour 
apoptosis at the time of cell division and inhibition of cell migration. The Optune device has recently 
been approved for patients with newly diagnosed GBM. Despite progress and knowledge, and the 
multiplicity of avenues and therapeutic options, the improvements in terms of survival for the patient 
remain insignificant and suggest to propose innovative strategies for local delivery of 
chemotherapeutics. 
1.9 Local delivery of chemotherapeutics 
Current conventional methods of treatment for GBM are mainly insufficient followed by inevitable 
tumour recurrence due to the drug delivery challenges in the brain as illustrated in Figure 1.11. A 
major reason for this failure is the unique brain microenvironment and the presence of the BBB which 
prevents the effective delivery of cytotoxic drugs at the tumour site. In fact, over 95 % of tumour 
recurrence cases occur within 1-2 cm from the margins of the resection cavity [90]. Therefore, the 
application of local drug delivery systems that will enable therapeutic concentration of the drugs to 
reach the tumour site avoiding adverse side effects, seems a hopeful alternative to overcome the 
barriers to effective brain tumour treatment. Current developments in the local drug delivery to the 




Figure 1.11: Illustration summarising the drug delivery challenges encountered in the treatment of GBM. 
Direct injection of chemotherapeutics via a repeated needle-based injection is the earliest method 
used for GBM local drug delivery targeting the injection of chemotherapeutic agents into the 
resection cavity or the brain parenchyma. In 2003, Prados et al evaluated the efficacy of direct 
injection of HSV-TK gene vector producer cells followed by intravenous GSV administration on 30 
patients and observed severe effects in 16 patients, confirming that gene expression was only present 
few millimeters from the resection cavity [91]. Despite being a simple and easy method to apply for 
local drug delivery, there are several limitations to this injection strategy. More specifically, repeated 
surgical operations are required thus increase the risk of local side effects such as infection and 
intracranial hemorrhage. Additionally, the drug distribution into the tumour and the surrounding 
brain parenchyma is poor due to the limited depth of diffusion and high concentrations of the drug 
can be found mainly around the injection point [92]. 
Therefore, another approach was developed to facilitate local drug distribution to the brain and 
overcome the inadequacy of the direct injection method. CED relies on the direct continuous 
diffusion of the chemotherapeutic agent in the brain parenchyma using a micro-catheter connected 
to a motor-driven pumping device which allows wider distribution of the drug in the brain tissue 
[93]. Bruce et al in 2011 performed a Phase I trial evaluating the safety profile of CED of topotecan 
in 16 patients with recurrent malignant gliomas and they observed early response in 4 patients (25 
%), pseudoprogression in 2 (44 %), progressive disease in 5 (31 %) and dose limiting toxicities in 2 
(13 %) [94]. However, disadvantages of this method involve the continuous refilling of the reservoir, 
dependence of the drug distribution on the features of the device, drug properties and infusion 
parameters (rate, volume and duration) and potential neurotoxicity.  
1.9.1 Liposomes for the treatment of GBM 
Liposomes have been studied extensively as drug carriers since several decades and their use for the 
treatment of GBM was investigated due to several features of these systems. Firstly, they can cross 
the BBB through the inter-endothelial gaps of the blood brain tumour barrier in case of high-grade 
gliomas. Secondly, the relatively simple and cost-effective preparation procedure, long-term stability 
in plasma and biocompatibility are key factors for the effective application of these systems. 
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Moreover, liposomes have the ability to efficiently encapsulate high concentrations of hydrophilic 
or amphiphilic anticancer agents and should decrease the systemic toxicity of anti-neoplastic agents 
[95].     
The potential of liposomes for the delivery of anticancer drugs has been investigated extensively in 
different types of cancer. Liposomes are constituted of a double lipid membrane, some can be surface 
linked with polyethylene glycol (PEG-coated) and/or can be functionalised by means of antibody or 
peptide-coated membrane to bind more specifically transporters expressed by the BBB or receptors 
expressed by glioma cells. Commercially available liposomes (Caelyx®) loaded with DOX have 
been approved for clinical trials in several types of cancer and they are under investigation for the 
treatment of GBM [96]. Recently, Lu et al developed a multifunctional liposomal glioma-targeted 
drug delivery system modified with cyclic RGD (c(RGDyK)) and p-hydroxybenzoic acid (pHA) in 
which c(RGDyK) could target integrin αvίγ overexpressed on the BBTB and glioma cells [97]. 
Moreover, Yu et al presented an effective method to improve the drug delivery to brain tumour. 
Particularly, as shown in Figure 1.12, they conjugated the iNGR peptide to liposomes to enable them 
to specifically recognise and penetrate across the tumour blood vessels, thereby increasing the drug 
concentration on tumour tissue [98]. Thus, their simple and large-scale production, easily tunable 
composition, their ability to penetrate the BBB and the preferential accumulation within the tumour 
tissue renders them very promising drug delivery systems for the treatment of GBM.   
  
 
Figure 1.12: Tumour vessel recognising and tumor penetrating system is developed by modifying the iNGR 
peptide to the surface of liposomes (iNGRSSL/DOX). The iNGR-SSL/DOX first binds to tumour blood vessel 
by the interaction of iNGR and CD13 receptor. Then iNGR is proteolytically cleaved to iNGRt, which 
specifically binds to NRP-1 overexpressed on tumour blood vessel. The iNGRt mediates the liposome 
penetration through tumour neovascularisation and tumour tissue, and finally the cellular uptake by 
glioblastoma cells. Adapted from Zhou et al [98]. 
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Despite the advantages from the application of liposomes for the treatment of GBM, this method 
suffers from several limitations. To date, there is insufficient knowledge on clinical studies of these 
therapeutic systems for the treatment of GBM. The majority of the studies are restricted to n vitro 
and in vivo conditions and no clinical trials are ongoing.  
1.9.2 Nanomedicine for the treatment of GBM 
The development of new technologies based on nanoparticles (NPs) for cancer treatment has been 
extensively investigated in the past two decades [99]. Particularly, integration of nanomedicine into 
conventional chemotherapy has provided significant advantages in terms of solubility, stability and 
side effects of the conventional chemotherapeutic drugs. NP  have attracted much interest in the 
targeted drug delivery due to their physical properties. More specifically, their small size, ther 
tunable degree of surface coating, the drug loading capacity and the controllable release profile are 
essential elements for their successful application in drug delivery. In addition, these materials can 
improve the plasma circulation half -life of the drug molecules, rendering them promising drug 
carriers for local delivery. Particularly, NPs for brain drug delivery should be nontoxic, 
nonimmunogenic, biocompatible and biodegradable, protecting the encapsulated drug from any 
means of degradation [100]. Additionally, encapsulation of chemotherapeutic drugs into NPs 
facilitates the penetration of the BBB or BBTB in the brain [101].  
Intravenous administration of NPs has been emerged as promising strategy for GBM treatment due 
to their versatility in surface modification [102].  Interestingly, Steiniger et al investigated the use of 
poly (butyl cyanoacrylate) (PBCA) nanoparticles loaded with DOX, with or without surface coating 
of PS80 as targeting moiety against intracranial 101/8 GBM tumour del in rats [103]. Animals 
treated with DOX loaded NPs demonstrated prolonged survival time and histological analysis 
confirmed slight reduction in the size of the tumour. Gao et al developed PEG-poly(caprolactone) 
(PEG-PCL) NPs with surface coating of interleukin-13 (IL-13) peptide, which preferentially binds 
with the IL-1γRαβ receptor overexpressed in gliomas [104]. Highest cellular uptake and better 
targeted delivery was observed with the coated NPs. It is well known that PEGylated NPs, such as 
Doxil® with encapsulated DOX allow surface functionalisation to penetrate the BBB and was shown 
to stabilise malignant glioma patients [105]. In another study, magnetic iron oxide NPs were 
modified through the PEGylation, conjugation by chlorotoxin and cyclodexterin, loaded with 
fluorescein and paclitaxel. These formulations led to increased uptake of NPs by GBM cells, thus 
paclitaxel could act more efficiently in suppressing GBM and malignant drug resistant cells [106].  
The local delivery of drugs through NPs system is a major challenge and consequently several 
methods have been developed to achieve the highest localised drug delivery due to the contribution 
of ultrasounds (US). For example, Hall et al investigated the development of ultrasound sensitive 
microbubbles (MBs) that were consisted of silica-based materials, presenting significant stability and 
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potential to be used for localised drug delivery [107]. Additionally, in another study from the same 
group, the impact of US as potential trigger for the release of drugs encapsulated in silane-
polycaprolactone (SiPCL) MBs was investigated [108]. SiPCL MBs were loaded with docetaxel and 
the release was further studied in either with the effect of ultrasound as trigger or not. The cytotoxicity 
of the released docetaxel on C4-2B cells was evaluated and increased cytotoxicity was observed, 
concluding that US as trigger, enhances the local delivery of the drug. 
It is generally believed that the delivery of drugs to the brain is extremely challenging due to the low 
permeability of the BBB as discussed in section 1.6. It has been demonstrated that the combination 
of focused ultrasound (FUS) and NPs or MBs can reach brain tissues with minimally invasive 
methods [109]. The MBs interact strongly with low-intensity US, producing mechanical forces on 
the endothelium that result in transient disassembly of tight junctions. Safe disruption or loosening 
of the BBB is significantly important to deliver chemotherapeutic agents and overcome the 
limitations arise from the tight junctions of the barrier. Successful delivery of the drugs can be 
achieved through BBB disruption using focused US as illustrated in Figure 1.13.    
 
Figure 1.13: Illustration of the application of FUS for disruption of the BBB. The BBB is impermeable to 
many drugs. FUS can reversibly loosen this barrier, allowing drugs to penetrate.  
Recently, Aryal et al developed a FUS-based strategy to improve the delivery of liposomal DOX in 
a rat glioma model. They tested the impact of three weekly sessions of FUS and liposomal DOX on 
9L rat glioma tumours. Treated animals with combination of FUS and liposomal DOX demonstrated 
significant increase in survival time compared to animals received only FUS or DOX or no treatment 
[110]. Moreover, transcranial FUS has been demonstrated to disrupt the BBB in a focal and reversible 
manner and its potential application to brain tumour treatment has been recently demonstrated in rat 
models [111], [112]. Rutka et al have demonstrated the use of Magnetic Resonance-Guided FUS in 
order to induce disruption of the BBB in rats and allow the targeted delivery of cisplatin loaded gold 
NPs to the tumour margins [113]. 
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According to the promising results gathered from in vitro and in vivo experiments at the preclinical 
stage of NPs based therapy, further clinical studies are required for the successful application of these 
systems on the treatment of devastating GBM. 
1.9.3 Implantable drug polymers 
Another drug delivery approach in the treatment of GBM is the use of implantable drug loaded 
polymers. Polymers present several advantages in the local drug delivery. Firstly, they allow 
sustained release of the drug through degradation of the polymer matrix. Secondly, polymers can be 
easily manipulated during their implantation in the resection cavity avoiding invasive surgical 
manners.  
FDA and the National Institute for Health and Clinical Excellence (NICE) have only approved the 
use of polymeric wafers Gliadel® loaded with BCNU for local chemotherapy in the treatment of 
malignant glioma [114]. Particularly, this type of wafers, mainly consists of a biodegradable 
copolymer formed of 1,3-bis-(p-carboxyphenoxy)propane (pCPP) and sebacic acid (SA), are 
implanted along the margins of the tumour resection cavity as shown in Figure 1.14 and release 
BCNU in a controlled manner into the surrounding brain tissue over 2-3 weeks. 
                                                                               
Figure 1.14: Stages of wafer implantation in the resection cavity, A. Surgical resection of GBM, B. 
Administration of Gliadel® wafers along the wall of the resection cavity of a patient at the time of the surgery. 
Up to 8 wafers can be placed to cover as much as of the resection cavity, C. Surgicel® may be placed over the 
wafers to secure them against the cavity surface, D. Close and ensure cavity integrity. Adapted from reference 
[115]. 
The recommended dose of BCNU is 61.6 mg, represented by 8 wafers (7.7 mg BCNU each) that are 
implanted intracranially to fill the resection cavity. Multiple clinical trials have reported the 
prolonged survival time for patients treated with Gliadel®. Particularly, Valtonen et al investigated 
the effects of BCNU wafers or placebo on patients with newly diagnosed malignant gliomas and they 
observed significantly longer survival for the group of patients treated with wafers compared with 
the placebo group [116]. Therapeutic strategies using Gliadel wafers have demonstrated prolongation 
of survival in GBM patients, albeit, tumour recurrence cases have been reported in the majority of 
treated groups. Additionally, there are several concerns about the use of wafers for the treatment of 
brain tumours. Adverse side effects have been associated with their use including seizures, 
intracranial hypertension, impaired neurosurgical wound healing, brain oedema, meningitis and 
wafer migration [117]. In addition, rapid release of carmustine within the first 5-7 days of 
implantation instead of sustained release within 3 weeks in vivo studies in mammalian models has 
been reported [118]. The short half-life of BCNU, approximately 20-30 minutes and the solid nature 
A    B C D 
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of these wafers does not allow homogeneous distribution of the drug. Therefore, several groups 
focused on the administration of implantable polymers with other chemotherapeutic agents in the 
resection cavity. For example, Manome et al developed a PLGA implant loaded with DOX which 
was exposed to the glioma induced significant inhibition of the tumour growth. Khang et al tested 
BCNU-loaded PLGA wafers on 9L gliosarcoma cells and on a solid tumour model of 9L gliosarcoma 
and they also observed substantial regression of the tumour [119], [120]. Finally, it is of paramount 
importance to develop new strategies that will overcome some of the limitations of implantable 
polymers. Hydrogels used as targeted chemotherapy systems own a promising role in the treatment 
of GBM. 
1.9.4 Hydrogels for the treatment of GBM   
During the last decades, many therapeutic approaches have been developed to treat GBMs, among 
them the local delivery of chemotherapeutic drugs in the resection cavity has gained a lot of attention. 
Many researchers have focused on different drug delivery systems. Among them, injectable drug-
loaded hydrogels have shown promising results. Hydrogels are three-dimensional, hydrophilic 
crosslinked networks capable of absorbing large amounts of water or biological fluids. They are used 
for many applications in the medical and pharmaceutical field such as for cell culture and as drug 
delivery systems [121], [122]. Their unique physical properties, particularly their biocompatibility, 
tunable mechanical properties, hydrophilic nature and the structural resemblance to the extracellular 
matrix of living tissues rendering them attractive in a variety of biomedical applications. 
Particularly, the in situ gelation is one of the key elements in the success of hydrogels in the 
biomedical field and it will be further discussed in Chapter 2. In recent years, the injection of gel 
forming solutions has been considered a promising method to deliver drugs at targeted reas. 
Injectable hydrogels possess several advantages over the conventional approaches for drug delivery 
systems [123]. Firstly, their initial liquid formulation can flow easily and turn into gel, thus filling 
any cavity shape. Secondly, the hydrogel can be loaded with a variety of therapeutic agents including 
hydrophobic drugs, growth factors or cells. Thirdly, the polymer formulation can be stored at room 
temperature or at lower temperature before the administration and turn into gel at physiological 
conditions. Above all, there is no requirement for an invasive surgical procedure for implantation. 
The therapeutic agent can be delivered directly into the targeted site by a simple injection of a liquid 
formulation, which undergoes thermal gelation at body temperatur . 
Interestingly, hydrogels have been used in several studies for the investigation of GBM treatment 
and they are summarised in Table 1.1. They have been involved in the fabrication of complex 
microenvironment models to study the mechanobiology and migration behaviour of glioma cells 
[124], [125]. They have also been used in the development of a three-dimensional culture system in 
order to assess the response of malignant gliomas to radiation and chemotherapeutic drugs [126]. To 
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date, hydrogels have extensively been studied as anticancer drug delivery systems for the treatment 
of malignant brain tumours. These systems can be administered in the brain after craniotomy in the 
resection cavity via intracerebroventricular injection or intracerebral implantation. Albeit, few 
studies have been focused on the administration of hydrogels in the resection cavity and very little is 
described in the literature. 
Table 1.1: Examples of hydrogels developed for intracranial implantation for local treatment of GBM. 
     Hydrogel matrix         Active agent Type of study Reference 
PEG-based hydrogel CRGDS and a MMP-
cleavable peptide 
In vitro tumour model             124 
Collagen-HA hydrogel                 - GBM behaviour in 3D 
matrix 
            125 
ExtracellTM TMZ, BCNU, cisplatin Ex vivo culture of GBM              126 
OncoGelTM               TMZ Intracranial GBM model               127, 128 
GemC12-LNC hydrogel Lauroyl-gemcitabine Human xenograft GBM 
model 
              129, 130 
PEG-based hydrogel               TMZ Human GBM model               131 
Chitosan-based 
hydrogel 
         TMZ/ 131I In vivo study in nude 
mice 
              132 
Collagen-based 
hydrogel 
         Cyclopamine Human xenograft GBM 
model 
              133 
Alginate-based hydrogel PTX-loaded PLGA 
microspheres 
Xenograft GBM model               134, 135 
 
Recently, Tyler et al investigated the use of OncoGelTM in an intracranial 9L GBM model alone or 
in combination with TMZ and radiotherapy [127], [128]. OncoGel TM consists of ReGel TM which is 
a copolymer of PLGA and PEG that forms a biocompatible gel at body temperature. It can be injected 
in the proximity of the tumour and provide controlled release of paclitaxel for 6 weeks with dose-
limiting toxicities. Interestingly, Bastiancich et al proposed the use of a novel hydrogel formed of 
lipid nanocapsules (LNC) and Lauroyl-gemcitabine (GemC12) for the local treatment of GBM [129]. 
The GemC12-LNC hydrogel was well tolerated in mouse brain after 2 and 6 months of exposure and 
the researchers proceeded with the intratumoural administration of the hydrogel in an orthotopic 
human xenograft GBM model for further investigation. They reported the antitumour efficacy of the 
nanomedicine hydrogel after injection in the resection cavity of an orthotopic human xenograft model 
and the significant increase in survival in mice treated groups [130] as demonstrated in Figure 1.15. 
Although, further studies in other animal models are required to ensure the efficacy of this system in 
comparison with other chemotherapeutic drugs or radiotherapy. 
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Figure 1.15: A. Images taken from the intratumoural administration of the GemC12-LNC hydrogel: tumour 
tissue visible within the 2x2 mm cranial window (left), biopsy punch twisting (middle) followed by aspiration. 
GemC12-LNC hydrogel (5µL) injected into the resection cavity (right), B. Axial (T2-weighted) images of 
mouse brain following resection: untreated (day 31 post-resection, left) and treated with GemC12-LNC (day 61 
post-resection, right), demonstrating the antitumour efficacy of the specific hydrogel. Adapted from 
Bastiancich et al [130].  
In the field of photopolymerisable hydrogels, Danhier et al described the development of an 
injectable hydrogel for the local delivery of TMZ in the resection borders of the tumour cavity. This 
injectable hydrogel consisted of a mixture of PEG dimethacrylate and water at a ratio of 75:25 and 
0.5 % of Lucirin-TPO® was used as photoinitiator. The antitumour effect of this hydrogel was 
evaluated in nude mice on a subcutaneous human GBM model, which showed that the tumour growth 
of mice treated with the photopolymerised TMZ hydrogel significantly decreased compared with 
control (untreated animals) [131]. In another study, Puente t al investigated the use of a 
biodegradable injectable chitosan-based hydrogel for the local chemoradiotherapy treatment of 
GBM. The hydrogels were loaded with TMZ or radioactive isotopes agents (iodine, 131I) in nude 
mice and their efficacy on tumour growth was evaluated. Tumour growth was significantly delayed 
and the survival was improved in treated groups compared with the control group [132].  
Despite the growing number of research studies in the field of injectable hydrogels, up to now, just 
few focused on the development of systems for trapping glioma cells. As mentioned in section 1.3, 
malignant glioma cells intend to invade and migrate along white matter tracts and blood vessels. 
Recently, Bellamkonda et al exploiting this characteristic of glioma cells, by means of engineered 
aligned or smooth PCL-based nanofibers in order to mimic the structure of white matter tracts and 
blood vessels. These nanofibers allowed tumour cells to invade and then guide them from the primary 
tumour site to a collagen-based hydrogel loaded with cyclopamine as cytotoxic drug [133]. More 
specifically, they inserted the nanofibers in a conduit which was placed in the margins of an 
intracortical human glioblastoma U87MG xenograft model as shown in Figure 1.16. They observed 
that a considerable number of human GBM cells managed to invade and migrate along the aligned 





                                                    
 
                           
Figure 1.16: A. Schematic illustration of the conduit inserted into the rat brain with GBM from an angled 
view. B. Digital image of fixed extracted brain containing a conduit from the top view, C. Scanning electron 
microscopy image of the aligned polycaprolactone-based nanofiber film, D. Fluorescence images showing the 
tumour core in the brain i the tumour control condition, the smooth film conduit and the nanofiber film conduit 
condition. The tumours are outlined with green colour. Scale bars: 3.75 mm. Adapted from Puente et al [133].  
In the context of non-CNS tumours, Williams et al developed a medical device that was implanted 
into a tumour site and studied the tumour microenvironment. This device consisted of a transparent 
hydrogel that was loaded with growth factors to be released into the tumour site forming a gradient. 
The hydrogel was formed by 20 % of polyethylene glycol diacrylate, 7 % methoxy polyethylene 
glycol monoacrylate and Irgacure 2959 as photoinitiator. The aim of their study was the evaluation 
of migration of the invasive cells towards the gradient concentration of the released growth factors 
from the tumour site to the device. The sustained release of the chemoattractants such as epidermal 
growth factor (EGF) efficiently contributed to the migration of adenocarcinoma cells [136]. 
However, considering the very well-known knowledge about the stimulating impact of EGF on 
tumour growth, it would be particularly dangerous to apply this strategy to cure cancer patients. 
To date, the majority of the research studies has focused on the local delivery of anticancer drugs in 
the resection cavity by using injectable hydrogels as delivery systems. However, the aforementioned 
strategies suffer from several disadvantages, including the absence of molecules that naturally exist 
in the brain extracellular matrix and most importantly, they lack from effective chemoattractants. 
Consequently, residual invasive tumour cells remain in the margins of the resection cavity, or even 
at distance from this, leading to inevitable tumour recurrence. 
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1.10 Thesis objectives and overview 
After decades of intense clinical research, there is not an efficient treatment for GBM. Therefore, 
there is an urgent need to develop new methods and understand the complex behaviour and 
microenvironment of GBM tumours. The key challenge in successful GBM treatment lies in 
destroying the cancer cells that invade the brain tissue and already exist in the brain parenchyma at 
the time of the removal of the primary tumour bed by neurosurgeon.  
This thesis aims to shed light on and tackle the majority of different limitations of the conventional 
methods of GBM treatment outlined in sections 1.7 and 1.8. In order to address these challenges, we 
here investigated the use of 3D matrices such as hydrogels f r attracting and trapping glioma cells. 
Particular attention was given to those based on Hyaluronic Acid (HA). HA is a naturally occurring 
polysaccharide and it is the main component of the extracellular matrix of the brain tissue [137]. 
Recently, HA hydrogels have been involved in studies to explore glioma cell behaviour and 
migration [138], [139]. In this work, hydrogels were loaded with a small peptidic chemokine at a 
concentration gradient in order to achieve the migration of glioma cells to the hydrogel matrix and 
with a chemotherapeutic drug in order to induce apoptosis of the cells as illustrated in Figure 1.17. 
 
Figure 1.17: Illustration of hydrogel loaded with a chemoattractant at a concentration gradient and with a 
chemotherapeutic drug for attracting and inducing apoptosis of migrated glioma cells.  
The chemokine that was used is the vasoactive peptide urotensin II (UII). Recently, it has been 
established that glioma cells express thi peptide and its receptor UT which are involved in glioma 
cell migration and adhesion. UII used at gradient concentrations demonstrated chemoattracting 
migratory effects on glioma cells [140]. Hence, the proposed system for attracting and trapping brain 
cancer cells is safer and more effective than the currently available methods. The specific aims of 
this PhD thesis are as follows: 
1. Preparation of biocompatible polymeric hydrogels based on FDA approved materials and 
optimisation of their physical and mechanical properties for cell adhesion. 
2. Formulation of the material in order to achieve the transition from the liquid phase to gel 
phase and optimisation of the injectability of the system (e.g. r sponsive hydrogel). 
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3. Characterisation of the physicochemical and mechanical properties of the fabricated 
hydrogels. 
4. Formulation of the matrix to deliver the chemoattractant in a concentration gradient and 
allow controlled release of the loaded chemotherapeutic drugs. 
5. Evaluation of the biological response of glioma cells in the formulated hydrogels. 
 
In addition, an overview of the thesis structure is presented below:  
Chapter 1: Introduction 
This chapter aims to provide a brief overview of the challenges encountered in the treatment of GBM 
and the limitations of the conventional methods of treatment, highlighting the urgent need for 
alternative and more efficient therapeutic strategies. 
Chapter 2: Preparation of injectable polysaccharide-based hydrogels  
This chapter proposes the use of 3D scaffolds such as hydrogels in order to address the challenges of 
GBM treatment. In particular, this work focuses on the preparation of hydrogels based on 
polysaccharides including mainly hyaluronic acid, methylcellulose and xanthan gum. The 
crosslinking methods used and the protocols to fabricate these scaffolds are described. 
Chapter 3: Physicochemical and mechanical characterisation of hydrogels 
The physicochemical and mechanical properties are of paramount importance in determining if a 
material is suitable for a specific application. This section focuses on the characterisation methods to 
study the physicochemical and mechanical properties of the fabricated hydrogels. More specifically, 
hydrogels were mainly characterised by swelling studies, Scanning Electron Microscopy, enzymatic 
degradation experiments, Differential Scanning Calorimetry, Infrared Spectroscopy and Oscillatory 
Rheology. 
Chapter 4: In vitro  evaluation of glioma cells response on polysaccharide-based hydrogels 
Glioma cells were seeded on the fabricated hydrogels and their biocompatibility was mainly 
evaluated using MTS assay and Live/Dead staining. In addition, the chemoattraction of the hydrogels 
loaded with the chemokine was investigated. 
Chapter 5: Conclusion 
The general conclusion remarks of this PhD thesis are presented and a personal reflection on the 
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Chapter 2: Preparation of injectable polysaccharide-based hydrogels 
2.1 Introduction 
Current therapeutic strategies for the treatment of GBM, suffer from several limitations, including 
the absence of molecules that naturally exist in the brain ECM and scaffolds that can mimic its 
structure and mechanical properties. To date, the majority of the developed implantable 3D scaffolds 
such as hydrogels have focused on the delivery of anticancer drugs close to the tumour site as 
discussed in Chapter 1.  These matrices mainly lack of effective chemoattractants, thus the majority 
of the residual invasive tumour cells remain in the margins of the resection cavity, leading to 
inevitable tumour recurrence. The first section of this chapter will present a literature review on 
hydrogels used for biomedical applications and the following experimental section will focus on the 
preparation of injectable hydrogels based on polysaccharides. Particular attention will be given to 
HA-based hydrogels as they have been studied during this PhD thesis. The second half of this chapter 
will discuss the attempts to obtain injectable hydrogels based on methylcellulose which is another 
known polysaccharide. Subsequently, the fabricated hydrogels will be loaded with the 
chemoattractant and the response of glioma cells will be investigated in the following chapters. 
2.1.1 Hydrogels 
Hydrogels are 3D hydrophilic crosslinked polymer networks which are characterised by their ability 
to absorb significant amount of water or biological fluids and they have been extensively studied 
over the last decades as biocompatible materials. Another definition of hydrogels has been proposed 
by Hoffman and defines hydrogel as a permanent or chemical gel stabilised by covalently crosslinked 
networks [1]. The high hydrophilicity of hydrogels is mainly attributed to the presence of hydrophilic 
moieties such as carboxyl, amide, amino, and hydroxyl groups distributed along the backbone of 
polymeric chains. The soft consistency, elasticity and structural resemblance to body tissues are 
unique characteristics of hydrogels. Consequently, these crosslinked polymeric materials presenting 
great potential in a wide range of applications including tissue engineering [2], wound dressing [3], 
sensors [4], contact lenses [5] and drug delivery systems [6]. More than 30.000 scientific papers 
focused on hydrogels, published in the last 50 years, demonstrate the significance of this type of 
materials.   
2.1.2 Classification of hydrogels  
Numerous classifications of hydrogels have been proposed in the literature [7]. They are commonly 
classified according to their origin, method of crosslinking, degradability, response to different 
stimuli, ionic charge as summarised in Figure 2.1. Hydrogels can be classified into natural, synthetic 
or hybrid according to their origin. Naturally derived hydrogels are used in drug delivery, tissue 
engineering, regenerative medicine due to their inherent biocompatibility, low toxicity, and 




Figure 2.1: Schematic diagram summarising the main classification of hydrogels according to their source, 
method of crosslinking, degradability, response to stimuli and ionic charge.  
They are mainly produced from polysaccharides or natural fibrous proteins such as collagen, fibrin, 
alginate and hyaluronic acid, resembling the structure of the native ECM [10]. Polysaccharides 
are innately biodegradable and they are usually modified in order to form hydrogels allowing cell 
adhesion. On the other hand, synthetic polymers are more appealing because their physical and 
chemical properties are more tunable and controllable than those of natural polymers. Furthermore, 
they can be reproducibly prepared with specific block structures, molecular weights and degradable 
linkages, providing better control of chemical composition and matrix architecture. Representative 
examples of synthetic polymers are poly (vinyl alcohol) (PVA), poly (ethylene glycol) (PEG), poly-
lactic-glycolic acid (PLGA), poly (methyl methacrylate) (PMMA) and poly- (NIPAAM) [8]. More 
complex hydrogels can be derived either from copolymers, where multiple backbone groups are 
crosslinked together or inter-penetrating networks (IPNs), where a polymer mesh is constructed from 
the binding of oligomer chains within an already assembled polymeric scaffold [11], [12]. However, 
these polymers lack of inherent biological functionality, therefore they are usually conjugated to 
proteins or polysaccharides in order to increase the cellular interactions and achieve desirable 
responses in vivo.  
Hydrogels can also be classified into physical or chemical depending on the method of crosslinking. 
In physically crosslinked hydrogels, physical reversible interactions exist between the polymer 
chains, whereas in chemically crosslinked hydrogels, covalent bonds are present between the 
polymer chains. An increasing interest in physically crosslinked hydrogels is assigned to the absence 
of crosslinkers for their preparation. Common methods of physical crosslinking include hydrogen 
bonding, self-assembly interactions, crosslinking by crystallisation and ionic interactions [10]. 
Chemically crosslinked hydrogels typically present better mechanical resistance than the physically 
crosslinked networks and are characterised by their tunable elasticity. Focusing on polysaccharide-
based systems, several strategies have been exploited to form chemical hydrogels through covalent 
bonds. Common chemical crosslinking methods include free radical polymerisation, addition or 
41 
 
condensation chemical reactions and crosslinking using enzymes [13]. The well-known Michael’s 
addition is also another interesting approach for the formation of chemical hydrogels. Recently, 
thiolated hyaluronic acid has been used for a Michael addition with a methacrylated triblock 
copolymer leading to an injectable hydrogel [14].       
Unsurprisingly, stimuli responsive hydrogels represent a broad class of materials that can undergo 
reversible gelation in the presence of physical or chemical stimuli such as pH, temperature, UV light 
and changes in ionic strength [15], [16]. pH-responsive hydrogels consist a group of stimuli-
responsive systems capable of responding to changes in the environmental pH. The pH responsive 
behaviour of the hydrogels is due to the presence of ionisable side functional groups in the polymer 
backbone [17]. For example, natural polymers such as alginate, chitosan, gelatin and albumin are 
known for their pH responsive behaviour [18]-[21]. Polysaccharides including alginate and chitosan 
undergo swelling as a result of the ionisation of groups along the polysaccharide chain, whereas in 
the case of proteins such as albumin and gelatin, they will form helices stabilised by hydrogen 
bonding at specific pH and temperature conditions. When the pH of the solution is either lower or 
higher than the isoelectric point, electrostatic repulsions are developed that result in the swelling of 
the network. The process of swelling is reversible; thus, pH responsive hydrogels can be applied to 
controlled release of encapsulated drugs. For instance, Na et al fabricated doxorubicin loaded 
nanogels composed by hydrophobic pullulan – N-alpha-Boc-L-histidine conjugates and they studied 
their response to tumour extracellular pH [22]. The anticancer efficiency against breast cancer cell 
lines (MCF-7) was evaluated and the results showed that the nanogels can potentially be applied as 
antitumour drug carriers. 
Thermoresponsive hydrogels are vastly attractive due to their spontaneous gelation without the 
presence of any other chemical trigger. For temperature responsive hydrogels, a small variation in 
temperature induces phase transition as shown in Figure 2.2.  It is well known that the phase transition 
is governed by the equilibrium of hydrophilic and hydrophobic moieties on the polymer chain and 
on the Gibbs free energy of mixing [23]. According to the second law of thermodynamics (ΔG =
ΔΗ-ΤΔS) as the temperature increases, it favours the polymer chain association. Many natural 
polymers have demonstrated gelation upon temperature change. Recently, Stabenfeldt et al 
developed a thermosensitive hydrogel system based on methylcellulose [24]. They functionalised 
methylcellulose with the protein laminin in order to fabricate a bioactive scaffold for neural tissue 
engineering and they concluded that the concentration of methylcellulose could affect the 
temperature at which gelation occurs. Bhattarai et al reported the development of a biodegradable 
and thermoreversible hydrogel that consisted of chitosan functionalised with monofunctional 
methoxy poly (ethylene glycol) without the use of crosslinking agents. They observed that the 
presence of PEG improved the solubility of chitosan in water and the system was able to undergo 
thermoreversible transition from solution at low temperatures to gel at body temperature [25]. Gelatin 
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is another biopolymer with thermoreversible properties. Ohya and Matsuda grafted gelatin with 
NiPAAm in order to create a thermoresponsive extracellular matrix analogue. Interestingly, they 
observed that when the weight ratio of NiPAAm to gelatin chains was greater than 5.8, aqueous 
solutions showed a sol-gel transition at physiological temperature [26]. 
 
              
Figure 2.2: Illustration of thermoresponsive hydrogels which undergo gelation at body temperature. Adapted 
from Shaker et al [27].  
In the case of ionic triggered gelation, the formation of the hydrogel occurs upon treatment of an 
ionic polysaccharide with multivalent counterions. Several examples of ionic gelation exist of which 
alginate crosslinked with calcium is the most well-known [28]. The divalent cation of calcium 
electrostatically interacts with the anionic carboxylic groups of alginate to form a crosslinked 
network. Other representative examples of ionic crosslinked hydrogels include chitosan-polylysine, 
chitosan-glycerol phosphate salt and chitosan-alginate hydrogels [29]-[31]. Despite their easy 
preparation under mild conditions, these groups of hydrogels are not ideal candidates for tissue 
engineering due to their uncontrollable degradation. 
Moreover, photoresponsive hydrogels have attracted a lot of attention due to their mild gelation 
conditions. The most commonly used method to prepare this group of hydrogels involves 
photopolymerisation induced by UV or visible light and enables in situ gelation at physiological pH 
and temperature [32], [33]. Among the photopolymerisable groups, acrylate or methacrylate moieties 
are most commonly used. Leach et al investigated the conjugation of photopolymerisable 
methacrylate groups to hyaluronic acid and the photopolymerisation of these conjugates in order to 
form hydrogels for tissue engineering applications [34]. Photopolymerised systems provide the 
advantage of controllable gelation process and injectability which contribute to their successful 
application in tissue engineering.    
2.1.3 Injectable hydrogels as biomaterials 
Significant interest has been recently paid on injectable hydrogels formed in situ. Historically, 
hydrogels used to be preformed and implanted afterwards using highly invasive surgical 
manipulations. However, improvements in synthetic chemistry and materials science demonstrated 
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that hydrogels precursors can be injected locally through a standard syringe and crosslinked in situ 
avoiding invasive surgical techniques.  
Injectable hydrogels can be formed in situ either by physical or chemical crosslinking as illustrated 
in Figure 2.3. As discussed earlier, many methods have been employed for their preparation including 
thermal gelation, pH-triggered gelation, ionic interaction, physical self-assembly, 
photopolymerisation or chemical crosslinking with agents such as genipin, glutaraldehyde and adipic 
acid dihydrazide [35], [36].  
 
Figure 2.3: Injectable hydrogels can be delivered as liquid precursors which are either physically or chemically 
crosslinked into stable hydrogels at the site of injection. Common chemical crosslinking methods include free 
radical polymerisation, addition or condensation chemical reactions and crosslinking using enzymes. 
To date, several reviews have been focused on injectable hydrogels and the methods for their 
preparation. For instance, Ruel-Gariepy and Leroux have studied the in situ formation of 
thermosensitive hydrogels from natural or synthetic polymers, while Jeong et al have focused on the 
fabrication of thermosensitive sol-gel reversible hydrogels [37], [38.  
Injectable hydrogels present several inherent advantages over other preformed hydrogels. More 
specifically, these systems are aqueous solutions before administration and they rapidly turn into gel 
at the injection site under physiological conditions or in response to external stimuli such as 
temperature, pH, ion concentration or UV light. In addition, their injectable nature allows them to 
mould into the shape of the injection cavity minimising the adverse effects of invasive surgical 
approaches. Most importantly, injectable hydrogels based on natural polymers present a similar 
microstructure to the ECM rendering them one of the most promising biomaterials in the field of 
drug delivery and tissue engineering.  
It is of paramount importance to exploit the advantages of using injectable hydrogels for a variety of 
applications including tissue engineering, wound healing and drug delivery systems for local cancer 
therapy that will be further discussed below [39], [40]. Intra-tumour drug delivery with injectable 
biodegradable hydrogels has attracted a lot of attention due to the fact that they can provide a 
sustained drug release within the tumour site and simultaneously minimising the adverse effects of 
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systemic exposure to the drug. Targeted therapy with injectable hydrogels can overcome the 
limitations of poor drug solubility observed with many chemotherapeutic agents, by decreasing the 
required amount of the drug and increasing the concentration that reaches the tumour site as discussed 
in Chapter 1 [41], [42]. Specifically, in case of brain tumours the presence of the BBB limits the 
effective delivery of drugs to the tumour site thus direct application of therapeutics to the brain has 
been tested [43], [44]. Recently, Kwon et al fabricated 5-fluorouracil (5-FU)-loaded Pluronic® F-
127 thermosensitive hydrogels (5-FU-HP) with encapsulated formulations of DOX-loaded 
microcapsules (DOX-M) or FU-loaded di-block copolymer hydrogels (5-FU HC) in order to 
optimise tumour toxicity from the synergistic action of the loaded drugs on the hydrogels as depicted 
in Figure 2.4 [45].  
 
Figure 2.4:  Schematic representation of synergistic tumour suppression via intratumoural injections of dual-
drug depots and controlled release of DOX and 5-FU. Adapted from Kim et al [45]. 
These formulations were solutions at room temperature and formed gel at body temperature, 
indicating the injectability of the system. The results from the intratumoural injection of the above 
formulations containing DOX and 5-FU demonstrated significant antitumour activity, confirming the 
synergistic inhibitory effects of both drugs on tumour growth. To date, intratumoural injection of 
formulations loaded with combination of anticancer drugs on animals has received little attention, 
thus, further studies should be carried out for the development of an efficient in vivo drug delivery 
system. 
Injectable pH-responsive hydrogels have been used for targeted drug delivery for the treatment of 
several cancers. For example, Wu et al synthesised pH-sensitive hydrogels through a Schiff-base 
reaction between aldehyde-functionalised four-arm PEG and 4-arm PEG-b-poly (l-lysine) for local 
delivery of metformin (ME) and 5-FU for colon carcinoma [42]. The pH-dependent release of the 
drugs exhibited a synergistic inhibitory effect on cell proliferation in C26 colon adenocarcinoma 
cells. In addition, animal studies revealed significant therapeutic outcome of the drug-loaded 
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hydrogel in terms of tumour growth inhibition and they demonstrated less toxicity than the free drugs 
in animal models.   
Photopolymerisable hydrogels are of interest for several drug delivery and tissue-engineering 
applications due to their ability to be administered in aqueous solutions and form hydrogels in 
situ following photopolymerisation. Fourniols et al prepared TMZ-loaded photopolymerisable PEG 
dimethacrylate (PEG-DMA) injectable hydrogel by using Lucirin-TPO® as a photoinitiator for the 
treatment of GBM [46]. The hydrogel was photopolymerised rapidly (less than 2 minutes) in a brain 
tumour resection cavity using ultraviolet (UV) light allowing sustained release of TMZ. The 
antitumour activity of the TMZ-loaded hydrogel contributed to the regression of tumour in xenograft 
U87MG tumour-bearing mice and higher apoptosis at the centre of the tumour as summarised in 
Figure 2.5. 
 
Figure 2.5: Antitumour efficacy of TMZ/PEG-DMA hydrogels. A. Ratios between tumour weights 7 days 
after treatment and initial tumour weights of xenografted human U87MG tumour-bearing nude mice untreated 
(control), treated with unloaded hydrogel, TMZ-loaded hydrogel, or intravenous injection of TMZ. TMZ dose 
was 4.75 mg/kg, B. Pictures of tumours after 7 days of post-implantation in nude mice (n = 5 to 7). Stars: 
Represent complete regression of tumours. Adapted from Fourniols et al [46]. 
In addition, except from polymeric hydrogels for localised drug delivery in cancer, low molecular 
gelators (LMWGs) have also been investigated. LMWGs are one of the most representative examples 
of self-assembly responsive systems including amino acids and sugars that can self-assemble into a 
3D fibrous network by non-covalent interactions. Singh et al focused on the synthesis of LMWGs 
based on derivatives of L-alanine and they prepared injectable hydrogels loaded with DOX. These 
systems showed promising anticancer activity in mice models. Importantly though, subcutaneous 
injection of the DOX- loaded gel close to the proximity of the tumour achieved a greater decrease in 
tumour load than by intravenous injection of DOX alone and local injection of DOX alone at the 
tumour site [47]. However, the majority of LMWGs present poor mechanical properties and their 
applications as injectable scaffolds in drug delivery are limited. 
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In overall, the unique properties of the hydrogels render them very promising systems for localised 
drug delivery applications. Injectable hydrogels loaded with chemotherapeutic agents for drug 
delivery provide several advantages over the conventional intravenous delivery of the 
chemotherapeutics in terms of localised and sustained delivery of the drugs in the tumour vicinity. 
Several studies have been focused on the effectiveness of these drug delivery systems in vitro 
environment, however, further clinical trials in animal models or humans could address more 
precisely the efficiency of these drug delivery matrices for local chemotherapy and cancer treatment.  
2.1.4 Polymeric hydrogels as engineered 3D microenvironments 
As mentioned earlier, polymeric hydrogels are promising biomaterials due to their tunable 
mechanical properties and the structural similarity to the native ECM. These matrices have attracted 
significant attention as engineered 3D microenvironments because of the easy and not invasive 
manipulation and the fact that they can support cell growth due to the mechanical resemblance to the 
ECM. 
Collagen type I is a protein of the ECM, responsible for the structural frame of cells and it promotes 
adhesion of cells through the cell-matrix interactions [48]. Collagen-based hydrogels can be prepared 
by physical crosslinking and the presence of environmental stimuli such as pH or temperature can 
trigger the gelation process. The formation of fibrillar collagen matrices can be induced by increasing 
the temperature and the pH of the acidic precursor solutions [49]. Despite its unique properties, 
collagen presents several disadvantages, mainly weak mechanical properties, susceptibility to 
enzymatic degradation and batch-to batch variation. To date, several chemical crosslinking methods 
have used genipin or PEG as crosslinkers or enzyme-mediated crosslinking reactions have been 
reported in order to produce stiffer and more stable hydrogels that are less prone to enzymatic 
degradation [50], [51]. Fibrin hydrogels have gained a lot of attention in a wide range of biomedical 
applications such as drug delivery or as therapeutic implants due to their innate biocompatibility, 
ease of fabrication and biodegradability. These hydrogels are mainly prepared by the ionic 
crosslinking of fibrinogen with thrombin where thrombin cleaves fibrinogen’s N-terminal end that 
induces polymerisation of fibrin into fibrous hydrogel network [52]. However, fibrin-based 
hydrogels suffer from high degradation rates and ongoing studies intend to overcome this limitation.  
Hydrogels prepared from synthetic polymers have also been used in neural engineering applications, 
demonstrating better mechanical properties and more tunable physicochemical characteristics. The 
most representative example is PEG which is a bioinert and hydrophilic polymer. Interestingly, the 
survival and proliferation of neural progenitor cells in vitro on photopolymerised hydrogels 
composed of polylysine and PEG has been reported [53]. Polylactic acid (PLA) is another 
biocompatible and biodegradable FDA approved synthetic polymer that has been used in several 
biomedical applications.  To date, the majority of synthetic biomaterials that has been used for in 
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vivo delivery in brain is restricted to solid implants composed of polyglycolic acid (PGA) or poly 
(lactic-co-glycolic acid) (PLGA) scaffold particles and few have been applied to in vivo cell 
transplantation applications [54]. 
2.1.5 Polysaccharide-based hydrogels: the present and the future 
Polysaccharides have been widely used in pharmaceutical and biomedical applications, particularly 
in regenerative medicine and drug delivery due to their high hydrophilicity, biocompatibility, 
structural diversity and biodegradability [55]. Commonly used polysaccharides include chitosan, 
cellulose, xanthan gum, alginate, chondroitin sulfate, dextran and hyaluronic acid [56], have received 
extensive interest due to their favourable properties and versatile chemical structures as presented in 
Figure 2.6.  
 
Figure 2.6: Chemical structures of commonly used polysaccharides: chitosan, hyaluronic acid, cellulose and 
alginate. These polysaccharides are the subject of much interest due to their physical characteristics and 
structural versatility. 
Advantages of polysaccharides include natural abundance and the presence of functional groups 
which allow chemical modification of their backbone. Additionally, they are biodegradable since 
they can be degraded enzymatically or by hydrolysis and their tunable physicochemical properties 
contribute to their successful application as drug delivery systems.  
Several polysaccharides have been used for the preparation of biocompatible hydrogels for 
biomedical applications. Natural polymers such as fibrin, collagen, alginate, hyaluronic acid and 
chitosan have already been used in clinical applications. The structural similarity with the ECM of 
the biological system is one of the most important unique features of polysaccharide-based 
hydrogels.  Polysaccharides can form hydrogels through physical or chemical crosslinking. The high 
number of functional groups such as -OH, -COOH, -NH2 that are present in the polysaccharides’ 
backbone allow facile modification leading to a 3D polymeric network [57]. The chemical 
modification of the functional groups allows conjugation of polysaccharides with synthetic polymers 
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leading in the formation of stimuli responsive hydrogels [58]. Different types of crosslinking have 
been reported, including graft copolymerisation of a synthetic monomer on polysaccharide backbone 
in the presence of a crosslinker or direct crosslinking of the polysaccharide. For instance, Paulino et 
al fabricated thermoresponsive hydrogels from the graft copolymerisation of NIPAAM on the 
cellulose backbone [59]. 
Chitosan is a cationic polysaccharide and is obtained from alkaline deacetylation of chitin extracted 
from the external skeleton of marine crustaceans such as crabs and shrimps. It is widely used in a 
variety of applications including tissue engineering and drug delivery [60]. Chitosan-based hydrogels 
have received a lot of interest due to their unique properties such as easy manipulation, 
biocompatibility, biodegradability and bioadhesive nature. Commonly used methods of preparation 
of chitosan-based hydrogels include ionic gelation, chemical crosslinking or stimuli triggered 
gelation (pH or thermo-responsive gelation). The presence of the cationic amine groups in the 
chemical structure of chitosan allow ionic crosslinking with multivalent counter anions such as 
phosphate bearing molecules forming reversible hydrogels [61]. Several examples of ionically 
crosslinked chitosan hydrogels have been reported in the literature and the majority of them used in 
controlled drug delivery [62], [63]. Aldehydes such as glutaraldehyde and genipin have extensively 
been used as crosslinkers for the preparation of chemically crosslinked chitosan hydrogels 
demonstrating good biocompatibility [64], [65]. In terms of GBM treatment, chitosan has been used 
as an excipient for the preparation of nanoparticles due to its biodegradable and biocompatible nature. 
Van Woensel et al investigated the use of siRNA-loaded chitosan nanoparticles in order to inhibit 
the expression of Galectin-1 in human GBM cells. Galectin-1 is associated with tumour growth and 
it possesses a potential immune suppressing role in the tumour microenvironment [66]. Kim et al 
developed chitosan b-glycerophosphate (Ch/b-GP) thermo-sensitive hydrogel for the delivery of 
ellagic acid for the treatment of brain cancer. They investigated the release of ellagic acid from the 
chitosan hydrogels and the viability of human U87MG and rat C6 glioma cells was evaluated, 
demonstrating inhibition of cell growth [67].    
Another widely used polysaccharide is alginate which is an anionic polysaccharide that is composed 
of ί-D-mannuronic acid (M) and α-l-guluronic acid (G) units. Many clinical applications of alginate 
are connected with its ability to efficiently bind to divalent cations such as Sr2+and Ca2+, leading to 
formation of hydrogels [68], [69]. Hydrogels can be formed by physical or chemical crosslinking 
strategies or ionic crosslinking which is the most widely used. The gelation mechanism is based on 
the chelation of the divalent ions by the alginate chains which results in the fabrication of a swollen 






Figure 2.7: Schematic representation of alginate hydrogel formation. Ionic crosslinking with calcium-induces 
chain–chain association of guluronate blocks resulting in the formation of junction zones responsible for 
gelation (egg-box model). Adapted from Costa et l [70]. 
Alginate-based hydrogels due to their biocompatibility and easy fabrication process have numerous 
applications in wound healing, drug delivery, cell encapsulation and tissue regeneration. Degradation 
of ionically crosslinked hydrogels can be induced by the exchange between the divalent cations and 
monovalent cations that are present in the human body. Another benefit is that alginate, as chemically 
versatile molecule, allows the conjugation of peptide sequences such as RGD (arginine–glyci –
aspartic acid) in order to promote cell adhesion [71]. Chitosan-alginate hydrogels have been used as 
mimic scaffolds of glioma tumour microenvironment. More specifically, Kievit t al studied the 
response of U87MG and C6 cells cultured on chitosan-alginate scaffolds and they observed that these 
scaffolds provided a 3D microenvironment for glioma cells that was representative of the in vivo 
tumour [72].  
HA is an anionic glycosaminoglycan consisting of N-acetyl-D-glucosamine and D-glucuronic acid, 
is commonly used in a variety of clinical applications including tissue engineering and regenerative 
medicine [73]. Methylcellulose (MC) is a polysaccharide derived from cellulose by partial 
substitution of hydrophilic hydroxyl groups with hydrophobic methoxy groups. MC based hydrogels 
are promising materials for regenerative medicine and tissue engineering applications. Both 
polysaccharides will be discussed further in the following sections as they are main components of 
the fabricated hydrogels.  
In overall, polysaccharide-based hydrogels demonstrate high biocompatibility and their structure 
closely resembles the ECM composition, maximising their potential for injection in human body. 
Additionally, the choice of the polysaccharide to form a hydrogel for a specific application it is of 
paramount importance and depends on the desirable features of the designed biomaterial. Moreover, 
it is also important to point out that the availability from renewable sources, the hydrophilic 
properties and the chemical modification of their backbone render them very promising candidates 
for the preparation of functional biomaterials. Further clinical studies with this group of biomaterials 
will broaden the comprehension of the unique interactions between the polysaccharide-based 
matrices and cells in animal models.  
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2.1.6 HA-based hydrogels 
HA is a high molecular weight glycosaminoglycan and one of the main components of the brain 
ECM. It is ubiquitous in the native ECM throughout the human body at all ages, but is significantly 
abundant in the fetal brain, indicative of its critical role in the CNS development [74]. HA plays a 
substantial role in cellular processes such as cell proliferation, migration and cell adhesion since it 
interacts with cells through its surface receptors CD44 and RHAMM [75], [76]. HA has been used 
in a variety of medical and pharmaceutical applications due to its versatile structure, biodegradability, 
non-immunogenicity, biocompatibility and viscoelastic behaviour. Recently, the development of 
different strategies for chemical modification of its backbone has allowed the fabrication of new 
biomaterials that can be used in regenerative medicine and drug delivery applications.  
HA in its innate structure, is characterised by poor mechanical properties and high degradation rates 
due to the presence of hyaluronidase which is an enzyme that catalyses the degradation of HA. 
Therefore, various chemical modifications of the HA backbone have been developed in order to 
prepare mechanically robust HA-based biomaterials that will demonstrate better mechanical 
properties and long-term stability n vivo environment [77]. There are three different target functional 
groups in the HA structure that are prone to chemical modification: the primary and secondary 
hydroxyl groups, the carboxylic group and the N-acetyl group after deacetylation as highlighted in 
Figure 2.8. 
 
Figure 2.8: Chemical structure of HA with highlighted the three different target functional groups that are 
prone to chemical modification. 
The hydroxyl groups can be modified through esterification, formation of ethers or crosslinking with 
divynilsulfone, while carboxyl groups are modified by esterification, amidation or carbodiimide-
mediated reactions [78].  
Although, HA solutions are highly viscous, chemical crosslinking is required for the formation of a 
stable hydrogel for in vitro and in vivo applications since it is less susceptible to enzymatic 
degradation. In the literature, there are several examples of HA-based hydrogels that have been used 
in a variety of clinical and biomedical applications. Seidlits et al studied the differentiation of neural 
progenitor cells on HA hydrogels with different mechanical properties [79]. HA was modified with 
photocrosslinkable methacrylate (MA) groups at different molar ratios for the fabrication of HA-MA 
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hydrogels. It was observed that the differentiation of neural cells was dependent on the mechanical 
properties of the hydrogels. Recently, Florczyk et al developed a 3D porous scaffold composed of 
HA and chitosan polyelectrolyte complex in order to mimic the ECM of GBM microenvironment 
[80]. The HA-chitosan matrix promoted tumour spheroid formation and increased the stem like 
properties of GBM cells as it was confirmed by the overexpression of the stem cell markers, 
indicating that this scaffold could be used for in vitro screening of cancer therapeutics or for other 
biomedical applications.     
2.1.7 MC-based hydrogels 
Cellulose is another well-known polysaccharide obtained from wood pulp or cotton and is commonly 
used in a variety of applications due to its biocompatibility and inexpensive resources. However, 
cellulose mainly suffers from low water solubility, due to the inter-molecular hydrogen bonds 
occurring between hydroxyl groups that are present in its backbone, leading to the formation of 
highly ordered crystalline structures. Therefore, cellulose is usually modified with methyl groups 
which disrupt its rigid crystalline structure and improve the polysaccharide’s hydrophilicity [81]. The 
most commonly used derivative of cellulose is methylcellulose (MC) which is derived from the 
partial substitution of hydroxyl groups with methoxy groups. MC as FDA approved material is water 
soluble and is useful for numerous applications due to the mild gelation properties of its aqueous 
solutions [82].  
MC dissolved in aqueous solutions forms thermoresponsive hydrogels that undergo sol-gel transition 
at specific temperatures depending on its concentration and the addition of salts. In addition, 
chemical crosslinking methods have been developed in order to develop MC-based hydrogels with 
long-term stability in vivo conditions. For example, Stalling et al fabricated photopolymerisable 
methacrylated methylcellulose (MA-MC) hydrogels through esterification with methacrylic 
anhydride [83]. They observed that MA-MC hydrogels maintained their shape and did not 
demonstrate any significant inflammatory response when they implanted in CD-1 mice as presented 
in Figure 2.9. 
 
Figure 2.9: Representative images of MC-MA hydrogels at different concentrations implanted in CD-1 mice 
in vivo and ex vivo for 7 days. Adapted from Stalling et al [83].   
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Zhuo et al developed injectable HA-MC hydrogels using PEG as a crosslinker and they evaluated 
the cytotoxicity of this scaffold on L929 mouse fibroblasts [84]. Interestingly, they observed good 
relative cell viability proposing these scaffolds as a potential for tissue engineering applications. Kim 
et al fabricated thermosensitive hydrogels composed of soluble ECM (sECM) and MC for injectable 
stem cell delivery in skin wounds and as promising matrix for tissue regeneration [85].     
2.2 Experimental 
2.2.1 Materials 
Hyaluronic acid (hyaluronic acid sodium salt, from Streptococcus equiv. MW = 1.5 -1.8 mDa) and 
Adipic Acid Dihydrazide (ADH, MW = 174.2 Da) were purchased from Sigma Aldrich. 1-Ethyl-3-
(dimethylaminopropyl) carbodiimide hydrochloride (EDC, MW = 191.7 Da) and N-
Hydroxysulfosuccinimide Sodium Salt (Sulfo-NHS, MW = 217.13) were purchased from TCI 
Europe. Bovine Serum Albumin (BSA) (lyophilised powder, ≥ 98 %, MW = 66 kDa), Methyl 
cellulose (MC, suitable for cell culture, MW = 14 kDa, viscosity: 15 cPs, D.S 1.5-1.9), Xanthan gum 
(XG) from Xanthomonas campestris (viscosity: 800-1200 cPs) all were purchased from Sigma 
Aldrich. Deionised water was prepared from 200 nm nylon membrane filters from Millipore. 
Phosphate buffer saline tablets (1 tablet dissolved in 200 mL of deionised water, yields 0.01 M 
phosphate buffer solution, pH 7.4) were purchased from Fischer Scientific.    
2.2.2 Methods 
2.2.2.1 Preparation of HA-ADH hydrogels 
All hydrogels were prepared from HA of high molecular weight (1.5 - 1.8 mDa) and crosslinked with 
ADH as crosslinker and EDC as crosslinking agent similar as described by Prestwich t al [86]. The 
preparation protocol was slightly modified.  Briefly, the ratios of ADH to HA and HA to EDC were 
adjusted to obtain hydrogels optimised for cell adhesion. Four different crosslinking densities of HA-
ADH hydrogels were investigated and the detailed protocol for one of them is described below. HA 
sodium salt (10 mg, 6.25 nmoles) was dissolved in 800 μL of deionised water and EDC (0.26 mg, 
1.35 μmoles) was dissolved in 100 μL of deionised water and added to the aqueous HA solution. 
EDC was allowed to dissolve before the addition of ADH. The crosslinker ADH (0.25 mg, 1.43 
μmoles) was subsequently dissolved in 100 μL of deionised water and was added to the activated 
HA solution. The pH of the solution was adjusted at pH 5.5 with the addition of HCl 0.1 M. Gelation 
was allowed to occur with gentle vortexing. HA-ADH hydrogels were washed 3 times with PBS for 
the removal of any excess of unreacted crosslinker. 
2.2.2.2 Preparation of HA-BSA hydrogels 
All hydrogels were prepared from HA of high molecular weight. Four different crosslinking densities 
of HA- SA hydrogels were prepared and the detailed protocol for one of them is described below. 
The ratios of BSA, sulfo-NHS and EDC were adjusted to obtain hydrogels optimised for cell 
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adhesion. Briefly, HA sodium salt (6 mg, 3.75 nmoles) was dissolved in 800 μL of deionised water 
and it was activated with EDC (2 mg, 10.4 μmoles) and sulfo-NHS (0.5 mg, 2.3 μmoles) mixture in 
a molar ratio 4:1 in 200 μL of deionised water and the pH was adjusted at pH 6.0 with the addition 
of HCl 0.1 M before the reaction with the protein. The reaction was allowed to proceed for 2 minutes 
by vortexing. Then BSA (3 mg, 45.4 nmoles) was added as a powder to the activated HA solution 
for further crosslinking and gelation was allowed to occur with gentle vortexing. HA-BSA hydrogels 
were washed 3 times with PBS for the removal of any excess of unreacted crosslinker.   
2.2.2.3 Preparation of MC hydrogels 
MC solutions were prepared by a dispersion technique similar as described by Tate et al [87]. MC 
powder with approximate viscosity of 15 cP according to the manufacturer’s specifications, was 
used. Briefly, approximately half of the required volume of PBS was heated above 90 °C. The MC 
powder was mixed with heated PBS and agitated until all polymer particles were thoroughly wetted. 
The remainder of PBS was added cold and the mixture was gently stirred until MC was completely 
dissolved. As the temperature was lowered to 0 °C using an ice bath, the polymer became water-
soluble, forming a clear solution and gentle agitation was continued for 30 minutes. The solutions 
were allowed to equilibrate at 4 °C overnight. Different compositions of MC solutions (2 % w/w, 4 
% w/w, 6 % w/w and 8 % w/w in 1×PBS, 2 % w/w, 4 % w/w and 6 % w/w in 5×PBS, 2 % w/w and 
4 % w/w in 10×PBS) were prepared and the solutions were heated until gelation was observed. 
2.2.2.4 Preparation of blend XG/MC hydrogels 
XG solutions were prepared by slow addition of XG powder into PBS solution with vigorous stirring 
until the polysaccharide was completely dissolved and the solution was kept at 4 °C overnight with 
gentle stirring as described by Liu et al [88]. MC solutions were prepared as described in Section 
2.2.2.3. XG/MC composite solutions were prepared by adding XG powder into MC solution followed 
by overnight gentle stirring at 4 °C. XG/MC solutions were prepared at different compositions (XG 
1% w/w and MC 3 % w/w, XG 1 % w/w and MC 6% w/w, XG 1% w/w, XG 1 % w/w and MC 8% 
w/w, XG 2 % w/w and MC 6 % w/w, XG 2 % w/w and MC 1% w/w, XG 3 % w/w and MC 1% w/w) 
and gelation was allowed to occur with heating.   
2.2.2.5 Preparation of blend HA/MC hydrogels 
HA and MC blend solutions were prepared as previously described by Gupta et al [89]. MC was 
dissolved in deionised water at 90 °C until all the particles were thoroughly wetted. Phosphate buffer 
saline (pH 7.4) was added to the solution in equal quantity to water and subsequently cooled to 0 °C 
using an ice bath for an additional 30 minutes, after which it was allowed to equilibrate at 4 °C 
overnight. HA was then added as a powder to the MC solutions at a range of concentrations and 
allowed to get completely dissolved at 4 °C overnight with gentle stirring. Gelation was allowed to 
occur with heating at 37 °C. HA/MC solutions were prepared at different compositions and they are 
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as follows: 0.25 % w/w HA and 0.5 % w/w MC, 0.5 % w/w HA and 0.5 % w/w MC, 0.5 % w/w HA 
and 1 % w/w MC, 0.5 % w/w HA and 3 % w/w MC, 0.75 % w/w HA and 0.75 % w/w MC, 1 % w/w 
HA and 2 % w/w MC.    
2.3 Results and Discussion     
2.3.1 Preparation of HA-ADH hydrogels at various crosslinking densities   
Scaffolds prepared from polysaccharides are promising biomaterials for mimicking the in vivo 
tumour microenvironment. They structurally resemble glycosaminoglycans which are main 
components of the ECM. Particularly, HA is one of the major components of the brain ECM and is 
associated with the GBM growth and invasion [90]. HA presents several desirable properties such as 
biocompatibility, hydrophilicity, biodegradability, tunable viscoelastic properties and non-
immunogenicity which are essential elements for its application in the biomedical field.  
HA as a natural polymer in its native structure is characterised by its poor mechanical properties and 
rapid degradation in vivo conditions. It has been extensively used in the preparation of hydrogels for 
various biomedical applications such as wound healing and drug delivery [91]. For the preparation 
of HA-based hydrogels with good mechanical properties, various chemical crosslinking methods 
have been developed, although sometimes the cytotoxicity derived from the crosslinking agents is 
inevitable [92]. Many commercially available injectable HA hydrogels have been crosslinked with 
butanediol diglycidyl ether (BDDE) or divinylsulfone and glutaraldehyde as crosslinking agents [93]. 
In this study, HA was chosen as the main component of the hydrogels due to its numerous advantages 
over other polysaccharides. An inexpensive and straightforward approach for their preparation is 
proposed below. 
HA of high molecular weight was chosen, since it has been found that high molecular weight HA 
presents anti-angiogenic and anti-inflammatory properties, whereas low molecular weight fragments 
(<100 kDa) show the opposite biological activity [94]. Herein, HA hydrogels were prepared by 
amidation reaction of the free carboxylic groups of HA in the presence of a carbodiimide as 
crosslinking agent. EDC is commonly used as crosslinking agent due to its high-water solubility and 
it is well known for its ability to crosslink carboxylic groups with amines. Different compounds with 
free amino groups were checked if they could react with the carboxylic groups of HA and form amide 
bonds. Particularly, β,β′-(Ethylenedioxy) bis(ethylamine) (EBE), branched Polyethylenimine (PEI) 
and ADH as shown in Figure 2.10 were used and underwent screening under different experimental 
conditions but no reaction was observed in the case of the amines and they will not be further 
discussed. However, ADH successfully reacted with the carboxylic groups of HA at different molar 




Figure 2.10: Chemical structures of β,β′-(Ethylenedioxy) bis(ethylamine) (EBE), branched Polyethylenimine 
(PEI) and Adipic Acid Dihydrazide (ADH). 
Therefore, ADH was used as a crosslinker and as a low molecular weight compound with a hydrazide 
group at each end, it was very reactive. Generally, dihydrazides have much lower pKa values of 2-3 
than the diamines which allows the successful crosslinking with the HA in the presence of 
carbodiimide as crosslinking agent. On the other hand, amines have high pKa values (pKa > 9), 
which makes it more difficult to conjugate them to HA. ADH, due to its high-water solubility and 
low toxic properties, has commonly been used as a crosslinker in the preparation of hydrogels for 
biomedical applications [95]. For instance, Motokawa et al developed HA hydrogels crosslinked 
with ADH in the presence of bis(sulfosuccinimidyl) suberate (BS3) as crosslinking agent for the 
sustained release of erythropoietin [96], whereas Hu et al evaluated the in vitro and in vivo 
performance of oxidised HA-ADH hydrogels for the prevention of post-operative epidural fibrosis. 
These scaffolds presented reasonable biocompatibility for neural and Schwann cells [97].  
Herein, HA was crosslinked with ADH at different crosslinking densities in the presence of EDC as 
a coupling agent. The reaction mechanism has been studied extensively by Nakajima and Ikada in 
1995 [98]. Briefly, EDC activates the carboxylic group of HA forming an unstable reactive O-acyl 
isourea ester. The second step of the reaction is the nucleophilic attack of the chosen amine on the 
activated HA forming an amide bond. However, the O-acyl isourea intermediate can be further 
hydrolysed forming a stable water-soluble N-acyl urea by-product as it is demonstrated in Figure 
2.11. In this reaction, the nucleophile was the ADH which supplied free amine groups and we 
hypothesised that the carboxylic groups of HA could react with EDC and form amide linkages with 
ADH. The reaction is strongly dependent on the pH and the activation of carboxylic acid by EDC 
takes place in acidic environment (pH 4.5-6.0). At higher pH values, EDC is hydrolysed into N-acyl 







Figure 2.11: Plausible mechanism of crosslinking with EDC, which activates the carboxylic group of HA 
forming an unstable reactive O-acylisourea ester. Followed by the nucleophilic attack of the chosen amine on 
the activated HA leading to the formation of an amide bond. Hydrolysis of the O-acylisourea intermediate 
results in the formation of N-acyl urea as by-product.   
Table 2.1 summarises the trials that have been made in order to obtain self-supporting hydrogels 
from the crosslinking of HA with ADH in the presence of EDC. Particularly, HA solutions of 
concentration 4.0 mg/mL and 8.0 mg/mL were prepared and crosslinked with different molar ratios 
of ADH and EDC at pH 5.5. In all cases, not self-supporting hydrogels were obtained, therefore it 
was considered necessary to increase the concentration of HA at 10 mg/mL. 











Finally, four different crosslinking densities of HA-ADH hydrogels were prepared and the molar 
ratios of ADH to HA and HA to EDC were adjusted to obtain hydrogels optimised for cell adhesion 
Sample                            HA             
abbreviation            (mg/nmole) 
   ADH 
(mg/μmole) 
   EDC 
(mg/μmole) 
pH         Formation of        
hydrogel             
HG1                          4.0/2.5 0.25/1.43 0.26/1.36 5.5    Solution       
HG2                          4.0/2.5 0.5/2.87 0.6/3.12 5.5            Solution 
HG3                          4.0/2.5 1.5/8.6 1.6/8.35 5.5            Solution 
HG4                          4.0/2.5 3.5/20.1 3.6/18.8 5.5            Solution 
HG5                          4.0/2.5 8.0/45.9 8.1/42.2 5.5    Solution 
HG6                          8.0/5.0 0.25/1.43 0.26/1.36 5.5    Viscous solution 
HG7                          8.0/5.0           0.5/2.87             0.6/3.12 5.5    Viscous solution 
HG8                          8.0/5.0 2.5/14.3 2.6/13.6 5.5    Viscous solution 
HG9                          8.0/5.0 3.5/20.1 3.6/18.8 5.5    Viscous solution 
L1                             10.0/6.25 0.25/1.43 0.26/1.36 5.5    Self-supporting gel 
L2                            10.0/6.25 0.5/2.87 0.6/3.12 5.5    Self-supporting gel    
H1                            10.0/6.25 2.5/14.3 2.6/13.6 5.5    Self-supporting gel 
H2                            10.0/6.25 3.5/20.1 3.6/18.8 5.5    Self-supporting gel 
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and culture. Table 2.2 summarises the critical conditions for the formation of HA-ADH hydrogels 
and their gelation time. 






Self-supporting hydrogels were prepared at four different crosslinking densities as shown in Figure 
2.12. Briefly, HA sodium salt (10 mg, 6.25 nmoles) were dissolved in deionised water in a glass vial 
with inner diameter 12 mm and different molar ratios of ADH and EDC were added and gelation 
was allowed to occur with gentle vortexing. The transition from the solution (viscous) to the gel 
phase was monitored by the test tube inversion method as reported by Gupta et al [89]. The gelation 
time was determined as the time at which the gel did not flow and it was mainly dependent on the 
crosslinking density of the hydrogels. The higher crosslinking density of the hydrogels, the shorter 
gelation time observed.  
    
                                                   
                                 
    
Figure 2.12: A. Photo of HA-ADH precursor solution before gelation. HA-ADH precursor solution is a viscous 
solution. B. Photos of HA-ADH hydrogels at four different crosslinking densities. The transition from the 
solution (viscous) to the gel phase was monitored by the test tube inversion method.  
The successful crosslinking reaction of the HA with ADH was characterised by Fourier Transform 
Infrared Spectroscopy (FT-IR) as presented in Figure 2.13 and it will be further discussed in Chapter 
3. Briefly, FT-IR spectroscopy was performed on HA, ADH and HA-ADH lyophilised hydrogel 
(xerogel) in order to confirm any changes in the structure of the HA backbone. In the spectrum of 
HA-ADH xerogel, the peak at 1686 cm-1 corresponds to the formation of a new amide bond (C=O 
stretch of secondary amide) and the peak at 1558 cm-1 is assigned to stretching vibration of N-H 
bond. 
Sample                          HA 
abbreviation            (mg/nmole)     
    ADH 
(mg/μmole) 
     EDC 
(mg/μmole) 
pH         Gelation time 
 (minutes)           
L1                          10. /6.25 0.25/1.43 0.26/1.36 5.5          4  
L2                          10. /6.25 0.5/2.87 0.6/3.12 5.5                  3      
H1                          10. /6.25 2.5/14.3 2.6/13.6 5.5                  2 
H2                          10. /6.25 3.5/20.1 3.6/18.8 5.5                  2 
A B Self-supporting HA-ADH hydrogels 
L1 L2 H1 H2 
Gelation 





Figure 2.13: FT-IR spectra of native HA, ADH and HA-ADH xerogel. FT-IR spectroscopy confirmed the 
successful crosslinking reaction of HA-ADH. 
2.3.2 Preparation of HA-BSA hydrogels at various crosslinking densities   
In an effort to optimise the formulation of the aforementioned HA-based hydrogels and decrease the 
viscosity of the precursor gelator solution which will result in better injectability of the system, 
another method of crosslinking of HA is proposed in the presence of Bovine Serum Albumin.  
Albumin is the most abundant protein in human plasma and it has numerous biochemical applications 
including ELISA (Enzyme-Linked Immunosorbent Assay) and immunohistochemistry. 
Additionally, albumin is characterised by its unique physical properties such as stability, 
biodegradability and non-toxicity that contribute to its wide use in biomedical applications [99]. BSA 
is a single polypeptide of molecular weight of 66 kDa that consists of 59 lysine residues, of which 
30-35 have primary amines that can react further with carboxylic groups and form amide bonds. In 
the literature, the chemical crosslinking of the lysine residues of BSA with different crosslinkers such 
as bis(sulfosuccinimidyl) suberate (BS3), disuccinimidyl suberate (DSS) or disuccinimidyl glutarate 
(DSG) for the characterisation of its 3D structure has been reported [100]. The 3D structure of BSA 
has been shown to be very similar to HSA (Human Serum Albumin), because the two proteins share 
76 % sequence identity [101]. On that account, BSA was chosen as the model protein for crosslinking 
with HA.     
In this work, HA was activated with EDC/sulfo-NHS and further crosslinked with the free amine 
groups that are present in the BSA molecule. Generally, sulfo-NHS is used to prepare amine-reactive 
esters of carboxylic groups for chemical crosslinking. The carboxylic groups of HA react with sulfo-
NHS in the presence of EDC, resulting in a semi-stable sulfo-NHS ester, which may then be reacted 
with primary amines to form amide bond as shown in Figure 2.14. The presence of sulfo-NHS usually 
is not necessary in carbodiimide reactions, albeit their use significantly enhances the efficiency of 































          
Figure 2.14:  Plausible mechanism of crosslinking with EDC in the presence of sulfo-NHS. EDC activates the 
carboxylic group of HA forming an unstable reactive O-acylisourea ester which further reacts with sulfo-NHS 
forming a semi-stable reactive NHS ester. Then the reactive ester reacts with the chosen amine forming an 
amide bond.  
The activation reaction with EDC and sulfo-NHS is most efficient at acidic pH, thus the pH of the 
HA solution was adjusted at pH 6.0 with the addition of HCl 0.1 M. Table 2.3 summarises the 
different molar ratios of EDC/sulfo-NHS that were investigated for the preparation of HA-BSA 
hydrogels at different crosslinking densities. 
Table 2.3: Summary of crosslinking reactions of HA with BSA at different molar ratios in the presence of 
EDC/Sulfo-NHS.   
 
As shown in Table 2.3, self-supporting hydrogels were formed at specific ratios of EDC/sulfo-NHS 
and BSA using an initial concentration of HA at 5 mg/mL. These hydrogels (HB10-HB15 samples) 
presented poor mechanical properties (data are not shown), therefore, higher concentration of HA (6 
Sample 
abbreviation 




    EDC 
(mg/μmole) 
    BSA 
(mg/nmole)    
 pH     Formation of hydrogel                          
HB1        4.0/2.5            0.5/2.3 2.0/10.4     2.0/30.0  6.0    Solution       
HB2        4.0/25             0.5/2.3 2.0/10.4     5.0/75.7       6.0    Solution 
HB3        4.0/2.5            0.5/2.3 2.0/10.4   10.0/151.0     6.0    Solution 
HB4        4.0/2.5            0.5/2.3 2.0/10.4   15.0/ 227.0    6.0    Solution 
HB5        5.0/3.1 1.25/5.86 5.0/26.1    2.0/30.0  6.0    Viscous solution 
HB6        5.0/3.1         1.25/5.86 5.0/26.1    5.0/75.7  6.0    Self-supporting gel 
HB7        5.0/3.1            1.25/5.86            5.0/26.1  10.0/151.0  6.0    Formation of aggregate 
HB8        5.0/3.1          1.25/5.86 5.0/26.1  15.0/227.0  6.0    Formation of aggregate 
HB9        5.0/3.1            0.5/2.3 2.0/10.4  2.0/30.0  6.0    Viscous solution 
HB10        5.0/3.1 2.5/11.5 10.0/52.2  2.0/30.0  6.0    Self-supporting gel 
HB11        5.0/3.1 3.75/17.2 15.0/78.2  2.0/30.0  6.0    Self-supporting gel 
HB12        5.0/3.1 0.5/2.3 2.0/10.4  3.0/45.4  6.0    Self-supporting gel 
HB13        5.0/3.1 1.25/5.86 5.0/26.1  3.0/45.4  6.0    Self-supporting gel 
HB14        5.0/3.1 2.5/11.5 10.0/52.2  3.0/45.4  6.0    Self-supporting gel 
HB15        5.0/3.1 3.75/17.2 15.0/78.2  3.0/45.4  6.0    Self-supporting gel 
HB16        6.0/3.7 0.5/2.3 2.0/10.4  3.0/45.4  6.0    Self-supporting gel 
HB17        6.0/3.7 1.25/5.86 5.0/26.1  3.0/45.4  6.0    Self-supporting gel 
HB18        6.0/3.7 2.5/11.5 10.0/52.2  3.0/45.4  6.0    Self-supporting gel 
HB19        6.0/3.7 3.75/17.2 15.0/78.2  3.0/45.4  6.0    Self-supporting gel 
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mg/mL) was used for the fabrication of mechanically robust hydrogels. Finally, four different 
crosslinking densities of HA-BSA hydrogels were further investigated and the characterisation of 
their physicochemical and mechanical properties will be discussed in Chapter 3. Table 2.4 presents 
the four chosen HA-BSA crosslinked hydrogels and their gelation time. The gelation time was 
determined as the time at which the gel did not flow and it was dependent on the crosslinking density 
of the hydrogels.    
Table 2.4: Critical conditions for the preparation of HA-BSA hydrogels at different crosslinking densities. 
 
Self-supporting hydrogels were prepared at four different crosslinking densities as presented in 
Figure 2.15. The transition from the solution to the gel phase was monitored by the test tube inversion 
method as described earlier. The precursor gelator solution underwent instant gelation once the pH 
of the reaction mixture was adjusted at pH 6.0 under gentle vortexing.    
 
                                     
Figure 2.15: A. Photo of HA-BSA solution before gelation. Photos of HA -BSA hydrogels prepared at different 
crosslinking densities, B. HB16, C. HB17, D. HB18 and E. HB19 hydrogel. The transition from the solution 
to the gel phase was monitored by the test tube inversion method. 
The successful crosslinking reaction of the HA with BSA was confirmed by FT-IR spectroscopy as 
shown in Figure 2.16. Briefly, FT-IR spectroscopy was performed on HA, BSA and HA-BSA 
xerogel in order to confirm the presence of characteristic peaks of HA and BSA in the HA-BSA 
conjugate. In the spectrum of HA-BSA xerogel, the main differences compared to that of the 
unmodified HA focused on the appearance of a peak at 1714 cm-1 which corresponds to the formation 
of an amide bond (C=O stretch of secondary amide), indicative of the successful crosslinking of HA 
with BSA. Additionally, the sharp peaks at 1676, 1556 and 1243 cm-1 assigned to C=O, N-H and C-
N stretching vibrations of the amide bonds respectively, confirmed the presence of BSA in the 
structure of the xerogel.  
Sample 
abbreviation 




     EDC 
(mg/μmole) 
     BSA 
(mg/nmole)    
       pH    Gelation time  
      (minutes) 
HB16       6.0/3.7    0.5/2.3 2.0/10.4  3.0/45.4        6.0             2 
HB17       6.0/3.7    1.25/5.86 5.0/26.1  3.0/45.4        6.0             3 
HB18       6.0/3.7    2.5/11.5 10.0/52.2  3.0/45.4        6.0             6 
HB19       6.0/3.7    3.75/17.2 15.0/78.2  3.0/45.4        6.0             8 
Precursor solution Self-supporting HA-BSA hydrogels 
Gelation 




Figure 2.16: FT-IR spectra of native HA, BSA and HA-BSA xerogel. FT-IR spectroscopy confirmed the 
successful crosslinking reaction of HA-BSA. 
2.3.3 Preparation of MC hydrogels in different compositions of PBS solution  
MC is a biocompatible FDA approved material and is useful for numerous applications due to its 
mild gelation conditions. Its physicochemical properties allow gelation at physiological conditions 
and also injection as liquid precursor which turns into gel in any shape of cavity at body temperature. 
In 1997, Wells et al demonstrated that MC could promote nerve regeneration in peripheral nerve 
conduits, which indicated the potential of MC in brain tissue engineering [102]. Similarly, Tate et al 
investigated the use of injectable MC hydrogels for the repair of brain defects [103]. MC 
demonstrated low viscosity at room temperature, whereas at 37 °C a soft hydrogel was formed in the 
presence of salts. Subsequently, this minimally invasive polymer matrix was injected in the injury 
cavity in the brain of rats and its biocompatibility was assessed, highlighting the potential of this 
polymer in brain tissue engineering.  
As described above, MC presents several advantages as injectable material in the brain tissue 
engineering, due to its mild gelation properties and the facile fabrication of hydrogels. Therefore, in 
this study MC hydrogels were prepared using various concentrations of the polysaccharide in PBS 
solution of different salt concentration in order to identify the optimal conditions for the formation 
of self-supporting hydrogels at 37 °C that will promote cell adhesion. Table 2.5 summarises the 
different concentrations of MC in different compositions of PBS solution that were investigated and 














































Table 2.6 summarises the different compositions of PBS solution that they were used for the 
preparation of MC hydrogels and the corresponding concentrations of the salts. 





Briefly, different concentrations of MC solutions were prepared in PBS in glass vials with inner 
diameter 12 mm and they were placed in a GrantTM digital block heater for the precise heating of the 
vials. The heating rate was 1 °C per min and the gelation behaviour was monitored by inversion of 
the vials. The transition from the solution to the gel phase was validated qualitatively by the test tube 
inversion method as described earlier and as shown in Figure 2.17. The gelation temperature was 
determined as the temperature at which the gel did not flow with inversion of the vial. Different 
phase transitions of the solutions at various temperatures were observed and can be classified into 
three distinct phases: clear solution, formation of soft gel and white, phase-separated gel. The 
transparency of MC hydrogels also decreased as the concentration of MC and salts increased as 
demonstrated in Figure 2.17. 
It is widely known that MC is soluble in aqueous solutins at low temperatures due to the presence 
of ʺcagelikeʺ water structures or hydrogen bonds surrounding MC chains. At higher temperatures, 
these structures are destroyed upon heating, leading to the formation of hydrophobic aggregates and 
the subsequent formation of a gel network. As shown in Table 2.5, all MC compositions presented 
gelation temperature below body temperature except for the second one, which turned into gel at 
higher temperature. The gelation temperature was highly dependent on the composition of PBS and 
the concentration of MC in the aqueous solutions. It has been reported that the gelation behaviour of 
MC is affected by salts concentration that are present in the solution. More specifically, Na2HPO4 
MC Concentration 
  (% w/w)                       
      PBS 
Composition 
   Gelation 
Temperature (°C) 
Formation of hydrogel 
 
           2                      1×PBS        - Viscous solution 
           4                    1×PBS       42 Self-supporting hydrogel 
           6                       1×PBS       37 Self-supporting hydrogel 
          8                 1×PBS       34 Self-supporting hydrogel 
           2               5×PBS       35 Self-supporting hydrogel 
           4              5×PBS       32 Self-supporting hydrogel 
           6                          5×PBS                   30 Self-supporting hydrogel 
           2           10×PBS       28    Self-supporting hydrogel 
           4          10×PBS       25 Self-supporting hydrogel 
 
PBS composition        
  Na2HPO4  
Concentration 
      (M)  
   KH2PO4 
Concentration 
         (M) 
     NaCl 
Concentration 
       (M) 
       KCl 
Concentration 
       (M) 
 
pH 
           1×PBS                 0.0043            0.00147        0.137        0.0027 7.4 
           5×PBS              0.0215     0.00735              0.685                  0.0135        7.4 
         10×PBS            0.043    0.0147            1.37        0.027 7.4 
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and NaCl salts present strong polar interactions with water in the MC solution and consequently, the 
degree of polar interactions affects the gelation behaviour of MC. In this study, it was observed that 
the higher the concentration of the salts present in the MC solutions, the lower gelation temperature 
for MC solutions. Ions such as Clˉ tend to draw water molecules away from the MC polymer chains, 
as they can attract more water molecules to surround them due to their strong hydration abilities, 
leading to a poorer solubility of MC in water upon heating. As a result, there are more hydrophobic 
MC aggregates facilitating the formation of a gel network at lower temperatures.   
   
    
                       
 
         
Figure 2.17: Photos of MC hydrogels. A. MC precursor solution , B. 2 % w/w MC in 1×PBS, C. 4 % w/w MC 
in 1×PBS, D. 6 % w/w MC in 1×PBS, E. 8 % w/w MC in 1×PBS, F. 2 % w/w MC in 5×PBS, G. 4 % w/w 
MC in 5×PBS, H. 6 % w/w MC in 5×PBS, I.  2 % w/w MC in 10×PBS, J. 4 % w/w MC in 10×PBS. The 
transparency of MC hydrogels decreased as the concentration of MC and salts increased. Due to the light 
artifacts, this is not clearly presented in the above photos.                                          
The gelation mechanism of MC has been studied extensively including two main steps as described 
by Kobayashi et al [104]. Clustering of MC chains occurs which is driven by hydrophobic 
association, while at higher temperature the gelation is associated with liquid-liquid phase separation. 
Kato et al proposed that the association at low temperatures is addressed by aggregation of the most 
hydrophobic groups, whereas at high temperatures, the association is mainly caused by less 
hydrophobic groups [105]. At lower temperatures, water molecules in the presence of salts are 
attracted from ions and this results in hydrophobic association as stated above. The hydrogen bonds 
between water molecules and MC can be stronger than those at high temperatures and consequently 
water molecules will return to the hydrophobic groups progressively. In the presence of salts, the 
hydrophobic interactions are promoted from the salt-out effect and the strength of these interactions 
are highly dependent on the nature of the ions. 
Heating 
Self-supporting MC hydrogels 
 MC precursor     
solution 
A C D E 




2.3.4 Preparation of different compositions of blend XG/MC hydrogels 
Various blend hydrogels that combine two or more components with complementary shear thinning 
properties have been reported in the literature [106]. This group of hydrogels possesses the 
advantages of low cost, easy preparation and improved mechanical properties. Xanthan gum (XG) is 
a biocompatible and biodegradable high molecular weight anionic polysaccharide and is mainly 
produced from bacterial fermentation [107]. It consists of D-glucosyl, D-mannosyl, and D-
glucuronyl acid residues in a 2:2:1 molar ratio and various ratios of O-acetyl and pyruvyl residues a 
shown in Figure 2.18. 
 
Figure 2.18: Chemical structure of xanthan gum which consists of D-glucosyl, D-mannosyl, and D-glucuronyl 
acid residues. 
In aqueous solutions, XG adopts two different conformations. At low temperatures it obtains an 
ordered and rigid double helical conformation, whereas at high temperatures a disordered and 
flexible coil structure prevails [108]. XG forms a 3D network when the temperature is below its 
midpoint transition temperature (Tm) and it shows a weak gel-like behaviour. Dyondi et al prepared 
an injectable hydrogel from a blend of gellan gum and XG for growth factor delivery for bone 
regeneration, highlighting its potential as an injectable scaffold in tissue engineering [109].   
Herein, commercially available XG and MC were used in order to prepare injectable, biocompatible 
blend XG/MC hydrogels. XG/MC blend solutions were prepared at different compositions in 1×PBS 
(pH 7.4) as summarised in Table 2.7 and the gelation properties were investigated. The transition 
from the solution to the gel phase was validated qualitatively by the test tube inversion method as 
described earlier and as shown in Figure 2.19. The gelation temperature was determined as the 
temperature at which the gel did not flow and it was highly dependent on the concentration of XG 
and MC in the blend solution. As described earlier, different compositions of XG/MC solutions were 
prepared in PBS as shown in Table 2.7 in glass vials with inner diameter 12 mm and they placed in 
a GrantTM digital block heater for the precise heating of the vials. The heating rate was 1 °C per min 




Table 2.7: XG and MC concentrations in various blend solutions of XG/MC in 1×PBS. 
 
All XG/MC compositions presented gelation temperature below body temperature as it was 
determined by the test tube inversion method. In addition, it can be concluded that the addition of 
XG decreased the gelation temperature of MC. 
 
                                                 
                            
                                                     
Figure 2.19: Photos of blend XG/MC hydrogels. A. Precursor solution of XG/MC, B. XG1/MC0, C. 
XG1/MC3, D. XG1/MC6, E. XG1/MC8, F. XG2/MC1, G. XG2/MC6, H. XG3/MC1 in 1×PBS.  
XG contains carboxylic groups that could induce dehydration of the MC and thus decrease the 
gelation temperature of MC [89]. Additionally, the presence of salts in PBS cause dehydration of 
MC which results in lower gelation temperature for MC as explained in section 2.3.3. XG solutions 
present a weak gel behaviour and sheer thinning properties due to the 3D network formed by the 
helical conformation, while MC possesses thermal gelation properties. MC was used in higher 
concentration than XG in the blend solutions thus the 3D network of XG is partially interrupted from 
the MC molecules. In blend solutions, both components keep their own structures and their 




        MC 
Concentration 
  (% w/w)                   
        XG 
Concentration 
   (% w/w) 
   Gelation 
temperature 
      (°C) 
      
     Formation of hydrogel 
XG1/MC0            0                         1           -       Self-supporting hydrogel 
XG1/MC3            3                           1          35       Self-supporting hydrogel 
XG1/MC6           6                       1          34       Self-supporting hydrogel 
XG1/MC8            8                   1          29       Self-supporting hydrogel 
XG2/MC1            1                    2          37       Self-supporting hydrogel 
XG2/MC6            6                            2                             28       Self-supporting hydrogel 
XG3/MC1            1              3          32       Self-supporting hydrogel 
heating 
Precursor solution Self-supporting hydrogels 
A B C D E 
F G H 
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up, the results demonstrated that the blend solutions of XG/MC are viscous at room temperature and 
after heating they form self-supporting hydrogels below body temperature, indicating their potential 
as injectable scaffolds.  
2.3.5 Preparation of different compositions of blend HA/MC hydrogels 
Blends of polysaccharides represent an emerging class of biomaterials due to the merge of the 
advantages of each component. The investigation of polysaccharide-based blend solutions that can 
form hydrogel network upon heating continued with the preparation of blend solutions composed of 
HA of high molecular weight and MC. HA/MC blend solutions can form hydrogels due to the 
dehydration of MC induced by the carboxylic groups of HA. HA as sodium salt when it is dissolved 
in water it is ionised and induces the salt-out effect which contributes to the development of 
hydrophobic interactions. Moreover, the addition of HA increases the viscosity of the MC solution 
by increasing the number of molecular entanglements. Recently, Shoichet et al developed an 
injectable blend hydrogel composed of HA and MC for drug delivery to the injured spinal cord [89]. 
They prepared different compositions of HA/MC blend solutions and they evaluated the injectability 
of the scaffold and its biocompatibility in vivo studies which showed that HA/MC is biocompatible 
in the intrathecal space. Blends of HA and MC have also been used for various applications, including 
wound healing and stroke repair [110], [111].  
One specific aim of this work was to investigate the effect of HA of high molecular weight on the 
thermogelation and biocompatibility of its blends with MC. The rationale was to investigate a new 
possible scaffold for trapping glioma cells. MC is known for its thermoresponsive behaviour, while 
HA for its biocompatibility and biodegradability. HA/MC blend solutions were prepared at different 
compositions as summarised in Table 2.8 and they were evaluated for their gelation properties upon 
heating. 
Table 2.8: XG and MC concentrations in various blend solutions of HA/MC. HA and MC were not used at 









In section 2.3.4, it was stated that XG/MC blend solutions are viscous solutions at 4 °C and they turn 




       HA 
Concentration 
   (% w/w) 
      MC     
Concentration 
  (% w/w)                    
 
Formation of hydrogel 
HA0.25/MC0.5         0.25        0.5                         Solution 
HA0.5/MC0.5         0.5        0.5         Solution 
HA0.5/MC1         0.5        1.0                           Solution 
HA0.5/MC3         0.5        3.0                       Solution 
HA0.75/MC0.75         0.75        0.75         Solution 
HA1/MC2         1.0        2.0              Viscous solution 
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heating they remain solutions and no formation of gel network was observed. The concentration of 
HA in the blends of HA/MC was chosen to be less than 1 % w/w as it was noticed that the 
manipulation of the precursor solution was really difficult due to high viscosity at higher 
concentrations. Finally, blend HA/MC solutions will not be studied further due to their poor gelation 
properties. 
2.4 Conclusions 
The first sections of this chapter aimed to provide a literature review on the hydrogels used for 
biomedical applications and their unique properties and versatility over other materials. Particular 
focus was given to polysaccharide-based hydrogels as potential scaffolds for attracting and trapping 
glioma cells. Scaffolds prepared from natural polysaccharides are promising biomaterials for 
mimicking the in vivo tumour microenvironment due to the fact that they structurally resemble 
glycosaminoglycans which are main components of the ECM. In the first experimental section of 
this work, HA was chosen as the main component for the preparation of hydrogels due to its unique 
advantages and structural versatility over other polysaccharides. HA is one of the main constituents 
of the brain ECM and is closely related to the proliferation and migration of GBM cells. Chemical 
modification of its backbone allows the formation of 3D polymeric hydrophilic networks that present 
viscoelastic properties similar to the elastic modulus of the brain tissue.  
Herein, an inexpensive and relatively simple preparation of hydrogels based on HA was proposed. 
Hydrogels were prepared by amidation reaction of the free carboxylic groups of HA in the presence 
of EDC as crosslinking agent and ADH as crosslinker. HA of high molecular weight was chosen and 
it was crosslinked with different molar ratios of ADH and EDC. Transparent self-supporting HA-
ADH hydrogels obtained at four different crosslinking densities and the characterisation of their 
physicochemical and mechanical properties will be discussed in Chapter 3 in order to identify the 
optimal crosslinking density that promotes cell adhesion. Moreover, in an effort to optimise the 
aforementioned formulation of hydrogels and improve the injectability of the formulation, another 
method of crosslinking of HA was developed in the presence of BSA. Taking into consideration the 
free primary amines that are present in lysine residues of the BSA molecule and the size of this 
protein, we proposed the potential crosslinking reaction of the carboxylic groups of HA with the 
primary amines of BSA which will result in the formation of amide bonds and the fabrication of a 
3D network. HA-BSA self-supporting hydrogels were prepared at different crosslinking densities 
and they will be further characterised in the following chapter.    
Furthermore, in the second experimental section of this chapter we investigated the use of MC for 
the fabrication of injectable hydrogels. MC presents several advantages as injectable material in the 
brain tissue engineering, due to its mild gelation properties. MC-based hydrogels were prepared using 
various concentrations of MC in PBS solutions of different salt concentration in order to identify the 
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optimal conditions for the formation of self-supporting hydrogels at 37 °C. It can be concluded that 
the concentration of MC and the composition of PBS affects the gelation behaviour of the 
polysaccharide. The preparation of blend hydrogels based on MC was investigated due to the fact 
that this group of hydrogels benefits from the physicochemical properties of each component. Blend 
solutions of XG/MC were successfully prepared at different compositions and their gelation 
properties were investigated upon heating, while HA/MC solutions presented poor gelation 
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Chapter 3: Physicochemical and mechanical characterisation of hydrogels 
3.1 Introduction 
The characterisation of the physicochemical and mechanical properties is of paramount importance 
in determining if a material is suitable for a specific application. As discussed in Chapter 2, hydrogels 
are crosslinked hydrophilic polymeric networks that can be prepared by physical or chemical 
crosslinking methods using natural or synthetic polymers. In the former case, hydrogels are prepared 
by the formation of physical bonds including hydrogen bonds, ionic or hydrophobic interactions. In 
the latter case, hydrogels are formed by covalent interactions between the polymer chains. The 
physicochemical and mechanical properties of the hydrogels are highly dependent on the method of 
crosslinking. Thus, the characterisation of the properties of hydrogels designed for biomedical 
applications is imperative.  
The aim of this chapter is to present and discuss several experimental methods devoted to the 
characterisation of the fabricated hydrogels as described in Chapter 2. In particular, attention will be 
focused on the determination of swelling degree, characterisation of the surface morphology using 
Scanning Electron Microscopy, determination of the enzymatic degradation rate i vitro conditions, 
characterisation of the mechanical properties using oscillatory rheology and investigation of the drug
release profile. 
3.1.1 Characterisation of hydrogels by Fourier-Transform Infrared Spectroscopy  
FT-IR (Fourier-Transform Infrared Spectroscopy) is a useful technique for the study of structural 
changes occurring during the formation of hydrogels. The principle of FT-IR spectroscopy relies on 
the fact that chemical bonds can be excited and absorb infrared light at specific frequencies which 
are typical of the chemical bonds. On the interaction with the infrared light, chemical bonds stretch, 
contract or bend in a specific wavelength as mentioned above. This technique is widely used to 
investigate structural changes and confirm the presence of specific chemical groups in the hydrogel 
network compared to the main components of the hydrogel [1], [2]. 
3.1.2 Scanning Electron Microscopy 
To date, various imaging techniques have been applied to study the surface morphology of the 
hydrogels. Hydrogels morphology is usually investigated by Scanning Electron Microscopy (SEM) 
[3] as shown in Figure 3.1. This type of microscopy provides a large depth of field and a range of 
magnifications that allow to easily focus on the area of interest. SEM provides information about the 
surface morphology and the porosity of the hydrogels. In addition, estimation of the pore size and 
relevant information regarding the homogeneity or heterogeneity of the hydrogel network can be 
obtained from SEM analysis. SEM under standard operating conditions, requires lyophilisation of 
the hydrogel sample. Although, this method is not representative of the native state of the hydrogel 
structure, it is indicative of the morphology and porosity of the hydrogel. Lyophilised hydrogels are 
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usually coated before SEM analysis, in order to increase the conductivity of the sample. Typically, 
hydrogels are coated with a thin layer of a conductive metal such as chromium, palladium or gold.  
 
Figure 3.1: Schematic illustration of HA-based hydrogel and SEM image of its lyophilised form. SEM 
provides information on the morphology and porosity of the hydrogels. 
3.1.3 Swelling studies 
Due to their hydrophilic nature, hydrogels have the capacity to absorb large quantity of water, without 
the dissolution of the polymer as illustrated in Figure 3.2. During swelling, hydrogels as hydrophilic 
crosslinked structures continue to demonstrate properties of solid-like materials and present physical 
features similar to soft tissues [4]. The swelling capacity of hydrogels is highly dependent on the 
crosslinking density which defines the space within the polymer network [5]. In the case of highly 
crosslinked hydrogels, the swelling behaviour is mainly controlled by the diffusion mechanism.  
 
Figure 3.2: Schematic illustration of swelling process in a hydrogel network. Hydrogels due to their 
hydrophilic nature, absorb large amount of water and expand their volume. 
The swelling process depends on the rate at which the water molecules can diffuse into the hydrogel 
network structure. For example, low crosslinked hydrogels demonstrate higher swelling capacity 
compared to high crosslinked hydrogels. In a polysaccharide-based hydrogel, the swelling is a 
consequence of the interactions between polymer and water molecules which increase with the 
hydrophilicity of the macromolecules. The swelling characteristics are of paramount importance in 
biomedical and pharmaceutical applications particularly in case of injectable hydrogels for tissue 
engineering. The determination of the swelling equilibrium of a hydrogel is necessary as 
uncontrollable swelling can cause adverse effects on the area of the injection.   
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When equilibrium in swelling of a hydrogel is reached, two opposing forces take place according to 
Flory and Rechner [6]. One is the thermodynamic force derived from the polymer-water mixing and 
contributes to swelling. While the other is the elastic force stored in the polymer chains preventing 
the swelling [7]. At equilibrium swelling, these two forces balance each other as described in the 
following equation (1) in terms of total Gibbs free energy:   
                                                     ΔGtotal = ΔGelastic + ΔGmixing            (1) 
ΔGelastic  arises from the elastic forces stored in the polymer chains and ΔGmixing comes from the mixing 
of the polymer chains with the water molecules. In terms of chemical potential, the above equation 
is modified as bellow (2):  
                                                   Δμtotal = Δμelastic + Δμmixing               (2)  
Ιn the equilibrium state, the chemical potential outside the hydrogel should be equal with that inside 
the hydrogel. In the case of ionic hydrogels, an additional chemical potential factor is taken into 
consideration due to the contribution of the charged groups in the network as shown in the following 
equation (3): 
                                             Δμtotal = Δμelastic + Δμmixing + Δμionic       (3)              
In ionic hydrogels, the swelling capacity is higher and increases with the content of the ionic groups. 
The number of counterions in the hydrogel network increase and this results in an additional osmotic 
pressure which induces swelling [8]. The extent of swelling of ionic hydrogels depends on the pH of 
the aqueous media. Cationic hydrogels demonstrate increased swelling in low pH, whereas anionic 
hydrogels swell more in aqueous media of high pH due to chain repulsion. The swelling behaviour 
of polymers with hydrophilic backbone and hydrophobic moieties is dependent on the temperature. 
This group of hydrogels present sensitivity to temperature due to the presence of hydrogen bonds 
and hydrophobic interactions which are highly dependent on the temperature [9]. 
3.1.4 Degradation of hydrogels 
Besides swelling, the degradation of the hydrogels is another noteworthy characteristic which it 
should be taken into consideration for hydrogels designed for biomedical applications [10]. 
Controlled degradation of hydrogels is significantly desirable for biomedical purposes including soft 
tissue engineering and controlled drug release. Hydrogels are usually composed of degradable 
polymeric backbones, degradable side groups or degradable crosslinkers which allow degradation of 
the matrix. The degradation rate of the hydrogel network is highly dependent on the specific 
application of the degradable hydrogel. For example, for controlled release applications rapid 
degradation of the drug loaded hydrogel results in rapid release of the drug which can be desirable 
or cytotoxic depending on the specific application. Regarding tissue engineering applications, the 
degradation rate of the matrix should match the rate of formation of the new tissue [11]. The 
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degradation rate of the scaffold can be controlled by increasing the crosslinking density which results 
in smaller pores size, increased mechanical resistance and consequently slower degradation. Smaller 
pores size limits the penetration of the degradable molecules such as enzymes within the hydrogel 
due to lower diffusion rate [12]. The rate of degradation can be influenced by the chemical nature of 
the degradable crosslinker which is conjugated to the hydrogel. For example, side chains conjugated 
to the polymer backbone including esters, amides or ethers can be degraded by hydrolysis [13]. 
Hydrogels can be degraded by several mechanisms including enzymatic degradation, hydrolysis, 
reversible click reactions or light-mediated degradation as summarised in Figure 3.3. As mentioned 
previously, synthetic hydrogels containing esters linkages can be degraded by hydrolysis resulting in 
the formation of a carboxylic acid and an alcohol. The degradation rate can be controlled by the 
crosslinking density of the network and the local pH. Thomas et al synthesised biodegradable 
crosslinkers with lactate and glycolate esters. The fabricated hydrogels consisted of specific ratio of 
crosslinker incorporated into 2-hydroxypropyl methacrylate (HPMA). The authors investigated the 
hydrolytic degradation rate of the hydrogels at 37 °C and at pH 7.4 by varying the number of lactate 
and glycolate residues [14]. Enzymatic degradation mainly takes place in hydrogels composed of 
natural polymers or proteins. The mechanism of the enzymatic hydrolysis is based on the catalytic 
role of the enzyme during the hydrolysis process. For instance, HA-based hydrogels can be degraded 
in the presence of hyaluronidase which is an enzyme that catalyses the hydrolysis of C–O, C–N and 
C–C bonds. Lee et al studied the degradation of HA-tyramine hydrogel for protein delivery in the 
presence of hyaluronidase [15]. Sustained release of the protein was observed due to the subsequent 
degradation of the hydrogel network by hyaluronidase. 
 
Figure 3.3: Different degradation mechanisms of hydrogels mainly including hydrolysis, enzymatic 




The hydrogel degradation rate can be influenced by the enzyme concentration, pH, temperature and 
the crosslinking density. Enzymatically degradable hydrogels are mainly used for targeted drug 
delivery applications due to the fact that the enzyme concentration is highly dependent on the cell or 
tissue type, which acts as trigger for the drug release. Hydrogels susceptible to enzymatic hydrolysis 
have also been used in bone regeneration and wound healing [16], [17]. 
Degradation of synthetic hydrogels induced by reversible click reactions is not commonly used 
despite their advantages on the formation of the hydrogel network. Reversible click reactions mainly 
include Michael-type addition and retro Diels-Alder cycloreversion which are necessary tools to 
mediate hydrogel degradation. Baldwin et al studied the degradation of heparin-based hydrogels 
prepared by Michael-type addition reaction between the multifunctional PEG-thiols and maleimide 
-functionalised heparin [18]. Interestingly, they found that the pKa and the hydrophobicity of the 
scaffolds affected the degradation rate of the fabricated hydrogels. In another study, Koehler et al 
investigated the degradation of PEG-maleimide-based hydrogels loaded with furan functionalised 
peptides derived from the thermally reversible Diels-Alder reaction of the furan and maleimide 
moieties. Specifically, dexamethasone was conjugated to the furan containing peptide and sustained 
release was achieved by the mediated degradation of the hydrogel [19]. 
Furthermore, hydrogels can be degraded by light-mediated hydrolysis. This degradation mechanism 
requires hydrogels composed of photoresponsive moieties. Anseth et al prepared photodegradable 
PEG-based hydrogels consisted of an acrylated nitrobenzyl ether-derived moiety attached to PEG-
bis-amine or amine-terminated peptides [20]. The hydrogel photodegradation was induced by UV 
irradiation. In another complementary study, Anseth et al studied the light-mediated degradation of 
disulfide-bonded PEG hydrogels using photoinitiators [21]. By irradiation, free radicals were formed 
from the photoinitiator which resulted in the fragmentation of the disulfide bonds and the subsequent 
hydrogel degradation.    
Degradation on hydrogels can occur by surface or bulk erosion which depends on the crosslinking 
density and the water diffusion rate or diffusion of the enzymes to the interior of the hydrogel [22]. 
Surface degradation occurs when water molecules or enzymes can not penetrate the hydrogel 
network due to the high crosslinking density, whereas bulk erosion takes place when the hydrogel 
network is degraded homogeneously. Degradation by bulk erosion is more common on hydrogels 
prepared at lower crosslinking densities.  
In summary, degradation of hydrogels can be induced by different mechanisms in accordance to their 
specific application. Ideally, the degradation rate of the hydrogels should be controlled and tunable 
in order to avoid the formation of by-products that are not biocompatible and eliminate any potential 
side effects. Importantly though, balance between the biodegradability and the mechanical properties 
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including the elastic modulus and the integrity of the scaffold is critical and fundamental to ensure 
the functionality of the hydrogel within a desirable period of time. 
3.1.5 Oscillatory rheology 
The mechanical characterisation of the hydrogels is of significant importance for several biomedical 
applications such as tissue engineering. The viscoelastic properties of the hydrogels should be similar 
to the mechanical characteristics of the tissue since cellular activities such as adhesion, migration 
and differentiation are highly dependent on the stiffness of the matrix as it will be discussed further 
in Chapter 4. Undoubtedly, hydrogels are complex systems and their rheological characterisation is 
an important tool to investigate further their properties and evaluate their potential use in various 
biomedical applications. Their hydrophilic nature contributes to their soft and viscoelastic 
consistency which closely resembles the mechanical properties of the living tissues [23], [24]. The 
structural, chemical and mechanical properties of the hydrogels can be addressed to mimic those of 
the native ECM, rendering these scaffolds as attractive biomaterials in tissue engineering as stated 
above. 
A wide range of methods have been used to characterise the mechanical properties of the hydrogels 
including tensile testing for the characterisation of the elastic behaviour, dynamic mechanical 
analysis for the characterisation of viscoelastic materials and compression tests [25], [26]. For tensile 
tests, hydrogel samples are cut and prepared into dumb-bell shape and placed between two clamps. 
The applied force and elongation of the hydrogel are used to obtain stress-strain curve and determine 
several mechanical properties including Young’s modulus. In compression testing which can be 
confined or unconfined, hydrogels are usually prepared as round samples and compressed between 
two non-porous plates as shown in Figure 3.4. Similar to the tensile test, the force and the 
displacement for the compression of hydrogels are recorded and the Young’s modulus can be 
determined. During dynamic mechanical analysis a sinusoidal stress is applied and the strain in the 
material is measured, allowing to determine the complex modulus of the hydrogels. 
 
Figure 3.4: Schematic illustration of different types of set up for the mechanical characterisation of hydrogels. 
A. Tensile testing, B. Compression, C. Confined compression and D. Dynamic mechanical analysis. 
A B C D 
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Oscillatory rheology is another mechanical characterisation technique that enables the investigation 
of the viscoelastic properties of the hydrogels. The principle of oscillatory rheology relies on 
measuring the stress response induced by a sinusoidal shear deformation on hydrogel at a constant 
frequency [27]. Τhe shear strain and the oscillatory stress in the hydrogel sample are described by 
the following equations (4) and (5) respectively: 
                                                             ΰ = ΰοsin(ωt)                               (4)      
                                                            τ = τοsin(ωt+δ)                           (5)    
where ω is the applied angular frequency, ΰ is the shear strain, t is the time, τ is the oscillatory stress 
and δ is the phase angle. In particular, the mechanical response in terms of shear stress is obeyed to 
the following equation (6): 
                                             τ = Ǵ (ω)ΰsin(ωt) + Ǵ ΄(ω)ΰcos(ωt)           (6)  
and it is intermediate between an ideal pure elastic solid (obeying to the Hooke’s law) and an ideal 
pure viscous liquid (obeying to the Newton’s law). G΄ is the storage or elastic modulus and provides 
information on the elasticity or the energy stored in the material during the deformation. In contrast, 
G΄΄ is the loss or viscous modulus which describes the viscous behaviour of the material or the energy 
lost as heat. The ratio between the viscous and elastic modulus defines the loss tangent or the loss 
factor as described in the following equation (7): 
                                                          tanδ = Ǵ ΄/G΄                             (7) 
The phase angle δ is equal to 90° for a viscous material, 0° for an elastic material and 0° < δ < 90° 
for viscoelastic materials. For the determination of the viscoelastic behaviour of a material, amplitude 
strain sweep experiments are performed at a constant oscillation frequency. Regarding viscoelastic 
materials such as hydrogels, both moduli are constant and strain dependent across a range of strain 
values. However, above a critical strain value ΰ, viscoelastic materials lose their nondestructive 
behaviour. Amplitude sweep tests establish the region of the linear viscoelastic behaviour and the 
determination of the strain value at which a crossover of both moduli G΄ and Ǵ΄ takes place and the 




Figure 3.5: Amplitude strain sweep experiment of a hydrogel. Typical strain dependence of the viscoelastic 
moduli within the linear viscoelastic regime. Above a critical strain value, crossover of both moduli takes place 
and the viscous behaviour is predominant. Adapted from Matricardi et al [28]. 
The viscoelastic behaviour of the hydrogels is also characterised by the frequency dependence of the 
viscoelastic moduli Ǵ and Ǵ΄. Οn this account, frequency sweep experiments are performed by 
keeping constant the oscillation amplitude strain within the linear viscoelastic regime (LVR) 
determined by performing the amplitude sweep experiment. In case of hydrogels, both G΄ and Ǵ ΄ 
are almost independent of the frequency and the elastic modulus G΄ is much higher than the viscous 
modulus Ǵ΄ as demonstrated in Figure 3.6. Frequency sweep experiments have proved to be 




Figure 3.6: Frequency sweep experiment of a hydrogel conducted in a range of frequency from 0.01 to 10 Hz 
keeping constant the LVR strain amplitude determined by performing the amplitude sweep experiment before. 
Both moduli are almost independent of the frequency and G΄ is greater than Ǵ́ confirming the viscoelastic 





3.1.6 Differential Scanning Calorimetry 
The thermal behaviour of hydrogels is mostly assessed by Differential Scanning Calorimetry (DSC). 
As illustrated in Figure 3.7, DSC is a thermoanalytical technique which allows the measurement of 
the difference in the amount of heat required to increase the temperature of a sample and a reference 
as function of temperature [30]. Both the sample and the reference are maintained at the same 
temperature during the experiment. Depending on the physical transformations such as phase 
transitions that a sample can undergo, more or less heat is required to it than to the reference to keep 
both at the same temperature. Specifically, when more heat flow to the sample is required then an 
endothermic phase transition takes place, while when less heat flow is required to increase the 
temperature of the sample, an exothermic transition exists.   
 
 
Figure 3.7: Illustration of set-up of a differential scanning calorimeter. It consists of a sample pan where the 
sample is inserted and a reference pan (typically empty). Both pans are maintained at the same temperature 
during the experiment. Adapted from reference [31]. 
The thermal transitions that are usually observed in hydrogels, take place due to the presence of 
different states of water in the hydrogel network. In particular, two types of water can be found in 
the hydrogel, including the bound and the free state. The bound state exists when the water molecules 
are attached to the polymer chain via the development of hydrogen bonds, while in the free water 
state the molecules of the water do not interact with the polymer [32]. In case of hydrogels, DSC 
thermographs usually demonstrate changes in the glass transition temperature (Tg) for crosslinked 
hydrogels and their initial components. For example, Zarzyka et l studied the influence of 
crosslinker on the glass transition temperature of poly (N-isopropylacrylamide) and poly (sodium 
acrylate) hydrogels using conventional DSC [33]. They observed that the addition of crosslinker 
resulted in an increase in the Tg of the polymer and the transition range became broader. These 
observations can be explained by the fact that the higher crosslinking density reduces the mobility of 
the polymer chains, so that the glass transition temperature increases. Overall, conventional DSC is 





3.1.7 Drug release from hydrogels 
In the last decades, due to their unique tunable physical properties, hydrogels have attracted 
significant attention in drug delivery applications for the treatment of various types of cancer [34]. 
Their hydrophilic nature and the structural resemblance to tissues contribute to their potential as drug 
delivery carriers. Their highly porous structure also allows the loading of drugs into the hydrogel 
matrix which protects labile drugs from degradation. In addition, their controllable degradability 
induces the release of the encapsulated drugs in a controlled manner which is highly dependent on 
the diffusion coefficient of the drug molecules through the hydrogel network. The release of the 
therapeutic agents from hydrogels mainly occurs through three main mechanisms including 
diffusion-controlled mechanism, swelling-controlled and degradation-controlled mechanism [35], as 
illustrated in Figure 3.8. 
  
 
Figure 3.8: Illustration of mechanisms of drug release from hydrogels. Drugs can be released from hydrogels 
through three main mechanisms including diffusion-controlled, swelling-controlled and degradation- 
controlled mechanism with subsequent diffusion.  
The diffusion is the most common mechanism for the controlled release of drugs from hydrogels. 
The rate of drug release depends on the crosslinking density and external stimuli such as pH and 
temperature. In addition, the mesh size of the hydrogels determines how quickly a drug can be 
released from the 3D matrix. The mesh size is the distance between the crosslinking points. For 
example, when the mesh size is larger than the drug molecule then the small drug molecules can be 
easily diffused through the network. In swelling-controlled mechanism, the diffusion of the drug is 
faster than the swelling. As discussed previously, the extent of the swelling is dependent on the 
crosslinking density of the hydrogels and the presence of external stimuli including ionic strength, 
pH and temperature. For example, in oral drug delivery systems the pH responsive swelling of the 
hydrogel is of paramount importance. In the acidic environment of the stomach, the swelling of the 









drug loaded hydrogels is negligible which protects the physically entrapped drug. In contrast, in 
neutral pH in intestinal tract a dramatic increase in swelling occurs which allows the burst release of 
the drug. The pH triggered release is also used in the targeted drug delivery to tumours where the 
environment is more acidic than the normal tissues which allows the diffusion of the drug to the 
tumour site. The controlled network degradation is another mechanism that induces the release of 
drugs entrapped in hydrogels. Hydrogels can be degraded by hydrolysis or enzymatic activity that 
results in the increase of mesh size allowing the drugs to diffuse out from the hydrogel network. 
3.2 Experimental  
3.2.1 Materials  
Hyaluronic acid (hyaluronic acid sodium salt, from Streptococcus equiv. MW = 1.5 -1.8 mDa) and 
ADH (MW = 174.2 Da) were purchased from Sigma Aldrich. EDC (MW = 191.7 Da) and Sulfo-
NHS (MW = 217.13 Da) were purchased from TCI Europe. BSA (lyophilised powder, ≥ 98 %, MW 
= 66 kDa), Methyl cellulose (MC, suitable for cell culture, MW = 14 kDa, viscosity: 15 cPs, D.S 1.5-
1.9), Xanthan gum (XG) from Xanthomonas campestris (viscosity = 800-1200 cPs) all were 
purchased from Sigma Aldrich. Phosphate buffer saline tablets were purchased from Fischer 
Scientific. Hyaluronidase from bovine testes was purchased from Sigma Aldrich. Human Urotensin 
UII (MW = 1388. 55 Da) and FITC-UII (MW = 1777 Da) were purchased from PolyPeptide 
Laboratories. TMZ (MW = 194.15 Da) and DOX HCl (MW = 543.52 Da) were purchased from 
Sigma Aldrich. Aluminum crucibles with lids for DSC analysis were purchased from Mettler Toledo. 
3.2.2 Methods  
3.2.2.1 Lyophilisation- Preparation of xerogels 
Lyophilisation or freeze-drying has been extensively used for the fabrication of porous hydrogels in 
order to characterise further their morphology, structure and thermal properties [36], [37]. This 
method involves rapid cooling of the hydrogel which results in thermodynamic instability within the 
network. Subsequently, the solvent which is mostly water is removed by sublimation under vacuum. 
In particular, hydrogels were prepared according to the protocol described in section 2.2.2.1 in small 
centrifuge tubes and then frozen by immersion in a block of dry ice at a temperature of -78.5 °C. The 
frozen hydrogels were lyophilised using a ScanVac Coolsafe freeze drier and xerogels were obtained. 
Xerogels are defined as solids formed by dehydration of hydrogels and they usually retain high 
porosity [38]. 
3.2.2.2 FT-IR spectroscopy 
The structure of the fabricated hydrogels was investigated by using a Perkin Elmer Spectrum One 
FT-IR spectrometer equipped with a diamond crystal. FT-IR spectra of the xerogels were obtained 
in the range of wavenumber from 4000 to 750 cm-1 by accumulating 16 scans. 
89 
 
3.2.2.3 SEM characterisation 
The microstructure of the hydrogels was evaluated using a FEG-SEM Hitachi SU8030 Scanning 
Electron Microscope. Prior to the SEM analysis, hydrogels were previously swollen in PBS for at 
least 24 h at 37 °C and subsequently were frozen by immersion in a block of dry ice in order to 
preserve the microstructure of the hydrogels. Frozen gels were then fractured with a scalpel and 
immediately placed on a lyophiliser for freeze drying as described in section 3.2.2.1. Subsequently, 
the hydrogels were affixed to a metal stub with carbon film and they were sputter-coated with a layer 
of gold for 2 minutes at 25 mA prior to observation using an Edwards Au coater. Several 
magnifications using accelerating voltage of 1.0 kV were obtained to study further the surface 
morphology and pore sizes of the hydrogels. 
3.2.2.4 Swelling studies on hydrogels 
The swelling behaviour of the hydrogels was calculated using a conventional gravimetric method 
[39]. Preweighed hydrogels prepared in glass vials with inner diameter 12 mm were immersed in 
phosphate buffered saline solution (pH 7.4 or pH 6.0) and incubated at 37 °C for predetermined 
periods of time. At regular time intervals, the solution was taken out carefully from the swollen 
hydrogels and wiped with a filter paper for the removal of any excess of PBS and then weighed in 
order to measure the weight of the swollen hydrogels. The % Swelling Degree (% SD) was calculated 
using the following equation (8): 
                                                    % SD = Ws- i/Wi  × 100            (8) 
where Ws is the weight of the swollen hydrogel at a specific time and Wi is the initial dry weight of 
the hydrogel. The measurements were carried out in triplicate and the results represent the mean with 
the corresponding standard deviation. 
3.2.2.5 In vitro enzymatic degradation of hydrogels  
In vitro degradation of hydrogels was performed by incubation with hyaluronidase enzyme solution 
at various concentrations at 37 °C. Briefly, hydrogels were incubated in PBS at 37 °C for 2 h. After 
this period, hydrogels were weighed (Wi) and subsequently incubated in 1 mL of PBS with 
hyaluronidase at 37 °C under constant agitation in a horizontal orbital shaker at 180 rpm.  Weight 
loss of the initially weighed hydrogels was monitored as a function of incubation time in PBS at 37 
°C. At specified time intervals, the hydrogels were weighed (Wf) and the degradation medium was 
replaced with freshly prepared enzyme solution every 24 h. In order to verify the absence of 
degradation phenomena due to temperature, a degradation test was carried out on control samples 
mixed with PBS and incubated at 37 °C. Measurements were performed until complete degradation 
of the hydrogels was observed. All measurements were performed in triplicate. The degradation was 
expressed as percentage of hydrogel mass and calculated using the following equation (9): 
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                                               % hydrogel mass = Wf / Wi × 100            (9) 
where Wi is the initial weight of the hydrogel before degradation and Wf is the weight of the hydrogel 
after degradation at regular time intervals. 
3.2.2.6 Differential Scanning Calorimetry  
DSC analysis was performed on hydrogels using a conventional differential scanning calorimeter 
Mettler Toledo DSC 822. Samples were precisely weighed into an aluminum pan on which aluminum 
lid with a centrally pierced hole was crimped. The thermal analysis of the xerogels was obtained as 
the temperature was increased from room temperature to 280 °C at a rate of 10 °C/min under N2.   
3.2.2.7 Oscillatory rheology 
The rheological characterisation of the hydrogels was performed on an Anton Paar MCR 302 
Rheometer using a cylinder (relative, ST10-4V-8.8/97.5) geometry configuration. Hydrogels were 
prepared into glass vials with inner diameter 14 mm as lower geometry and then the upper geometry 
(relative cylinder) was inserted into the hydrogel. Before each measurement, a delay time of 30 
minutes was set as for the hydrogel to settle. Oscillatory rheological measurements were performed 
to measure the viscoelastic moduli of the hydrogels as a function of shear strain (Amplitude sweep 
experiment) and as a function of frequency (Frequency sweep experiment). All the experiments were 
performed at 37 °C and this temperature was controlled throughout the measurement. The 
measurements were repeated at least three times to ensure reproducibility. 
Amplitude sweep test: Amplitude sweep experiments were performed to determine the LVR of 
deformation for each hydrogel at increasing shear strains. Strain scans were performed from 0.01 to 
100 % with a constant frequency of 1 Hz. The critical strain was determined as the point at which 
the elastic modulus Ǵ starts to deviate from linearity and crosses over the viscous modulus G΄΄. The 
average elastic modulus G΄ and viscous modulus G΄΄ were plotted vs amplitude strain.  Subsequently, 
frequency sweep experiments were carried out at a strain amplitude that was within the LVR. 
Frequency sweep test: Frequency sweep experiments were performed at a strain amplitude 
determined by the amplitude sweep test. Typically, angular frequencies in the range of 0.1 to 100 
rad/sec were tested at a strain amplitude of 5 % for all hydrogels. The average elastic modulus G΄ 
and viscous modulus G΄΄ were plotted vs angular frequency. 
3.2.2.8 DOX loading into HA-ADH hydrogels 
DOX was loaded in hydrogels prepared at different crosslinking densities. Briefly, different 
crosslinking densities of hydrogels were investigated and the detailed protocol for one of them is 
described below. HA sodium salt (10 mg, 6.β5 nmoles) was dissolved in 800 μL of sterile deionised 
water and EDC (0.β6 mg, 1.γ5 μmoles) was dissolved in 100 μL of deionised water and added at 
different molar ratios to the aqueous HA solution. EDC was allowed to dissolve before the addition 
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of ADH. The crosslinker ADH (0.β5 mg, 1.4γ μmoles) was then dissolved in 100 μL of deionised 
water and was added to the activated HA solution. Subsequently, 75 μL of DOX solution of 
concentration 0.66 mg/mL was added on the gelator solution. The final concentration of the drug in 
the hydrogels was 0.05 mg/mL. Gelation was allowed to occur with gentle vortexing. In order to 
ensure the drug encapsulation efficiency, DOX-loaded hydrogels were washed with PBS three times 
and the UV absorbance of the washing solutions was measured at 484 nm for the detection of DOX.  
3.2.2.9 TMZ loading into HA-ADH hydrogels 
Hydrogels of different crosslinking densities were loaded with various concentrations of TMZ. 
Hydrogels were prepared as described earlier in section 3.2.2.8 and 75 μL of TMZ solution of 
concentration 0.64 mg/mL were loaded on the gelator solution. The final concentration of TMZ in 
the hydrogels was 0.05 mg/mL. Gelation was allowed to occur with gentle vortexing. As mentioned 
previously, in order to confirm the TMZ encapsulation efficiency, the UV absorbance of the washing 
solutions was measured at 330 nm. 
3.2.2.10 DOX loading into HA-BSA hydrogels 
DOX was loaded into HA-BSA hydrogels at different crosslinking densities. Briefly, the protocol 
for the preparation for one of them is described below. HA sodium salt (6.0 mg, 3.75 nmoles) was 
dissolved in 800 μL of deionised water. Then HA was activated with EDC (2.0 mg, 10.4 μmoles) 
and sulfo-NHS (0.5 mg, 2.3 μmoles) mixture in a molar ratio 4:1 in 200 μL of deionised water and 
the pH was adjusted at pH 6.0 with the addition of HCl 0.1 M before the reaction with the protein. 
The reaction was allowed to proceed for 2 minutes by vortexing. BSA (3 mg, 45.4 nmoles) was added 
as a powder to the activated HA solution for further crosslinking. Subsequently, 75 μL of DOX 
solution of concentration 0.66 mg/mL was mixed with the precursor solution and gelation was 
allowed to occur with gentle vortexing. The final concentration of DOX in the hydrogels was 0.05 
mg/mL. 
3.2.2.11 TMZ loading into HA-BSA hydrogels  
Hydrogels were prepared as described in section 3.2.2.10 and then 75 μL of TMZ solution of 
concentration 0.64 mg/mL was loaded on the gelator solution. The final concentration of TMZ in the 
hydrogels was 0.05 mg/mL. Gelation was allowed to occur with gentle vortexing. As mentioned 
previously, in order to confirm the TMZ encapsulation efficiency, the UV absorbance of the washing 
solutions was measured at 330 nm. 
3.2.2.12 Drug release from hydrogels 
Drug loaded hydrogels were prepared in glass vials as described in the previous sections and they 
were allowed to settle for 24 h so the drug could be diffused throughout the hydrogel network. 
Subsequently, 1 mL of PBS as release medium was slowly added on hydrogels and they were 
incubated at 37 °C under constant agitation in a horizontal orbital shaker at 180 rpm. The 
92 
 
concentration of the drug in the release medium was measured at regular time intervals. To satisfy 
the perfect sink conditions, the release medium was replaced with fresh PBS pre-equilibrated at 37 
°C at each time point. The concentration of the released drug was determined by measuring the 
absorbance of the release medium using quartz cuvettes at 484 nm for DOX and 330 nm for TMZ. 
The UV absorbance was measured using a WPA Biowave II spectrophotometer. The concentration 
of the drug released from the hydrogel was determined using a calibration curve plotted for DOX 
and TMZ respectively (refer to the Appendix). All measurements were performed in triplicate and 
the % drug release was calculated using the following equation (10): 
 
                  % Drug release =                                                                              × 100      (10) 
  
3.2.2.13 Release of FITC-Urotensin (FITC-UII) from HA-ADH hydrogels 
Four different crosslinking densities of HA-ADH hydrogels were prepared in the wells of a 96-well 
plate and the detailed protocol for the preparation for one of them is described below. HA sodium 
salt (10.0 mg, 6.β5 nmoles) was dissolved in 800 μL of deionised water and EDC (0.26 mg, 1.35 
μmoles) was dissolved in 100 μL of deionised water and added at different molar ratios to the aqueous 
HA solution. EDC was allowed to dissolve before the addition of ADH. The crosslinker ADH (0.25 
mg, 1.4γ μmoles) was subsequently dissolved in 100 μL of deionised water and was added to the 
activated HA solution. A stock solution of the FITC labelled UII of concentration 10-4 M was 
prepared in DMEM and added in the gelator solution. The final concentration of the labelled 
chemoattractant in the hydrogel was 10-6 M. The pH of the solution was adjusted at pH 5.5 with the 
addition of HCl 0.1 M. Gelation was allowed to occur with gentle vortexing. Subsequently, FITC-
UII loaded hydrogels were incubated in DMEM at 37 °C. The release of the FITC-UII from the 
hydrogels was determined by measuring the fluorescence of the release medium at 520 nm at 
predetermined time intervals. The concentration of the FITC-UII released from the hydrogel was 
determined using a calibration curve and the % release was calculated as described in the previous 
section. 
3.3 Results and Discussion  
3.3.1 Physicochemical and mechanical characterisation of HA-ADH hydrogels  
HA-based hydrogels demonstrate advantageous properties such as high biocompatibility, easy 
manipulation, biodegradability and tunable viscoelastic properties which lead to their various 
applications in biomedical and pharmaceutical field. In the present work, inexpensive and relatively 
simple methods of preparation of biocompatible hydrogels based on HA were proposed and they 
were extensively discussed in Chapter 2. Hydrogels were prepared by chemical crosslinking of the 
Concentration of released drug 
Initial concentration of drug in the hydrogel 
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carboxylic groups of HA with ADH or BSA as crosslinkers. HA of high molecular weight was chosen 
and it was crosslinked with different molar ratios of ADH and EDC resulting in the fabrication of 
self-supporting hydrogels. HA was activated by EDC/sulfo-NHS chemistry and then crosslinked 
with BSA resulting in the formation of self-supporting hydrogels. Subsequently, the physicochemical 
and mechanical properties of the fabricated hydrogels were characterised and they will be discussed 
further in the following sections. 
3.3.1.1 FT-IR spectroscopy of HA-ADH hydrogels 
The fabrication of HA-based hydrogels requires chemical modification of the HA backbone in order 
to obtain chemically and mechanically robust materials. Herein, HA-based hydrogels were obtained 
by crosslinking HA with EDC as a carboxyl-activating agent and ADH as a crosslinker. As 
mentioned previously, HA-ADH hydrogels were obtained at different crosslinking densities and they 
are summarised in Table 3.1. Crosslinked hydrogels were analysed by FT-IR using Transmittance 
mode. FT-IR spectroscopy of the fabricated xerogels was conducted using a Perkin Elmer Spectrum 
One FT-IR spectrometer equipped with a diamond crystal. FT-IR spectroscopy was performed in 
order to investigate the structural changes of the prepared hydrogels compared to the structure of 
their precursor components and the nature of formation of the new bonds.   






As discussed in Chapter 2, during the crosslinking reaction, ADH with its free amine groups acts a 
nucleophile which attacks the activated by EDC carboxyl groups of HA resulting in the formation of 
amide bonds. The successful crosslinking of the activated HA with the amine moieties of the ADH 
was confirmed by FT-IR spectroscopy. The corresponding IR spectra of the hydrogel precursor 
components and HA-ADH xerogel demonstrated similar patterns as shown in Figure 3.9. 
Sample                       HA 
abbreviation         (mg/nmole)         
    ADH 
(mg/μmole) 
    EDC 
(mg/μmole) 
L1                           10.0/6.25 0.25/1.43   0.26/1.36 
L2                           10.0/6.25 0.5/2.87   0.6/3.12 
H1                           10.0/6.25 2.5/14.3   2.6/13.6 




Figure 3.9: FT-IR spectra of HA, ADH and HA-ADH xerogel. FT-IR spectroscopy was performed in order to 
investigate the structural changes of the prepared hydrogels compared to the structure of their precursor 
components and the nature of formation of new bonds. Graph adapted from Chapter 2.   
As depicted above, HA presents spectral characteristics typical for carboxylates anions, which are 
mainly absorption bands at 1607 and 1400 cm-1 assigned to the asymmetric and symmetric stretching 
vibrations of the carboxylate anions respectively. In the IR spectrum of the HA-ADH xerogel, the 
main differences compared to that of the unmodified HA are the appearance of the characteristic 
peaks of the ADH modification at 1686 cm-1 which corresponds to the formation of the amide bond 
(C=O stretch of secondary amide) and 1558 cm-1 (N-H bend of amide) [40]. Moreover, in the HA-
ADH spectrum, the absorption band at 2937 cm-1 represents the -CH2 stretching vibrations from the 
ADH moiety.   
 
Figure 3.10: FT-IR spectra of HA-ADH xerogels prepared at different crosslinking densities. 
As shown in Figure 3.10, the FT-IR spectra of the HA-ADH xerogels are identical and they presented 
























































successful crosslinking reaction in all cases. In addition, it is noteworthy that the increasing 
concentration of the crosslinker did induce a slight increase in the intensity of the peaks as highlighted 
in the above graph corresponding to the formation of the amide bond at approximately 1680 and 
1550 cm-1. 
3.3.1.2 Characterisation of surface morphology and porosity of HA-ADH hydrogels 
The scanning electron microscopy has been commonly used to provide important information 
regarding the morphology of the hydrogels and their characteristic network structure [41]. In 
addition, estimation of the average pore size and relevant information regarding the homogeneity or 
heterogeneity of the hydrogel network can be obtained from SEM. The average pore size, the pore 
size distribution and the pore interconnections are important factors of a hydrogel matrix that are 
usually difficult to determine. Hydrogels prior to SEM analysis, are usually freeze-dried and xerogels 
are obtained for the characterisation of their surface morphology. Despite the fact that freeze-drying 
method is not representative of the native state of the hydrogel network, it is indicative of the 
morphology and porosity of the hydrogel. 
Herein, HA-ADH hydrogels prepared at different crosslinking densities and they were flash frozen 
by immersion in dry ice. Frozen hydrogels were fractured into thin slices and lyophilised. 
Lyophilised hydrogels were coated before SEM analysis, in order to increase the conductivity of the 
samples and achieve better resolution. Thin slices of lyophilised hydrogels were coated with a thin 
layer of gold under Argon atmosphere as shown in Figure 3.11.  
 
Figure 3.11: Representative photo of lyophilised hydrogels coated by a thin layer of Au prior to SEM analysis. 
Hydrogels were coated using an Edwards Au coater under Ar atmosphere.  
Figure 3.12 shows the representative scanning electron micrographs of the obtained xerogels 
prepared at four different crosslinking densities. The SEM images were taken at three different 
magnifications as shown below. The xerogels derived from the crosslinking of HA with different 
concentrations of the crosslinker, presented a disorganised interconnected porous structure. Porous 
structure of hydrogels plays a critical role in swelling kinetics as these scaffolds allow penetration of 
water or surrounding media through the interconnected pores [42]. The porosity of scaffolds plays 
important role in cell adhesion and proliferation due to the fact that effective distribution of cell 
nutrients and metabolic waste is ensured through the 3D network. In the literature, it has been 
reported that the optimal pore size of scaffolds for potential application in tissue engineering should 
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be in a range of 20-200 μm. Scaffolds with these pore sizes allow cells sufficient space to grow and 
adhere to the matrix [43]. Moreover, besides the pore size, cell diffusion or migration within a 
scaffold is controlled by the total porosity, interconnectivity of the pores and the surface area of the 
scaffold.   
 
    
       
         
                      
Figure 3.12: SEM images of HA-ADH xerogels prepared at different crosslinking densities. 1A-1B-1C: L1 
hydrogel at magnifications 60x, 80x and 100x respectively, 2A-2B-2C: L2 hydrogel at magnifications 60x, 
80x and 100x respectively, 3A-3B-3C: H1 hydrogel at magnifications 60x, 80x and 100x respectively and 4A-
4B-4C: H2 hydrogel at magnifications 60x, 80x and 100x respectively. Scale bar: 500 μm.  
An interconnected network of pores improves the diffusion of oxygen and nutrients across the 
scaffold and multiple studies have proposed that highly porous scaffolds facilitate cell seeding and 
migration throughout the matrix [44]. As presented in Figure 3.12, all xerogels were characterised 
1A 1B 1C 
2A 2B 2C 
3A 3B 3C 
4A 4B 4C 
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by interconnected porous structure with various pore sizes. As expected, the hydrogel network was 
significantly denser with increasing concentration of the crosslinker. As mentioned in section 3.2.2.3, 
hydrogels were previously swollen in PBS for at least 24 h at 37 °C and the determination of the pore 
sizes of the lyophilised scaffolds was performed. The pore size was measured by choosing at least 
15 random pores from each image and measuring their diameter (as highlighted with arrows in the 
above images) using ImageJ software. The histogram in Figure 3.13 summarises the pore size of 
xerogels prepared at different crosslinking densities.  





































Figure 3.13: Histogram summarises the average pore size of HA-ADH xerogels prepared at different 
crosslinking densities. Error bars were calculated by the corresponding standard deviation. 
Hydrogels prepared at low crosslinking densities L1 and L2, presented an average pore size of 177 
and 150 μm respectively after swelling. In contrast, increasing concentration of ADH resulted in 
significantly smaller pores ranging from 90 to 65 μm for H1 and H2 crosslinking densities 
respectively. It can be concluded that the pore size of the hydrogels was highly dependent on the 
crosslinking density. Increasing degree of crosslinking resulted in increased pore density in the 
hydrogel network. Zhang et al reported a similar effect of the crosslinking density on the porous 
network of the fabricated PNIPAAm hydrogels [45]. The authors observed that the least crosslinked 
hydrogels presented larger average pore sizes compared to those with the highest level of 
crosslinking.    
3.3.1.3 Swelling studies of HA-ADH hydrogels 
Hydrogels are 3D dimensional crosslinked hydrophilic polymeric networks that are able to swell in 
an aqueous environment without dissolution [46]. The swelling profile of hydrogels is of paramount 
importance in biomedical and pharmaceutical applications particularly in case of injectable hydrogels 
for tissue engineering. The determination of the swelling degree of hydrogels designed for brain 
tissue engineering applications is a critical factor that should be taken into consideration. As stated 
in Chapter 2, hydrogels can obtain different shapes and fill amorphous cavities in the brain due to 
their tunable mechanical characteristics.  The volume of the injectable hydrogel and the extent of the 
swelling capacity should be precisely determined before the injection due to the limited open space 
within the brain tissue. For example, a large volume of hydrogel can present adverse effects on the 
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brain by increasing the pressure in the brain tissue surrounding the hydrogel. However, swelling in 
the brain is less of a concern due to the fact that the increase in overall size because of swelling is 
restricted by the counter forces of the surrounding tissue [47]. 
Generally, the swelling capacity of hydrogels under biological conditions renders them an interesting 
class of materials for biomedical applications including tissue engineering and drug delivery. The 
determination of the swelling characteristics of hydrogels is significant because the equilibrium 
degree of swelling affects their surface and mechanical properties. The degree to which a polymer 
network is able to swell is determined by the equilibrium between the elastic retractive forces arised 
from the polymer chains and the thermodynamic interaction of the polymer with the solvent 
molecules.  
In the present work, the swelling behaviour of the crosslinked hydrogels was calculated using a
conventional gravimetric method [39]. Hydrogels prepared at different crosslinking densities in glass 
vials with inner diameter 12 mm were initially weighed (Wi) and afterwards, they were immersed in 
PBS at pH 7.4 and incubated at 37 °C for predetermined periods of time. At regular time intervals, 
the PBS solution was removed carefully from the swollen hydrogels, wiped with a filter paper and 
then the weight of the swollen hydrogels was measured (Ws). Subsequently, the % SD of the  
hydrogels was calculated using the following equation (8): 
                                                    % SD = Ws-Wi/Wi  × 100                     (8)           
After 3 days of incubation in PBS, the low crosslinking densities of hydrogels L1 and L2 presented 
an equilibrium % swelling degree of 42 and 24 respectively, while H1 and H2 hydrogels reached 
equilibrium after 24 h,  presenting a mass increase of 6 and 5 % respectively as shown in Figure 3.14. 
After 6 days of incubation, low crosslinked hydrogels started undergoing hydrolytic degradation, 
whereas hydrogels prepared at high crosslinking densities remained relatively stable until the 
completion of the experiment. Also, hydrogels were prepared in the presence of the chemoattractant 
at a concentration of 10-8 M and as shown in Figure 3.14, it did not induce significant change in the 
% SD. It can be concluded that the swelling profile of the hydrogels highly depends on the 
crosslinking density of the hydrogels. The lower the crosslinking density of the hydrogels, the higher  
% SD, whereas high crosslinking densities resulted in lower % SD due to the increased density of 
the crosslinks which was also confirmed by the SEM analysis of the lyophilised networks. The 
increase of the concentration of ADH resulted in an increase of the crosslinking density which 






       
Figure 3.14: A. Swelling profile of hydrogels prepared at different crosslinking densities in PBS at 37 °C. B. 
Swelling profile of hydrogels prepared at different crosslinking densities loaded with the chemoattractant UII 
in PBS at 37 °C. The presence of UII did not affect the % SD of the hydrogels. The data represent the average 
of triplicate with the corresponding error bar calculated by standard deviation. 
Similarly, Zhou et al observed that the pore size and the swelling ratio of the fabricated composite 
gelatin-hyaluronic acid hydrogels decreased with increasing concentration of EDC as crosslinker 
[48]. The higher crosslinking density renders the network more dense resulting in smaller pores 
which limits the diffusion of the solvent into the scaffolds. Highly crosslinked hydrogels started to 
undergo syneresis on the fourth day of the swelling experiment. Syneresis is defined as the shrinkage 
of the hydrogels with simultaneous release of water that results in a lower volume of hydrogel. 
Typically, syneresis increases with increasing crosslinking density and can be problematic for 
applications that the gel integrity is important [49].     
Moreover, the effect of the pH and ionic strength on the swelling behaviour of the HA-ADH 
hydrogels prepared at low crosslinking densities L1 and L2 was investigated, as demonstrated in 
Figure 3.15. Hydrogels were prepared as described earlier in glass vials and immersed in DMEM 
(pH 7.8), PBS (pH 7.4) and deionised water (pH 6.5). They were incubated at 37 °C and the % SD 
was determined after specific time intervals as described previously. The degree of crosslinking in 
the polymer network is critical as it determines the extent of swelling as discussed earlier. As 
summarised in the graphs below, HA-ADH hydrogels swelled extensively in water reaching 
equilibrium % SD of 96 and 48 for the L1 and L2 crosslinking densities respectively after 48 h of 
incubation. This extensive swelling is facilitated by the presence of the free carboxylic acid groups 
on the HA backbone, which strongly interact with water molecules. The swelling behaviour of the 
HA-based hydrogels depends on the pH and it is closely related to the ionisation of the carboxylic 














































                                                       
Figure 3.15: Swelling profile of hydrogels prepared at low crosslinking densities in solutions of various pH 
and ionic strength. Changes in the pH and ionic strength presented significant effect on the swelling behaviour 
of the hydrogels. The data represent the average of triplicate with the corresponding error bar calculated by 
standard deviation.      
The ionisation of the carboxyl group induces the formation of anionic carboxylate moieties and 
consequently the electrostatic repulsion between the negatively charged groups results in dramatic 
swelling behaviour. In case of DMEM and PBS, lower swelling was observed for both hydrogels as 
it can be confirmed by the following photos of the swollen hydrogels in Figure 3.16. The 
concentration of the cations in the buffer increased which resulted in lower osmotic pressure due to 
decreased anion-anion electrostatic repulsion. 
 
                
                     
                     
Figure 3.16: Representative photos of HA-ADH hydrogels prepared at low crosslinking densities before and 
after swelling at 37 °C. A. Photos of L1 hydrogel before swelling (top left), after swelling in DMEM and PBS 
(in the middle), after swelling in dH2O (top right). B. Photos of L2 hydrogel before swelling (bottom left), after 
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3.3.1.4 In vitro enzymatic degradation studies of HA-ADH hydrogels 
The majority of the hydrogels designed for tissue engineering or release of therapeutic molecules, 
are formulated to be biodegradable. In the brain tissue engineering, the ability of a hydrogel to 
degrade is critical due to the occurrence of inevitable glial scarring in close proximity to the implant 
site [51]. Therefore, the temporary presence of a biodegradable hydrogel is more preferable 
compared to a permanent implant which can induce a lasting immune response and glial scarring. 
The process of degradation involves the cleavage of degradable chemical sites within the polymer 
chain leading to the formation of smaller biocompatible molecules that can be eliminated from the 
implant area. 
Typically, as mentioned in section 3.1.4, degradation takes place mainly through hydrolysis or 
enzymatic cleavage of chemical bonds that are present in the polymer chain. Hydrolytic degradation 
usually occurs in polymers containing chemical bonds such as ester, ether or amide bonds. For 
example, in the case of hydrogels consist of poly (α-hydroxy acids), the ester bonds between poly-
lactic or poly-glycolic acid moieties undergo hydrolysis resulting in the formation of lactic or 
glycolic acid units as shown in Figure 3.17. Hydrogels can undergo degradation by enzymatic 
cleavage of chemical sequences present in the polymer chain that are recognised by specific enzymes. 
For instance, HA-based hydrogels can be degraded in the presence of hyaluronidase which is an 
enzyme that catalyses the hydrolysis of C–O, C–N and C–C bonds.  
 
Figure 3.17: Hydrolytic degradation of poly (α-hydroxy acids) results in the formation of molecules containing 
carboxyl or hydroxyl groups.  
HA in its native form as biopolymer, presents short in vivo resistance due to its poor mechanical 
properties and the enzymatic degradation induced by hyaluronidase. Hyaluronidase specifically 
degrades HA by cleavage of glycosidic bonds between HA monosaccharides [52]. To overcome 
these limitations, crosslinking of HA takes place in order to form 3D scaffolds that demonstrate better 
mechanical properties and longer resistance to this enzyme. 
Herein, the integrity of the crosslinked HA hydrogels upon exposure to hyaluronidase was 
investigated. The in vitro degradation of hydrogels was initially performed by incubation with 
hyaluronidase enzyme solution at a concentration of 10 U/mL at 37 °C which is within the range of 
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concentrations that can be found in physiological conditions (0.0059 ± 0.0012 U/ml in human plasma 
to 38.5 U/ml in human ovaries) [53]. Briefly, hydrogels were prepared at different crosslinking 
densities in glass vials and incubated in PBS at 37 °C for 2 h. After this incubation period, hydrogels 
were weighed (Wi) and subsequently 1 mL of PBS with hyaluronidase at 37 °C was added on the top 
of the hydrogels. At specified time intervals, the enzyme solution was removed and the hydrogels 
were weighed (Wf).  The degradation medium was replaced with freshly prepared enzyme solution 
of the same composition every 24 h. The degradation was determined as the % hydrogel mass left as 
function of incubation time with the enzyme solution and it was calculated using the following 
equation (9): 
                                         % hydrogel mass = Wf / Wi × 100            (9) 
In order to verify the absence of degradation phenomena due to temperature or PBS, degradation test 
was carried out on control samples mixed with PBS and incubated at 37 °C. Measurements were 
performed until complete degradation of the hydrogels was observed. As shown in Figure 3.18, after 
2 days of incubation with hyaluronidase, low crosslinking densities of hydrogels L1 and L2, 
demonstrated significant % mass loss compared to the control hydrogels that started to undergo 
swelling reaching equilibrium on the third day of incubation. After incubation with hyaluronidase, 
L1 and L2 hydrogels were completely degraded after 4 and 5 days respectively. In contrast, as shown 
in Figure 3.18, hydrogels prepared at high crosslinking densities H1 and H2, presented longer 
degradation times of 10 and 14 days respectively. In addition, in case of control hydrogels a slight 
decrease in the % hydrogel mass was observed due to syneresis similarly to that during the swelling 
experiment. The longer degradation rate of H1 and H2 hydrogels compared to the lower crosslinked 
hydrogels, is correlated with the increased crosslinking density of their network. High crosslinking 
density results in the formation of a dense network that restricts the diffusion of the enzyme through 
the scaffold and prolongs the degradation rate. The degradation profile reported here is consistent 
with the results obtained from swelling studies. The higher % SD of the low crosslinked hydrogels 
resulted in higher degradation rate due to the increased interactions of the swollen scaffolds with the 
enzyme solution. It can be concluded that the degradation behaviour of the hydrogels is highly 
dependent on the crosslinking density. Similarly, Bulpitt et al reported that HA-based hydrogels with 
25% of ADH modification degree presented an eight-fold faster degradation rate than those with 
65% modification degree, highlighting the significant effect of crosslinking density on the 






Figure 3.18: Degradation profile of HA-ADH hydrogels prepared at different crosslinking densities in 
hyaluronidase solution of concentration 10 U/mL at 37 °C. A. Degradation profile of low crosslinked hydrogels 
L1 and L2, B. Degradation profile of high crosslinking densities of hydrogels H1 and H2. Hydrogels were 
prepared as control and incubated in PBS at 37 °C in order to ensure the absence of degradation phenomena 
due to PBS or temperature. The data represent the average of triplicate with the corresponding error bar 
calculated by standard deviation.      
Hydrogels were also incubated with different concentrations of hyaluronidase 10-200 U/mL and the 
effect on their degradation rate was investigated. Briefly, hydrogels were prepared at low and high 
crosslinking densities and digested with different concentrations of hyaluronidase as summarised in 
Figure 3.19. A linear relationship was observed between the degradation rate and the increasing 
concentrations of the enzyme applied for both crosslinking densities. The degradation rate of the 
crosslinked hydrogels was proportionally increased with increasing concentrations of hyaluronidase.  
 
        
Figure 3.19: Degradation rate of hydrogels prepared at L2 and H2 crosslinking densities. Hydrogels were 
incubated with different concentrations of hyaluronidase (10-200 U/mL) in PBS at 37 °C. The degradation was 
determined as the % hydrogel mass left as function of incubation time with the enzyme. A. Degradation profile 
of L2 hydrogels and B. Degradation profile of hydrogels prepared at H2 crosslinking density. The data 
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The obtained results are indicative of the degradation behaviour of the hydrogels and they do not 
represent the real-life scenario. Hydrogels were incubated directly with solution of hyaluronidase i  
vitro conditions that do not mimic the in vivo environment, where the response of the hydrogels 
would be different. The degradation of the scaffolds is expected to be slower in vivo conditions since 
the water content in the human body is relatively lower which decreases the hydrolysis rate of the 
hydrogels [55]. Recently, Kong et al reported the difference in the degradation rate of crosslinked 
alginate hydrogels in vitro and in vivo conditions. Hydrogels presented faster degradation rate in vitro 
conditions, whereas in the in vivo environment they maintained their integrity over the entire period 
of the experiment [56].   
3.3.1.5 Rheological measurements on HA-ADH hydrogels 
The mechanical features of the hydrogels are important to be considered for the design of scaffolds 
for pharmaceutical and tissue engineering applications. The mechanical profile of these 3D scaffolds 
play crucial role in the regulation of cell phenotype, cellular functions including cell proliferation 
and migration and it will be discussed further in Chapter 4. The chemical properties determine the 
crosslinking density of the hydrogels which consequently defines their physical and mechanical 
properties including the stiffness of these materials [57]. Crosslinking density can be modified by 
varying the amount of the crosslinker or changing the molecular weight of the polymer. Generally, 
higher crosslinking density results in stiff hydrogels suitable for bone tissue engineering, while lower 
crosslinking density produces softer hydrogels ideal for brain and neural tissue engineering. For 
example, Lampe et al observed that neuron cells demonstrated higher viability on soft hydrogels 
compared to cells seeded on stiffer environment. In contrast, Chatterjee et al using osteoblasts, 
demonstrated that osteogenesis was improved when the cells were cultured on hydrogels with higher 
stiffness close to that of bone tissue [58], [59]. Generally, the mechanical properties of the culture 
environments should be modified and mimic the stiffness of the specific cell types or tissues as 
summarised in Figure 3.20. Neural cell types prefer to grow on relatively soft substrates with elastic 
modulus being within the range of 100-1000 Pa.  
Therefore, in the present work taking into consideration all the critical mechanical features that the 
fabricated hydrogels should have in order to be applied as injectable scaffolds in the brain, the 
mechanical characterisation of the prepared hydrogels was performed. Oscillatory rheological 
measurements of the elastic modulus G΄ and the viscous modulus G΄΄ as function of shear strain 
(Amplitude sweep experiment) and as function of frequency (Frequency sweep experiment) were 
performed using an Anton Paar MCR 302 Rheometer equipped with a cylinder (relative, ST10-4V-







Figure 3.20: Stiffness of different healthy tissues found in the human body. The elastic modulus is expressed 
in logarithmic scale and measured in Pa. Adapted from Sachot et al [60].  
Briefly, hydrogels with a volume of 1 mL were prepared into glass vials with inner diameter of 14 
mm as lower geometry and then the upper geometry (relative cylinder) was inserted into the hydrogel 
as shown in Figure 3.21. Before each measurement, a delay time of 30 minutes was set as for the 
hydrogel to settle. All the experiments were performed at 37 °C and this temperature was controlled 
throughout the measurement. The measurements were repeated at least three times to ensure 
reproducibility.  
                                                
Figure 3.21: A. Photo of relative cylinder used as upper geometry. B. Photo of the set up of rheometer used, 
equipped with a relative cylinder geometry configuration which was inserted into a glass vial containing 1 mL 
of hydrogel. The illustrative photo A was provided by Dr. E. Sitsanidis. 
Initially, amplitude sweep experiment was performed to determine the LVR of deformation for each 
crosslinking density of hydrogels at increasing shear strains. Strain scans were performed from 0.01 
to 100 % with a constant frequency of 1 Hz. The critical strain was determined as the point at which 
the elastic modulus G΄ starts to deviate from linearity and crosses over the viscous modulus G΄΄. The 
elastic modulus G΄ and viscous modulus G΄΄ were plotted vs amplitude strain as presented in Figure 
3.22. 









       
Figure 3.22: Amplitude sweep experiments performed on A. L2 and B. H1 crosslinking densities of HA-ADH 
hydrogels. Strain scans were performed from 0.01 to 100 % keeping constant frequency at 1 Hz. 
Both moduli demonstrated constant and strain dependent relationship across the range of strain 
values measured which is typical behaviour of viscoelastic materials. As shown in Figure 3.22, L2 
and H1 crosslinking densities indicated linear viscoelastic behaviour up to a critical strain value of 
10 %. Therefore, a strain value of 5 % within the LVR was chosen for all hydrogels and applied 
subsequently to the frequency sweep experiment (for amplitude sweep experiment on L1 and H2 
crosslinking densities refer to the Appendix). Amplitude sweep experiment was run on the same 
sample (L1 crosslinking density) for 3 times in order to ensure the reversibility of the linear 
viscoelastic behaviour, when  the same sample is subjected to increasing amplitude oscillation strain. 
As presented in Figure 3.23, the three measurements were identical which indicated that the hydrogel 
can reverse to its initial state, highlighting the elasticity of the material.   
 
Figure 3.23: Amplitude sweep experiment on L1 hydrogel was repeated three times on the same sample. The 
graph demonstrates the reproducibility of the measurements and the high elasticity of the hydrogel. 
 
The effect of the increasing concentration of the crosslinker on the viscoelastic properties of the 
hydrogels was investigated by the frequency sweep test. The frequency sweep experiment was 
performed within the LVR at a constant strain of 5 % and angular frequencies in the range of 0.1 to 
100 rad/sec. The average elastic modulus G΄ and viscous modulus G΄΄ were plotted vs angular 
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as the elastic modulus Ǵ was higher than viscous modulus G΄΄ throughout the entire frequency range 
[61]. The frequency dependence of the moduli is a feature critical of hydrogels and indicative of the 
homogeneous crosslinked hydrogel network. As summarised in Figure 3.24, hydrogels prepared at 
high crosslinking densities H1 and H2 presented average elastic moduli of 254 and 289 Pa 
respectively higher than those of low crosslinked hydrogels. L1 and L2 hydrogels presented elastic 
moduli of 88 and 138 Pa respectively. The rheological measurements demonstrated that both G΄ and 
G΄΄ moduli were significantly dependent on the crosslinking density of hydrogels. Similarly, Jeon et 
al investigated the effect of crosslinking density of HA hydrogels on the mechanical properties and 
they observed that increasing crosslinking density of HA hydrogels resulted in increased elastic 
moduli [62].         
     
             
  
                
Figure 3.24: Frequency sweep experiments performed on A. L1, B. L2, C. H1 and D. H2 crosslinking densities 
of HA-ADH hydrogels using a constant strain of 5 % in angular frequencies in the range of 0.1 to 100 rad/sec. 
The data represent the average of three independent measurements with the corresponding error bar calculated 
by standard deviation.  
 
In summary, the rheological measurements revealed that the elastic moduli of the fabricated 
hydrogels were within the range of those of neural tissues and brain (100-1000 Pa), highlighting the 





































































3.3.1.6 DSC analysis of HA-ADH hydrogels  
The thermal behaviour of the crosslinked HA hydrogels was investigated by DSC analysis. In case 
of hydrogels, DSC thermographs usually demonstrate changes in the glass transition temperature 
(Tg) for crosslinked hydrogels and their initial components. Herein, the DSC thermographs of HA, 
ADH and HA-ADH xerogels were recorded using a conventional differential scanning calorimeter 
Mettler Toledo DSC 822 as shown in Figure 3.25. HA presented a broad endothermic peak 
approximately at 99 °C and a sharp exothermic peak at 237 °C. The endothermic peak is associated 
with the loss of water from the HA molecule, while the exothermic peak can be attributed to the 
thermal degradation of the polysaccharide [63]. ADH demonstrated a sharp endothermic peak at 181 










Figure 3.25: DSC thermographs of crosslinked HA xerogel and its components. A. DSC thermograph of HA, 
B. ADH and C. HA-ADH xerogel. 
HA-ADH xerogel showed the presence of a broad endothermic peak at 89 °C which is associated 
with the loss of water and a small exothermic peak at 214 °C that is connected with the thermal 
decomposition of the polymer. In overall, the DSC thermographs demonstrated that the endothermic 
and exothermic peaks of HA shifted after the successful crosslinking with ADH, indicating the 
altered polymer structure. 
3.3.1.7 Drug release from HA-ADH hydrogels 
As briefly discussed in section 3.1.7, the efficacy of cancer chemotherapy is restricted by the systemic 
mechanisms of administration including oral or intravenous routes. Therefore, there is an urgent need 
to develop localised drug delivery systems that will allow the targeted sustained release of the drug 
with negligible side effects. Among the drug delivery systems that have been investigated so far, 
hydrogels can provide all the necessary features for effective targeted controlled drug release close 
to the tumour site. The delivery of various drugs to the brain has always been challenging due to the 
unique morphology of the brain microenvironment and the presence of delicate barriers such as the 
blood-brain barrier as discussed in Chapter 1.  
In this study, crosslinked HA hydrogels were loaded with DOX or TMZ and their release profile was 
investigated. Hydrogels can be loaded with drugs in two different ways. In the first approach, the 
drug is mixed with the precursor polymer solution and gelation occurs with the drug within the 
matrix, while in the second approach the hydrogel is allowed to swell in a drug solution until 
equilibrium swelling is reached [64]. Herein, the drug was mixed with the gelator solution and the 
polymerisation took place with the drug being physically encapsulated in the hydrogel. Briefly, 
hydrogels loaded with DOX or TMZ were prepared in glass vials as described in detail in sections 
3.2.2.8 and 3.2.2.9. In order to ensure the drug encapsulation efficiency, DOX or TMZ-loaded 




measured at 484 nm or 330 nm for the detection of DOX or TMZ respectively. All hydrogels 
demonstrated facile encapsulation of DOX or TMZ and self supporting hydrogels were formed as 
shown in Figure 3.26.  
 
                              
                    
Figure 3.26: Photos of DOX-loaded and TMZ-loaded hydrogels prepared at L1 and H1 crosslinking densities. 
Self-supporting hydrogels were prepared in triplicate. 
DOX or TMZ were physically entrapped within the hydrogel network and any chemical interactions 
with the main components of the hydrogel were observed. The drug release profile of the DOX or 
TMZ-loaded hydrogels in PBS at pH 7.4 and 6.0 was studied as function of incubation time at 37 °C. 
In the literature, it has been reported that the pH of solid tumours varies in the range of approximately 
5.7 to 7.6 due to accumulation of acidic metabolites due to low blood pressure and hypoxia caused 
by abnormal tumour vessels [65]. At predetermined time intervals, the release medium was removed 
and the concentration of the drug was determined by measuring the absorbance at 484 nm or 330 nm 
respectively using a WPA Biowave II spectrophotometer. The concentration of the drug released 
from the hydrogel was determined using a calibration curve plotted for DOX or TMZ respectively 
(refer to the Appendix). Figure 3.27 summarises the results from the in vitro DOX and TMZ release 
from the hydrogels in PBS at pH 7.4. The drug release results performed in PBS at pH 6.0 are not 
shown due to insignificant changes in the release profile of the hydrogels.  
It can be observed that hydrogels presented a sustained  release of DOX and TMZ which was 
dependent on the crosslinking density. L1 and L2 hydrogels loaded with DOX presented a cumulative 
release of 55 and 47.5 % respectively after 96 h, while hydrogels prepared at higher crosslinking 
densities showed cumulative release of approximately 38 %. Similarly, L1 and L2 hydrogels loaded 
with TMZ presented a cumulative release of 62.8 and 51.9 % respectively, whereas in case of H1 
and H2 hydrogels the cumulative release was 36.1 and 24.4 % respectively, significantly lower  at 
the same period of time. Overall, hydrogels promoted sustained release of DOX or TMZ under 
physiological conditions over a specific period of time. This sustained drug release is desirable as 
one of the critical features of the fabricated hydrogels is the release of the loaded drug in a controlled 
DOX 0.05 mg/mL 
L1 H1 L1 H1 
TMZ 0.05 mg/mL 
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manner in order to induce gradually apoptosis of the cells that remain in the margins of the resection 
cavity.  
  
3.3.1.8 FITC-UII release studies from HA-ADH hydrogels 
One of the main objectives of this thesis, was the formulation of a chemoattractant loaded crosslinked 
network that would allow the formation of chemoattractant gradient. It has been reported that 
gradient concentration of UII promotes the migration of glioma cells and this will be discussed 
further in Chapter 4. Hence, the sustained release of the chemokine from the hydrogel to the margins 
of the tumour site will induce the migration of the invasive glioma cells that have not been removed 
by the surgery into the scaffold. Herein, the release profile of the chemoattractant loaded HA-ADH 
hydrogels was investigated. Hydrogels were prepared as described in section 3.2.2.13 and the FITC-
UII was efficiently entrapped in the matrix. The successful encapsulation of the chemoattractant in 
the hydrogel was confirmed by fluorescence spectroscopy of the washing supernatant solutions.  
 
Figure 3.28: % Cumulative release of FITC-UII from HA-ADH hydrogels prepared at different crosslinking 
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Figure 3.27: Drug release profiles of HA-ADH hydrogels prepared at different crosslinking densities. A. Drug 
release profile of DOX-loaded hydrogels and B. Drug release profile of TMZ-loaded hydrogels in PBS at 37 




The kinetics of the chemokine release from the hydrogels was determined by incubation of the 
hydrogels with 100 μL of DMEM as releasing buffer at γ7 °C. At specific time points, the supernatant 
solution was removed and the concentration of the released chemokine was determined by measuring 
the fluorescence at 520 nm. 
As presented in Figure 3.28, the release of the chemoattractant was highly dependent on the 
crosslinking density of the hydrogels. The highest % release was observed in low crosslinking 
densities. Specifically, L1 and L2 hydrogels presented cumulative release of 24 and 16 % 
respectively, while the release from the high crosslinked hydrogels H1 and H2 was 7.8 and 4.5 % 
respectively. These results indicated that hydrogels can promote the sustained release of the 
chemoattractant while high concentration of the chemokine remains entrapped in the scaffold which 
is desirable for our application. As stated previously, one of the main aims of this work, was the 
formation of a gradient concentration of UII in the drug loaded matrix that will allow release of the 
chemoattractant while most of it will remain within the matrix as illustrated in Figure 3.29. The above 
results showed that some of the loaded chemoattractant can be released reaching highest cumulative 
release of 24 %, while most of it remains inside the hydrogel facilitating the migration of glioma 
cells towards the scaffold.   
 
Figure 3.29: Illustration of a hydrogel loaded with a chemotherapeutic drug and chemoattractant that allows 
sustained release of the drug and chemoattractant while most of it remains within the matrix.    
3.3.2 Physicochemical and mechanical characterisation of HA-BSA hydrogels 
3.3.2.1 FT-IR spectroscopy of HA-BSA hydrogels 
In an effort to optimise the aforementioned formulation of hydrogels, another method of crosslinking 
of HA was developed in the presence of BSA. Taking into consideration the free primary amines that 
are present in lysine residues of the BSA molecule and the size of this protein, we proposed the 
potential crosslinking reaction of the carboxylic groups of HA with the primary amines of BSA which 
will result in the formation of amide bonds and the fabrication of a 3D network. As discussed in 
Chapter 2, the carboxyl groups of the HA were activated by EDC/sulfo-NHS chemistry and the 
activated polysaccharide was further crosslinked with the free amine groups that were present in the 
BSA molecule. HA-BSA hydrogels were prepared at different crosslinking densities as summarised 









                                                                                                               
The FT-IR spectra of the HA-BSA xerogel and its main components were recorded and compared as 
shown in Figure 3.30. In the spectrum of HA, the main absorption bands at 1611 and 1417 cm-1 can 
be assigned to the asymmetric and symmetric stretching vibrations of the carboxylate anions 
respectively. In the FT-IR spectrum of BSA, there are three main characteristic peaks that are unique 
to the secondary structure of the protein. The sharp peak at 1640 cm-1 is due to the stretching vibration 
of C=O bond of the amide I band, while the sharp peak at 1527 cm-1 is assigned to the bending 
vibration of N-H of the amide II band.  
   
 
Figure 3.30: FT-IR spectra of HA, BSA and HA-BSA xerogel were recorded and compared. Graph adapted 
from Chapter 2. 
The smaller peak at 1386 cm-1 is due to the C-N stretching vibration [66]. Regarding the spectrum of 
the HA-BSA xerogel, the main differences compared to that of the unmodified HA focused on the 
the appearance of a peak at 1718 cm-1 which corresponds to the formation of an amide bond (C=O 
stretch of secondary amide), indicative of the successful crosslinking reaction of HA with BSA. The 
sharp peaks at 1678, 1556 and 1286 cm-1 assigned to C=O, N-H and C-N stretching vibrations of the 
amide bonds respectively, confirmed the presence of BSA in the structure of the xerogel. FT-IR 

































   EDC 
(mg/μmole) 
    BSA 
(mg/nmole)    
HB16    6.0/3.7 0.5/2.3 2.0/10.4  3.0/45.4 
HB17    6.0/3.7 1.25/5.86 5.0/26.1  3.0/45.4 
HB18    6.0/3.7 2.5/11.5 10.0/52.2  3.0/45.4 






compared as demonstrated in Figure 3.31. All xerogels presented a sharp characteristic peak around 
1715 cm-1 indicative of the formation of a new amide bond in the structure of HA. As highlighted in 
Figure 3.31, it is also notable the increase in the intensity of this peak as the crosslinking density 
increases.   
 
Figure 3.31: FT-IR spectra of HA-BSA xerogels prepared at different crosslinking densities. 
 
3.3.2.2 SEM characterisation of HA-BSA hydrogels 
The effect of the increasing crosslinking density on the morphology and porosity of HA-BSA 
hydrogels was investigated by SEM analysis. Briefly, HA-BSA hydrogels were prepared at different 
crosslinking densities as described above and they were allowed to swell for 24 h in PBS. After this 
period, hydrogels were flash frozen by immersion in dry ice and subsequently, frozen hydrogels were 
fractured into thin slices and prepared for freeze-drying. Xerogels were obtained after 24 h of freeze-
drying and coated before SEM characterisation. The thin slices of xerogels were coated with a thin 
layer of gold as described previously and SEM images were taken at different magnifications as 
demonstrated in Figure 3.32. Xerogels presented an interconnected porous network similar to that of 




























              
      
      
       
Figure 3.32: SEM images of HA-BSA xerogels prepared at different crosslinking densities. 1A-1B-1C: HB16 
xerogel at magnifications 50x, 80x and 100x respectively, 2A-2B-2C: HB17 xerogel at magnifications 50x, 
80x and 100x respectively, 3A-3B-3C: HB18 xerogel at magnifications 50x, 80x and 100x respectively and 
4A-4B-4C: HB19 xerogel at magnifications 60x, 80x and 100x respectively. Scale bar: 500 μm-1mm.  
The pore size was highly dependent on the crosslinking density. The histogram in Figure 3.33 
presents the average pore size of each crosslinking density as it was calculated by ImageJ. Xerogels 
prepared at low crosslinking densities HB16 and HB17 presented pore size of 250 and 195 μm
respectively. In contrast, high crosslinked xerogels HB18 and HB19 were characterised with a pore 
size of 138 and 105 μm respectively. Overall, xerogels with these pore sizes can facilitate cells 
sufficient space to grow and adhere to the matrix. Moreover, it is notable that these xerogels presented 
higher pore sizes than those of HA-ADH xerogels due to the lower concentration of the 
polysaccharide used as summarised in the graphs in Figure 3.33.     
1A 1B 1C 
2A 2B 2C 
3A 3B 3C 
4A 4B 4C 
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Figure 3.33: Histograms demonstrate the average pore size of A. HA-BSA xerogels and B. HA-ADH xerogels 
prepared at different crosslinking densities measured by ImageJ. Error bars were calculated by the 
corresponding standard deviation. 
3.3.2.3 Swelling studies of HA-BSA hydrogels 
The porous structure of the crosslinked hydrogels presented above enables them to swell in aqueous 
environment. The crosslinking density determines the extent of the swelling capacity. Herein, the 
effect of the crosslinking density on the swelling behaviour of the crosslinked HA hydrogels was 
investigated. Hydrogels prepared at different crosslinking densities in glass vials with inner diameter 
12 mm were allowed to swell in PBS (pH 7.4) at 37 °C. At predetermined time intervals, the PBS 
solution was removed carefully from the swollen hydrogels, wiped with a filter paper and then the 
weight of the hydrogels was measured. The % SD was calculated as a function of incubation time as 
described previously and the obtained results from the swelling experiment are summarised in Figure 
3.34. After 2 days of incubation in PBS at 37 °C, the low crosslinking densities of hydrogels HB16 
and HB17 showed an equilibrium % SD of 49 and 38 respectively. On the other hand, HB18 and 
HB19 hydrogels presented an equilibrium % SD of 25.2 and 15.8 respectively. Compared to HA-
ADH hydrogels, those fabricated by the crosslinking of HA with BSA, demonstrated higher % 
swelling degree which is also consistent with the data obtained from the SEM analysis. The expected 






Figure 3.34: Swelling profile of HA-BSA hydrogels prepared at different crosslinking densities in PBS at 37 
°C. The data represent the average of triplicate with the corresponding error bar calculated by standard 
deviation.         
3.3.2.4 In vitro enzymatic degradation of HA-BSA hydrogels 
The degradation rate of the HA-BSA hydrogels upon exposure to hyaluronidase was investigated. 
The in vitro degradation of hydrogels was performed by incubation with hyaluronidase solution at a 
concentration of 10 U/mL at 37 °C which is within the range of enzyme concentrations that can be 
found in physiological conditions. Briefly, hydrogels were prepared at different crosslinking 
densities in glass vials and incubated in PBS at 37 °C for 2 h. After this incubation time, hydrogels 
were weighed and subsequently 1 mL of PBS with hyaluronidase at 37 °C was added on the top of 
the hydrogels. At predetermined time intervals, the enzyme solution was removed and the hydrogels 
were weighed. The degradation medium was replaced with freshly prepared enzyme solution of the 
same composition every 24 h. The degradation was determined as the % hydrogel mass left as a 
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Figure 3.35: Degradation profile of HA-BSA hydrogels prepared at different crosslinking densities in 
hyaluronidase solution of concentration 10 U/mL at 37 °C. A. Degradation profile of low crosslinked hydrogels 
HB16 and HB17, B. Degradation profile of high crosslinking densities of hydrogels HB18 and HB19. 
Hydrogels were also prepared as control and incubated in PBS at 37 °C in order to ensure the absence of 
degradation phenomena due to PBS or temperature. The data represent the average of triplicate with the 
corresponding error bar calculated by standard deviation. 
Hydrogels were also incubated in PBS at 37 °C in the absence of hyaluronidase in order to verify 
that the degradation process is not induced by temperature or the presence of PBS. Measurements 
were performed until complete degradation of the hydrogels was observed. As shown in Figure 3.35, 
low crosslinking densities of hydrogels HB16 and HB17 demonstrated significant % mass loss and 
complete degradation was observed after 2 and 3 days of incubation respectively. On the other hand, 
control hydrogels in the absence of the enzyme, started to undergo swelling. The degradation rate for 
the high crosslinked hydrogels was slower than that of lower crosslinking densities. HB18 and HB19 
hydrogels were completely degraded within 5 and 7 days respectively. In addition, in case of control 
hydrogels a slight increase in the hydrogel mass was observed due to swelling. These results are 
consistent with the corresponding swelling profile of the hydrogels. The high porosity of these 
scaffolds resulted in higher swelling capacity and increased interactions with the enzyme solution 
leading to shorter degradation time compared to HA-ADH hydrogels. 
3.3.2.5 Rheological characterisation of HA-BSA hydrogels 
The characterisation of the mechanical properties of the fabricated scaffolds prepared at different 
crosslinking densities was investigated by oscillatory rheology. HA-BSA hydrogels with a volume 
of 1 mL were prepared into glass vials with inner diameter of 14 mm as lower geometry and 
subsequently the upper geometry (relative cylinder) was inserted into the hydrogel as described 
previously. Before each measurement, a delay time of 30 minutes was set as for the hydrogel to settle. 
All the experiments were performed at 37 °C. Amplitude sweep experiment on the crosslinked 
hydrogels, was performed to determine the LVR of deformation for each crosslinking density at 
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constant frequency of 1 Hz. The elastic modulus G΄ and viscous modulus G΄΄ were plotted vs 
amplitude strain as shown in Figure 3.36. 
 
 
Figure 3.36: Amplitude sweep experiments performed on A. HB17 and B. HB18 crosslinking densities of HA-
BSA hydrogels. Strain scans were performed within a range from 0.01 to 100 % keeping constant frequency 
at 1 Hz. 
Both viscoelastic moduli demonstrated strain dependent relationship across the range of strain values 
measured which indicated the viscoelastic behaviour of these materials. As presented in Figure 3.36, 
hydrogels showed linear viscoelastic behaviour up to a critical strain value of 10 %. Therefore, a 
strain value of 5 % within the LVR was chosen for all hydrogels and applied subsequently to the 
frequency sweep test. In addition, the reversibility of the viscoelastic behaviour of the hydrogels was 
investigated by  amplitude sweep experiment which was run on the same sample (HB17 crosslinking 
density) for 3 times. The sample was subjected to increasing shear strain and the viscoelastic 
behaviour was identified. As presented in Figure 3.37, the three measurements showed the same 
trend which indicated that the hydrogel can reverse to its initial viscoelastic profile, highlighting the 
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Figure 3.37: Amplitude sweep experiment on HB17 hydrogel was run three times on the same sample. The graph 
demonstrates the reversibility of the viscoelastic properties of the material. 
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Frequency sweep test was performed within the LVR at a constant strain of 5 % and angular 
frequencies in the range of 0.1 to 100 rad/sec. The average elastic modulus G΄ and viscous modulus 
G΄΄ were plotted vs angular frequency as demonstrated in Figure γ.γ8. The frequency sweep 
experiment indicated that the fabricated scaffolds prepared at different crosslinking densities, 
presented viscoelastic behaviour as the elastic modulus G΄ was higher than the viscous modulus G΄΄
throughout the entire frequency range. The frequency dependence of both viscoelastic moduli was 
indicative of the homogeneous formation of a crosslinked hydrogel network. As shown in Figure 
3.38, the increasing crosslinking density presented significant effect on the stiffness of the hydrogels. 
Hydrogels prepared at high crosslinking densities HB18 and HB19 presented average elastic moduli 
of 100 and 180 Pa respectively. 
 
                     
                  
Figure 3.38: Frequency sweep experiments performed on A. HB16, B. HB17, C. HB18 and D. HB19 
crosslinking densities of HA-BSA hydrogels using a constant strain of 5 % in angular frequencies in the range 
of 0.1 to 100 rad/sec. The data represent the average of three independent measurements with the corresponding 
error bar calculated by standard deviation.  
In contrast, low crosslinking degree resulted in softer hydrogels HB16 and HB17 with elastic moduli 
of 22 and 45 Pa respectively. In comparison with the HA-ADH hydrogels, the crosslinking method 































































3.3.2.6 DSC analysis of HA-BSA hydrogels 
DSC measurements were performed to confirm the results obtained from FT-IR regarding the 
structural change of HA backbone. The FT-IR analysis showed that the crosslinking reaction between 
HA and BSA could have happened as there was slight change in the carbonyl region of the spectra. 
Figure 3.39 depicts the DSC thermographs of HA, BSA and HA-BSA xerogel. HA presented a broad 
endothermic peak approximately at 99 °C and a sharp exothermic peak at 237 °C. The endothermic 
peak is associated with the loss of water from the HA molecule, while the exothermic peak can be 
attributed to the thermal degradation of the polymer. BSA showed a broad endothermic peak at 204 
°C that can be assigned to the thermal degradation of the protein [67]. The DSC thermograph of the 
HA-BSA xerogel presented a broad endothermic at 74.1 °C due to the loss of water and a broad 
exothermic peak at 215 °C that corresponds to the thermal degradation of the system. Overall, the 
DSC curve of HA-BSA xerogel presented differences compared to the curves of the pure compounds. 
The DSC thermographs demonstrated that the endothermic and exothermic peaks of the HA slightly 













Figure 3.39: DSC thermographs of A. HA, B.  BSA and C. HA-BSA xerogel. 
3.3.2.7 Drug release from HA-BSA hydrogels 
The drug release profile of the HA-BSA hydrogels loaded with DOX or TMZ was studied. Similar 
to the protocol followed for the drug loading on the HA-ADH hydrogels, the drug was mixed with 
the precursor polymer solution and gelation was allowed to occur with the drug encapsulated within 
the hydrogel network. Briefly, the crosslinked hydrogels loaded with DOX or TMZ were prepared 
in glass vials according to the protocols described in sections 3.2.2.10 and 3.2.2.11. All hydrogels 
demonstrated facile encapsulation of DOX or TMZ and self supporting hydrogels were formed as 





      
               
Figure 3.40: Photos of DOX-loaded and TMZ-loaded hydrogels prepared at HB17 and HB18 crosslinking 
densities. Self-supporting hydrogels were prepared in triplicate. 
Subsequently, hydrogels were incubated in PBS (pH 7.4) at 37 °C and at specific time intervals the 
release medium was removed. The concentration of the released drug was determined and the % 
cumulative release was calculated as described in previous sections. Figure 3.41 summarises the % 
cumulative release profiles of HA-BSA hydrogels loaded with DOX or TMZ. The % drug release 
from hydrogels was affected by the crosslinking density as decreased % drug release was observed 
with an increase in the crosslinking density. A cumulative DOX release of 64 and 53 %  for low 
crosslinked hydrogels HB16 and HB17 respectively was observed, while the % DOX release for 
HB18 and HB19 hydrogels was 42 and 26.3 respectively. Similarly, the % TMZ release was higher 
in low crosslinking densities reaching  % cumulative release of 49 and 31 for HB16 and HB17 
hydrogels respectively and lower in high crosslinking densities HB18 and HB19 reaching cumulative 
release of 23 and 15 % respectively. These results indicated that the fabricated hydrogels promoted 
the sustained release of the loaded drugs over a period of time and they can be suitable candidates 
for the localised treatment of GBM.   
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HB16 TMZ 0.05 mg/mL
HB17 TMZ 0.05 mg/mL
HB18 TMZ 0.05 mg/mL
HB19 TMZ 0.05 mg/mL
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Figure 3.41: Drug release profiles of HA-BSA hydrogels prepared at different crosslinking densities. A. Drug 
release profile of DOX-loaded hydrogels and B. Drug release profile of TMZ-loaded hydrogels in PBS at 37 




3.3.3 Characterisation of blend XG/MC hydrogels 
3.3.3.1 FT-IR characterisation of blend XG/MC hydrogels 
As discussed in Chapter 2, XG and MC were used in order to prepare injectable, biocompatible blend 
XG/MC hydrogels, alternative to HA gels. Different compositions of blend hydrogels were prepared 
as described in Table 3.3 and they will be briefly characterised by FT-IR spectroscopy and Scanning 
Electron Microscopy due to their poor biocompatibility as it will be discussed in the following 
chapter. Self-supporting hydrogels were formed and xerogels were obtained according to the protocol 
described earlier. The changes in the structure of the XG/MC xerogels compared to the structure of 
the native polysaccharides were investigated by FT-IR spectroscopy. 








Figure 3.42 presents the FT-IR  spectra of the  XG/MC xerogel and its main components XG and 
MC. In the spectrum of the native XG, the broad peak at 3296 cm-1 is associated to the O-H stretch 
band, while the small peak at 2885 cm-1 is attributed to the -CH2 stretching vibrations. Moreover, the 
C=O band at 1738 cm-1 corresponds to the acetate groups of the mannose moiety, while the peak at 
1605 cm-1 is assigned to the carboxylate groups of the pyruvate unit and glucuronic acid [68]. 
 































      XG 
Concentration 
    (% w/w) 
      MC  
Concentration 
  (% w/w)                        
XG1/MC0         1            0                 
XG1/MC3         1            3                   
XG1/MC6         1            6               
XG1/MC8         1            8           
XG2/MC1         2            1            
XG2/MC6         2                                   6                       






The small characteristic peak at 2830 cm-1 presented in the spectrum of the native MC is associated 
to the stretching vibration of C-H in the methyl ester group. The broad peak at 3456 cm-1 corresponds 
to the O-H stretching vibration [69]. The C=O stretching vibration observed at 1641 cm-1 and the 
sharp peak at 1063 cm-1 is related to the stretching vibration of C-O bond. In the spectrum of XG/MC 
xerogel the characteristic peak at 2857 cm-1 that is attributed to the C-H band of the methyl ester 
group confirmed the presence of MC. The peak at 1652 cm-1 that represents the C=O stretching of 
the acetate groups was slightly shifted. In overall, the results from FT-IR analysis indicated that there 
was not formation of a new chemical bond and both polysaccharides kept their own chemical 
structures.  
3.3.3.2 SEM characterisation of blend XG/MC hydrogels 
Blend XG/MC hydrogels prepared at different compositions were freeze-dried and coated with gold 
as described previously. SEM micrographs were obtained at different magnifications as shown in 
Figure 3.43. XG1/MC0 xerogel presented a disorganised porous structure with various pore sizes, 
while in case of higher concentration of MC in XG1/MC6 xerogel the density of the network was 
significantly higher with low porosity. XG2/MC1 xerogel demonstrated a disorganised 
interconnected porous structure, whereas XG2/MC6  similar to XG1/MC6 sample presented a 
network consisted of dense polymer sheets. On the other hand, the porosity was higher in XG3/MC1 
xerogel.  
                
                                         
Figure 3.43: SEM micrographs of XG/MC xerogels prepared at various compositions. A. XG1/MC0, B. 
XG1/MC6, C. XG2/MC1, D. XG2/MC6 and E. XG3/MC1 hydrogel. SEM photos were obtained at different 
magnifications. Scale bar: 300-500 μm.   
As stated in the previous sections, the porous structure is beneficial for rapid diffusion of nutrients 
throughout the network, improving the efficacy in cell adhesion, proliferation and migration. In 




summary, these observations indicated that the presence of XG promoted porosity of the fabricated 
scaffolds, in contrast to MC which induced the formation of a denser network. The high incorporation 
of MC significantly changed the morphology of XG xerogels which resulted in lower porosity and 
low cell viability as it will be discussed further in Chapter 4.  
3.4 Conclusions 
The characterisation of the physicochemical and mechanical properties of hydrogels designed for 
biomedical applications is of paramount importance. The aim of this thesis was to prepare injectable 
biocompatible hydrogels that will mimic the mechanical properties of the brain tissue and facilitate 
cell invasion and migration in response to the loaded gradient chemoattractant UII. The first half of 
Chapter 2 focused on the preparation of HA-based hydrogels formed at differerent crosslinking 
densities, while in the second half, the preparation of blend hydrogels based on MC was discussed.  
The current chapter focused on the main experimental methods devoted to the characterisation of the 
fabricated hydrogels. In particular, attention  focused on the determination of swelling degree, 
characterisation of the surface morphology using SEM, characterisation of their structure using FT-
IR, determination of the enzymatic degradation rate in vitro conditions, characterisation of the 
mechanical properties using oscillatory rheology and investigation of the release profile of hydrogels. 
FT-IR spectroscopy allowed to investigate the changes in the structure of the polysaccharides after 
the crosslinking reaction, while the surface morphology and porosity of the fabricated crosslinked 
scaffolds were investigated by SEM. HA based hydrogels presented an interconnected porous 
structure and porosity that was highly dependent on the crosslinking density. In addition, the high 
porosity of the hydrogels enabled them to swell and the equilibrium swelling degree was determined. 
The degradation rate of the fabricated hydrogels incubated with hyaluronidase solution was found to 
be significantly dependent on the swelling degree and the enzyme concentration. The mechanical 
characterisation of the hydrogels revealed that their viscoelastic properties were close to those of the 
brain tissue, highlighting their potential as injectable scaffolds in the brain. The drug release studies 
performed on hydrogels showed that these crosslinked networks can promote sustained release of 
the drug over a specific period of time, while the release experiments of the FITC-loaded hydrogels 
demonstrated low amount of the chemoattractant is released as most of it remains inside the gel, 
which is desirable for the specific application. 
Overall, the physicochemical and mechanical features of the fabricated hydrogels showed that could 
facilitate cell growth and migration. The in vitro biocompatibility of the crosslinked hydrogels and 
the potential to promote migration of glioma cells when loaded with a gradient concentration of the 
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Chapter 4: In vitro evaluation of glioma cells response on polysaccharide-
based hydrogels 
4.1 Introduction 
Glioma cells are known for their aggressive and invasive nature which results in inevitable tumour 
recurrences. Current targeted strategies for GBM treatment including hydrogels as drug delivery 
systems lack of several limitations. As discussed in Chapter 1, the majority of the studies have 
employed these matrices as injectable anticancer drug delivery depots to the tumour site after 
resection of the tumour. The introduction of artificial scaffolds that can not mimic the structure and 
properties of the ECM is one of the key reasons why most of these systems are not functional. 
Moreover, these systems lack of effective chemoattractants, allowing residual glioma cells that have 
not been removed from the surgery to infiltrate healthy brain tissue and increase the risk for tumour 
reformation. Therefore, there is a number of reasons for the development of viable GBM treatment 
based on hydrogels derived from molecules that naturally exist in the brain ECM that can promote 
migration of glioma cells in response to loading of chemoattractants. 
Herein, in order to address the limitations of the anticancer drug-loaded hydrogels that have been 
used in the treatment of GBM, we proposed an easy and cost-effective fabrication of chemoattractant-
loaded hydrogels mainly consisted of molecules that naturally exist in the brain ECM such as HA. 
Specifically, fabricated hydrogels were loaded with human UII as chemoattractant at a ʺpotentially 
gradient concentrationʺ and subsequently with an anticancer drug in order to achieve cell migration 
in the hydrogel and apoptosis of migrated glioma cells into the hydrogel matrix.  
The first section of this chapter provides a brief review on the structure of the brain ECM and the 
scaffolds that have been fabricated so far in order to mimic this matrix. Chapters 2 and 3 have already 
presented the preparation methods and the physicochemical and mechanical characterisation of the 
hydrogels. In this chapter, the biocompatibility of the fabricated hydrogels and the in vitro response 
of glioma cells on them will be investigated. 
4.1.1 Brain ECM 
The ECM in the brain occupies up to 20 % of the adult brain volume and plays a vital role in neural 
development and function, whereas the majority of the CNS volume is composed of neural cells, e.g. 
neurons, astrocytes, oligodendroglial cells, microglia and blood vessels [1]. Although, the brain ECM 
has many components that can be found in the ECM of other tissues, there are some distinct 
differences in its composition. As illustrated in Figure 4.1, it is mainly composed of water, sulfated 
proteoglycans (PGs) such as chondroitin sulfate and glycosaminoglycans (GAGs) such as 
hyaluronan or hyaluronic acid (HA) which are long linear polysaccharides and they are localised at 
the intercellular spaces. In contrast, fibrillar components such as laminin present in the basal 
membrane for elasticity, fibronectin (mainly produced by fibroblasts) and collagen (mainly produced 
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by vascular components) that are typical constituents expressed in other tissues, are rarely found in 
the brain parenchyma, while their levels are rather low compared with the connective tissue [2].  
 
Figure 4.1: The main components of the CNS ECM including specific proteoglycans, low amounts of fibrillar 
adhesive proteins such as laminin, fibronectin, collagen and integrins as the major ECM adhesion receptors. 
Adapted from Zhu et al [3]. 
ECM proteins play a key role in cell-matrix interactions due to the fact they are recognised by cell 
surface receptors and are involved in physiological cellular processes e.g. proliferation, 
differentiation and migration. Cells express specific receptors on their surface for components of 
ECM, which mediate these responses. For example, HA binds to specific cell receptors such as the 
cluster determinant adhesion molecule (CD44) and to receptor for hyaluronan-mediated motility 
(RHAMM) that can regulate cell proliferation, adhesion and motility. 
4.1.2 ECM in brain tumours 
Many alterations occur in the composition of the ECM in case of brain tumours, as summarised in 
Table 4.1. The changes involve increased secretion of non-typical ECM components in the vicinity 
of the invading cells in front of the tumour bulk. Some of the secret d molecules such as vitronectin, 
tenascin C or some specific αvί integrins are associated with cell motility and angiogenesis which 
are both critical for tumour growth. This increased production of tumorous ECM molecules results 
in a significant increase in its volume through adhesion which contributes to intracranial pressure 
and oedema in the restricted extracellular space [4]. Extensive degradation of the ECM in close 
proximity to the tumour bed occurs, specifically in high-grade glioma. Then tumour cells overexpress 
αvί integrin receptors on their surface and are allowed to detach from the core tumour and migrate 
along tract structures within the brain.  
Furthermore, glycosaminoglycans such as HA is expressed in case of high-grade gliomas at high 
levels, which can be 20 times higher than in normal adult brain. Moreover, chondroitin sulfate 
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proteoglycans in the normal brain, are known for their inhibitory effect on stem cell migration, 
whereas in glioma they are upregulated and promote glioma cell migration [5]. In the context of 
GBM growing, fibrous proteins rarely found in normal brain, appear to be highly expressed by GBM 
cells [6], [7]. Tenascins (C and R) consist a family of glycoproteins present in the ECM and they are 
involved in proliferation, migration, and morphogenesis, playing an important role in the 
development of CNS. Galectins are also upregulated in glioma and they are involved in glioma cell 
migration and angiogenesis. Particularly, levels of Gal-1 are indicative of the aggressiveness of many 
tumours [8].  
Table 4.1: Representative ECM molecules present in the brain and brain tumours (+ indicates the presence of 
the molecule, +++ indicates the presence at high levels, - indicates the absence of the molecule).  
Molecules Location 
    Brain                Glioma 
Glycosaminoglycans (GAGs): 
 Hyaluronan (HA) 
    
       +                      +++ 
Proteoglycans (PGs): 
Chondroitin sulfate 
       +                      +++   
Glycoproteins: 
Tenascin: C and R 
       +                      +++ 
Galectins        +                      +++ 
Fibrous proteins (collagen, 
laminin, fibronectin) 
       -                        + 
 
4.1.3 Scaffolds to mimic the brain ECM properties 
The complexity and the diversity in the composition of brain ECM plays a significant role in GBM 
invasion, highlighting the significance of studying further glioma cells-ECM interactions. To date, 
several studies have focused on the development of biocompatible matrices in order to mimic the 
properties of the ECM and study extensively glioma cells behaviour. Yang et al fabricated composite 
hydrogels consisted of blends of collagen-chondroitin sulfate and collagen-HA i  order to mimic the 
ECM surrounding high-grade gliomas [9]. The effect of chondroitin sulfate and HA on glioma 
invasion was investigated. Chondroitin sulfate demonstrated an inhibitory role on glioma invasion, 
whereas HA did not present any important effect. Kievit t al developed a 3D scaffold that was 
composed of chitosan and alginate as model microenvironment to study the behaviour of glioma cells 
cultured on these scaffolds [10]. They found that these scaffolds were able to provide a growth 
environment for glioma cells in vitro. On the other hand, Pedron et al reported the use of gelatin 
modified with methacrylic anhydride for the preparation of scaffolds to investigate the impact of 
biophysical properties such as crosslinking density and stiffness on the glioma phenotype [11].  
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4.1.4 HA as main component of brain ECM and its role in glioma  
HA as a non-sulfated glycosaminoglycan is one of the main components of the native brain ECM 
and occupies a large part of the extracellular volume of the brain, mainly located in the white matter 
tracts [12], [13]. There is a lot of evidence that HA plays a critical role in glioma progression but 
most importantly higher levels of HA are present in malignant gliomas than in the normal brain 
tissue. HA through interaction with CD44 or RHAMM expressed by glioma cells promotes migration 
and invasion of glioma cells [14] as illustrated in Figure 4.2. CD44 is a membrane glycoprotein 
frequently overexpressed in gliomas and is correlated with increased malignancy and reduced mean 
survival time [15]. RHAMM is also well-known as a HA-binding protein and is expressed on the cell 
surface and in the cytoplasm, as well as in the cytoskeleton and nucleus [16]. As it was mentioned 
earlier, this protein regulates cell proliferation, adhesion and motility. The cellular signalling 
pathways involving RHAMM and CD44 receptors will not be discussed further as it is beyond of the 
scope of this thesis. 
 
       
Figure 4.2: A. Schematic illustration of brain tumour-favourable microenvironment highlighting the HA 
enriched ECM, B. Illustration of the three major components in HA production and degradation that are present 
in the ECM. Adapted from Cha et al [17]. 
Recently, there has been a growing interest in the development of hydrogels to understand tumour 
biology. Glioma cells-ECM interactions have been investigated on 3D matrices and they are mainly 
restricted to collagen or Matrigel based scaffolds [18], [19]. Limitations of these scaffolds due to the 
different consistency and structural organisation of brain parenchyma, render the understanding of 
invasion mechanism complicated. In chapter 2, some of the biomedical applications of HA-based 
hydrogels were noted, but only few studies have investigated the use of these matrices to study the 
cell-matrix interactions in GBM invasion. Rao et al developed multicomponent composite hydrogels 
composed of collagen and HA. Consequently, they studied glioma cell morphology and migration 
on these scaffolds. Glioma cells obtained rounded morphology and their migration was mainly 
dependent on the concentration of HA [20]. Ananthanarayanan et l fabricated HA-based hydrogels 




study the mechanobiology of glioma cell morphology and invasion which was dependent on RGD 
concentration as shown in Figure 4.3 [21]. 
 
 
       
Figure 4.3: A. Morphology of glioma cells adherd to RGD-functionalised HA gels with various 
concentrations of RGD peptide, B. 3D invasion of glioma spheroids through HA-RGD hydrogels. U373 MG 
cells dispersed and invaded as single cells (open arrows) whereas U87MG and C6 cells retained spheroid 
borders with cells invading at the edges (filled arrows). No cells invaded the dense 5 kPa hydrogel, C. 
Regulation of glioma cell motility by matrix stiffness. The graph depicts the average speed of random motility 
of U373 MG cells cultured on RGD functionalised HA gels of constant RGD peptide density and varying 
stiffness. Cell motility was higher on glass surface compared with hydrogel matrix. Adapted from 
Ananthanarayanan et al [21].                                                                      
Pedron et al reported the development of gelatin and PEG based hydrogels with the incorporation of 
HA into the hydrogel network [22]. They investigated the glioma cell phenotype on these scaffolds, 
highlighting the formation of clusters and the increased expression of malignancy associated genes 
in the HA containing hydrogels. 
4.1.5 Human Urotensin II as chemoattractant  
In the late 1970s, Conlon et al demonstrated the presence of urotensin in the brain of a tetrapod, the 
green frog Rana ridibunda [23]. Urotensin II (UII) is a cyclic peptide consisting of 11 amino acids 
in humans, including the presence of a cyclic hexapeptide C-terminal Cys-Phe-Trp-Lys-Tyr-Cys, 






Figure 4.4: Chemical structure of human Urotensin II, including the presence of a cyclic hexapeptide. 
UII is mainly located in the cardiovascular, renal and endocrine systems as well as within the CNS 
[24]. In humans, high expression levels of UII are found in the myocardium, the atria, and the 
ventricles [25]. Additionally, low amount of this peptide was detected in extracts of cerebrospinal 
fluid (CSF) in humans [26]-[28]. 
Recently, it has been reported that UII promoted proliferation of A549 lung adenocarcinoma cells 
and tumour growth in a nude mouse xenograft model [29]. This vasoactive peptide has been involved 
in the release of proinflammatory cytokines and matrix metalloproteinase-9 in the tumour 
microenvironment of lung adenocarcinoma [30]. In this context, UII overexpressed in malignant 
gliomas could play a key role in the tumour growth and the invasion of these tumour cells. As 
discussed in Chapter 1, one of the unique features of GBM is the highly invasive nature of glioma 
cells. The invasive behaviour can be attributed not only to chemoattractant factors such as growth 
factors but also chemokines or vasoactive peptides which activate G protein coupled receptors 
(GPCRs). Among these receptors, the chemokine receptor CXCR4 is widely recognised by glioma 
cells [31]. It is noteworthy that vasoactive peptide receptors have been involved in migration of 
various cancer cell lines such as neuropeptide Y on a breast cancer cell line and bradykinin on glioma 
cells [32], [33]. Most importantly, it has been demonstrated that UII can induce chemoattraction of 
human monocytes through its GPCR receptor (UT), highlighting its potential as a new chemokine 
[34]. Recently, Castel et al reported that GBMs highly express UII and demonstrated that gradient 
concentrations of UII (10-8 M) exhibited chemoattracting behaviour on glioma cells and HEK 293 
cells expressing human UT as presented in Figure 4.5 [35]. In contrast, it was observed that 
homogenous concentrations of UII (10-8 -10-10  M) drastically blocked cell motility of glioma cells.   
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Figure 4.5: Migration profile of HEK and SW1088 cells in response to gradient concentration of UII. A. 
Migration of human UT expressing HEK293 cells in the presence or absence of UII (10-9 M). B. Migration of 
astrocytoma SW1088 cells in the presence or absence of UII (10-9). Cell migration was evaluated by counting 
hemotoxylin stained cells on the transwell membranes. The histograms represent the percentage of migrated 
cells in comparison with the control (untreated cells). Each bar corresponds to mean ± SEM obtained from 3 
to 12 independent experiments in triplicates. Data adapted from Lecointre et al [35]. 
4.2 Experimental 
4.2.1 Materials 
Human UII (MW=1388.56 Da, purity: 86.2 %) was purchased from PolyPeptide Laboratories. 
Human fibronectin 0.1 % v/v was purchased from Sigma Aldrich. Dulbecco’s Modified Eagle 
Medium (DMEM), Antibiotic/Antimicotic (AA, Penicillin 10.000 U/mL, Streptomycin 10.000 
μg/mL and 25 μg/mL FungizoneTM) and Fetal Bovine Serum (FBS) were purchased from Gibco by 
Life Technologies. Sodium pyruvate solution and Dulbecco’s phosphate buffered saline (1×DPBS) 
were purchased from Sigma Aldrich. Trypsin-EDTA solution (0.05 %) was purchased from Gibco 
by Life Technologies. The human glioblastoma cell lines U87MG (ATCC, HTB-14, grade IV WHO 
classification) were purchased from American Type Culture Collection (ATCC Manassas, VA, 
USA). The other glioma cell lines 42 MG were provided by Professor J. Honnorat (CRNL, Lyon, 
France).  The cell culture flasks, 24, 48 and 96-well plates were purchased from Thermo Fischer 




Proliferation Assay) and it was purchased from Promega. Live/Dead Cell Viability/Cytotoxicity kit 
was purchased from Molecular Probes. Ki-67 antibody was purchased from Santa Cruz 
Biotechnology, 4',6-Diamidino-2-Phenylindole (DAPI) was purchased from Invitrogen. Normal 
Donkey Serum was purchased from Abcam. Alexa Fluor anti-goat 488 antibody was purchased from 
Molecular Probes. Corning Transwell polycarbonate membrane cell culture inserts and hematoxylin 
solution (Harris Modified) were purchased from Sigma Aldrich. CitiFluorTM mounting solution was 
purchased from Science Services and Mowiol mounting solution was purchased from Sigma Aldrich. 
DOX HCl, TMZ and Paraformaldehyde were purchased from Sigma Aldrich. 
4.2.2 Methods 
4.2.2.1 Cell culture 
Glioma cell lines (U87MG, 42 MG) were cultured in DMEM supplemented with 10 % FBS, 1% AA 
and 1 % sodium pyruvate at 37 °C and 5 % CO2 in a fully humidified incubator. Cells were routinely 
passaged upon reaching confluency using Trypsin EDTA 0.05 % for their detachment from the 
culture flask. 
4.2.2.2 Preparation of chemoattractant (UII)-loaded HA-ADH hydrogels 
Four different crosslinking densities of HA-ADH hydrogels were investigated and the detailed 
protocol for one of them is described below. HA sodium salt (10.0 mg, 6.25 nmoles) was dissolved 
in 800 μL of sterile deionised water and EDC (0.β6 mg, 1.γ5 μmoles) was dissolved in 100 μL of 
deionised water and added at different molar ratios to the aqueous HA solution. EDC was allowed to 
dissolve before the addition of ADH. The crosslinker ADH (0.β5 mg, 1.4γ μmoles) was subsequently 
dissolved in 100 μL of sterile deionised water and was added to the activated HA solution. A stock 
solution of the chemoattractant UII of 10-4 M concentration was prepared and added in the gelator 
solution. The final concentration of the chemoattractant in the hydrogel was 10-8 M. The pH of the 
solution was adjusted at pH 5.5 with the addition of HCl 0.1 M. Gelation was allowed to occur with 
gentle vortexing. HA-ADH hydrogels were washed 3 times with PBS for the removal of any excess 
of unreacted crosslinker.   
4.2.2.3 Preparation of chemoattractant (UII)-loaded HA-BSA hydrogels 
Four different crosslinking densities of HA-SA hydrogels were prepared and the detailed protocol 
for one of them is described below. The ratios of BSA, sulfo-NHS and EDC were adjusted to obtain 
hydrogels optimised for cell adhesion. Briefly, HA sodium salt (6.0 mg, 3.75 nmoles) was dissolved 
in 800 μL of sterile deionised water. HA was activated with EDC, (2.0 mg, 10.4 μmoles) and N-
hydroxysulfosuccinimide (sulfo-NHS) (0.5 mg, β.γ μmoles) mixture in a molar ratio 4:1 in β00 μL 
of sterile deionised water and the pH was adjusted at pH 6.0 with the addition of HCl 0.1 M before 
the reaction with the BSA molecule. The reaction was allowed to proceed for 2 minutes by vortexing. 
A stock solution of the chemoattractant UII of concentration 10-4 M was prepared and added in the 
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gelator solution. The final concentration of the chemoattractant in the hydrogel was 10-8 M.  Then 
BSA (3.0 mg, 45.4 nmoles) was added as a powder to the activated HA solution for further 
crosslinking and gelation was allowed to occur with gentle vortexing. HA-BSA hydrogels were 
washed 3 times with PBS for the removal of any excess of unreacted crosslinker.   
4.2.2.4 Preparation of DOX-loaded HA-ADH hydrogels 
Different crosslinking densities of HA-ADH hydrogels were investigated and the detailed protocol 
for one of them is described below. HA sodium salt (10 mg, 6.β5 nmoles) was dissolved in 800 μL 
of sterile deionised water and EDC (0.β6 mg, 1.γ5 μmoles) was dissolved in 100 μL of deionised 
water and added at different molar ratios to the aqueous HA solution. EDC was allowed to dissolve 
before the addition of ADH. The crosslinker ADH (0.β5 mg, 1.4γ μmoles) was subsequently 
dissolved in 100 μL of deionised water and was added to the activated HA solution. A stock solution 
of DOX of concentration 100 μM was prepared and 100 μL were added to the reaction mixture. The 
final concentration of the drug in the hydrogels was 10 μM. Gelation was allowed to occur with 
gentle vortexing. Hydrogels were washed with PBS for the removal of any excess of unreacted 
crosslinker. 
4.2.2.5 Preparation of DOX-loaded HA-BSA hydrogels 
Different crosslinking densities of HA-ΒSA hydrogels were prepared and the detailed protocol 
for one of them is described below. Briefly, HA sodium salt (6.0 mg, 3.75 nmoles) was dissolved in 
800 μL of sterile deionised water. HA was activated with EDC (β.0 mg, 10.4 μmoles) and sulfo-NHS 
(0.5 mg, β.γ μmoles) mixture in a molar ratio 4:1 in β00 μL of deionised water and the pH was 
adjusted at pH 6.0 with the addition of HCl 0.1 M before the reaction with the protein. The reaction 
was allowed to proceed for 2 minutes by vortexing. Then BSA (3.0 mg, 45.4 nmoles) was added as 
a powder to the activated HA solution for further crosslinking. A stock solution of DOX of 
concentration 100 μM was prepared and 100 μL were added to the reaction mixture. The final 
concentration of the drug in the hydrogels was 10 μM. Gelation was allowed to occur with gentle 
vortexing.   
4.2.2.6 Preparation of MC hydrogels for U87MG cell culture 
For detailed protocol refer to chapter 2 (Section 2.2.2.3). 
4.2.2.7 Preparation of blend XG/MC hydrogels for U87MG cell culture 
For detailed protocol refer to chapter 2 (Section 2.2.2.4). 
4.2.2.8 Glioma cell culture on HA-ADH hydrogels 
HA-ADH hydrogels at different crosslinking densities were prepared into the wells of a 48-well plate 
with a final volume of 250 μL in the presence or absence of the chemoattractant UII (10-8 Μ). The 
hydrogels were rinsed three times with PBS and they were incubated with 200 μL of DMEM (1 % 
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AA, 1 % sodium pyruvate, in the absence of FBS) for 2 h for buffer exchange. Then glioma cells 
(U87MG, 42 MG) were passaged and seeded on the surface of the hydrogels at a density of 5×103 
cells per well.  Subsequently, the cells were seeded for 4 days in DMEM supplemented with 1 % of 
AA and 1 % of sodium pyruvate in the absence of serum at 37 °C in a fully humidified incubator 
(IGO150 CELL life CO2 Incubator, Thermo Fischer Scientific). The culture medium was replaced 
every second day. The morphology of glioma cells seeded on the hydrogels was monitored as a 
function of incubation time and cultures were imaged using a camera connected to a NIKON inverted 
microscope. 
4.2.2.9 U87MG cell culture on HA-BSA hydrogels 
HA-BSA hydrogels at different crosslinking densities were prepared into the wells of a 96-well plate 
with a final volume of hydrogel 50 μL in the presence or absence of the chemoattractant (10-8 Μ). 
Τhe hydrogels were rinsed three times with PBS and they were incubated with 100 μL of DMEM 
(1% AA, 1 % sodium pyruvate, in the absence of FBS) for 2 h for buffer exchange. Then U87MG 
cells were passaged and seeded on the surface of the hydrogels at a density of 5×103 cells per well. 
The cells were seeded for 2 days in DMEM supplemented with 1 of % AA and 1% of sodium 
pyruvate in the absence of serum at 37 °C. The morphology of glioma cells seeded on the hydrogels 
was monitored as a function of incubation time and cultures were imaged using an EVOS FLoid Cell 
Imaging station. 
4.2.2.10 Cell viability-MTS assay on HA-ADH hydrogels 
The viability of U87MG and 42 MG cells seeded on HA-ADH hydrogels, measured as a function of 
mitochondrial activity, was determined by MTS assay.  Briefly, U87MG and 42 MG cells were 
seeded on 50 μL of different crosslinking densities of HA-ADH hydrogels at a density of 5×103 cells 
per well in a 96-well plate in 100 μL of DMEM supplemented with 10 % of FBS, 1 % of AA and 1 
% of sodium pyruvate in a fully humidified incubator. The cells were seeded on the hydrogels for 24 
and 48 h. After 24 and 48 h of incubation, MTS solution (20 μL) was added to the wells as per 
manufacturer’s protocol and the plate was placed in the incubator for 1 h. The absorbance was 
measured at 490 nm using a microplate reader (Tecan Infinite M200 Pro).  
% Cell viability was calculated assuming the well containing only U87MG or 42 MG cells as positive 
control (100 % viability). The resulting viability of the hydrogels was calculated using the following 
equation: 




As background for the positive control, wells contained only DMEM and MTS solution. As 
background for the conditions with the hydrogels, wells contained only hydrogels in DMEM and 
MTS. The background absorbance was subtracted from the absorbance of the wells containing cells. 
4.2.2.11 Cell viability-MTS assay on HA-BSA, MC and on blend XG/MC hydrogels 
The viability of U87MG cells on HA-BSA, MC and XG/MC hydrogels was evaluated by MTS assay 
as described above. For the detailed protocol refer to section 4.2.2.10.  
4.2.2.12 Live/Dead assay on HA-ADH hydrogels 
Live/Dead Cell Viability Assay Kit was performed in order to evaluate qualitatively the viability of 
cells seeded on HA-ADH hydrogels after 24 and 48 h of incubation. The Live/Dead assay kit 
containing Calcein AM (β μg/mL in PBS) and ethidium homodimer (4 μg/mL in PBS) reagents was 
prepared as per manufacturer’s protocol. Briefly, U87MG and 4β MG cells seeded on the hydrogels 
as described above were washed with DPBS and incubated with 100 μL of Live/Dead staining 
solution for 25-30 minutes at room temperature. Images of the cultured cells were taken with an 
EVOS FLoid Cell Imaging station or a camera connected to a NIKON inverted microscope 
respectively. Viable cells were stained green because of their reaction with the Calcein AM and 
damaged cell membranes were stained red due to their reaction with ethidium homodimer. The green 
and red fluorescence images from viable and dead cells respectively were merged to one using 
ImageJ.  
4.2.2.13 Live/Dead assay on HA-BSA hydrogels 
Live/Dead Cell Viability Assay was performed in order to evaluate qualitatively the viability of cells 
seeded on HA-BSA hydrogels after 24 and 48 h of incubation. For the detailed protocol, refer to 
section 4.2.2.12. 
4.2.2.14 Immunofluorescence 
Immunofluorescence analysis was performed on U87MG and 42 MG cells cultured on HA-ADH 
hydrogels for 2 days. To isolate the cells seeded on the hydrogels, trypsin-EDTA solution was added 
on each hydrogel and with thorough mixing with DMEM, the cell solutions were transferred into 
centrifuge tubes. Cell pellets were obtained after centrifugation at 125g for 5 minutes. Glass 
coverslips were coated with fibronectin (1:50 dilution) and placed in a 24-well plate. Cell pellet was 
resuspended and cells were allowed to adhere on the coverslips for 24 h. Next day, cells were fixed 
with 4 % paraformaldehyde (PFA), permeabilised using 0.05 % Triton-1× PBS and blocked using 2 
% NDS (Normal Donkey Serum), 10 % FBS in 1×PBS for 1 h at room temperature. After blocking, 
cells were incubated with the primary antibody Ki-67 (1:300 dilution) overnight at 4 °C. After 24 h, 
cells were washed with PBS and incubated with Alexa-conjugated secondary antibody Alexa Fluor 
anti-goat 488 (1:250 dilution) for 2 h at room temperature. Finally, cell nuclei were counterstained 
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with 4́ ,6-diamidino-2-phenylindole (DAPI) in 1:1000 dilution (stock concentration 1 μg/μL) and 
they were imaged by confocal microscopy (Leica TCS SP5 confocal laser scanning microscope).  
4.2.2.15 Boyden Chamber invasion and migration assay on HA-ADH hydrogels 
HA-ADH hydrogels were prepared at two different crosslinking densities (L1 and L2 conditions) 
according to the preparation protocol. A thin layer of hydrogel (100 μL) was applied to the upper 
part of the polycarbonate membranes with pore size 8 μm. U87MG and 42 MG cells were harvested 
by trypsinisation and 5×104 cells resuspended in 100 μL of DMEM in the absence of serum. 
Subsequently, cells were seeded on the hydrogel layer, whereas the lower chamber was filled with 
600 μL of DMEM in the absence of serum (control buffer) or in the presence of UII (10-8 M). U87MG 
and 42 MG cells were allowed to invade and migrate through the thin layer of hydrogel for 48 h at 
37 °C. At the end of the assay, the upper chambers were removed from the transwell unit and cells 
that had not migrated from the upper surface of the membrane were removed gently with a 
cottonwool swab. Then U87MG and 42 MG cells were fixed and stained with hematoxylin solution. 
Polycarbonate membranes with fixed cells were mounted on microscope slides. Photos of the 
membranes were taken with EVOS FLoid Cell Imaging station and quantification of the migrated 
cells was performed with ImageJ. 
4.2.2.16 Boyden Chamber invasion and migration assay on HA-BSA hydrogels 
HA-BSA hydrogels were prepared at three different crosslinking densities (HB16, HB17 and HB18 
conditions) according to the protocol. A thin layer of hydrogel (100 μL) was applied to the upper 
part of the membrane. U87MG cells were passaged and 5×104 cells resuspended in 100 μL of DMEM 
in the absence of FBS and they were seeded on the thin layer of the hydrogel. As described above, 
U87MG were allowed to invade the thin layer of hydrogel and migrate through the porous 
membranes for 48 h at 37 °C. Then cells were fixed and stained with hematoxylin and photos of the 
membranes were taken with an EVOS FLoid Cell Imaging station. 
4.2.2.17 In vitro cytotoxicity of DOX on U87MG cells 
The in vitro cytotoxicity of DOX on U87MG cells was evaluated by MTS assay. Briefly, U87MG 
cells were passaged, seeded into the wells of a 96-well plate at a density of 5×103 cells per well and 
allowed to adhere in DMEM supplemented with 10 % FBS, 1 % AA and 1 % sodium pyruvate for 
24 h. Subsequently, glioma cells were treated with various concentrations of DOX (0.01-10  μΜ) 
for 24, 48 and 72 h. After these incubation times, MTS solution (20 μL) was added to the wells as 
per manufacturer’s protocol and cells were incubated at γ7 °C for 1 h. The absorbance was measured 
at 490 nm and the % cell viability was calculated. The IC50 value of DOX was determined as the 




4.2.2.18 In vitro cytotoxicity of DOX-loaded HA-ADH hydrogels   
The in vitro cytotoxicity of DOX-loaded hydrogels was determined using MTS assay. Briefly, DOX- 
loaded hydrogels were prepared into the wells of a 96-well plate as described above in section 4.2.2.4. 
U87MG cells were passaged and seeded on the drug-loaded hydrogels at a density of 5×103 cells per 
well for 24 and 48 h. After these incubation times, MTS solution (30 μL) was added on the hydrogels 
and cells were incubated for 1 h at 37 °C. The absorbance was measured at 490 nm and the % cell 
viability was calculated as described above. Blank HA-ADH hydrogels were also prepared as 
negative control.   
4.2.2.19 In vitro cytotoxicity of TMZ on U87MG cells 
The cytotoxicity of TMZ on U87MG cells was evaluated by MTS assay. U87MG cells were passaged 
and seeded into the wells of a 96-well plate at a density of 5×103 cells per well and allowed to adhere 
overnight in DMEM as described previously. Fresh solutions of TMZ of various concentrations were 
obtained by diluting the stock solution with DMEM. The stock solution of TMZ in DMSO was
diluted more than 1000 times in order to prevent adverse effects on cells.  Subsequently, the cells 
were incubated with increasing concentrations of TMZ (50-515 μΜ) for 24, 48 and 72 h. After these 
incubation periods, MTS solution (20 μL) was added and the % cell viability was calculated. 
4.2.2.20 Statistical analysis 
Statistical analysis was performed using GraphPad Prism and the level of significance was 
determined by using Mann and Whitney’s test. Statistical difference was set at a probability of ** *P 
< 0.001, ** P < 0.01 and *P < 0.05.  
4.3 Results and discussion 
4.3.1 Glioma cell culture on HA-ADH hydrogels 
4.3.1.1 Morphology and proliferation of glioma cells on HA-ADH hydrogels  
As discussed in Chapter 2, four different crosslinking densities of HA-ADH hydrogels were prepared 
and the molar ratios of ADH to HA and HA to EDC were adjusted to obtain hydrogels optimised for 
cell adhesion. Glioma cells were seeded on the fabricated hydrogels and the morphology and 
proliferation was investigated. The experimental conditions for the preparation of HA-ADH 
hydrogels at different crosslinking densities are provided in Table 4.2. Briefly, hydrogels were 
prepared into the wells of a 48-well plate with a final volume of 250 μL in the presence or absence 
of the chemoattractant. Stock solution of the chemoattractant UII of concentration 10-4 M in DMEM 
in the absence of serum, was prepared. Subsequently, HA-ADH hydrogels were loaded with UII with 
final concentration of the chemoattractant in the hydrogels to be 10 -8 M. In addition, hydrogels were 
prepared in the absence of chemoattractant as control condition in order to control whether the 
chemokine peptide UII affects the morphology and proliferation of glioma cells. 
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Different glioma cell lines (U87MG and 42 MG) were passaged and seeded on the surface of the 
hydrogels at a density of 5×103 cells per well. U87MG and 42 MG cell cultures are shown in Figures 
4.6 and 4.7. The cells were seeded for 4 days in DMEM supplemented with 1 % of AA and 1 % of 
sodium pyruvate in the absence of FBS at 37 °C.  
 
  
              
Figure 4.6: Morphology of U87MG cells cultured on different crosslinking conditions of HA-ADH hydrogels 
in the absence or the presence of UII (10-8 M). Cells were seeded onto the hydrogels for 4 days in DMEM in 
the absence of FBS. Representative photos of cell cultures were taken using a NIKON inverted microscope. 
Magnification: 20x, Scale bar: 50 µm.   
 
Sample                  HA  
abbreviation     (mg/nmole)             
    ADH 
(mg/μmole) 
    EDC 
(mg/μmole) 
pH         
L1                       10. /6.25 0.25/1.43 0.26/1.36 5.5 
L2                       10. /6.25 0.5/2.87 0.6/3.12 5.5         
H1                       10. /6.25 2.5/14.3 2.6/13.6 5.5         
H2                     10.0/6.25 3.5/20.1 3.6/18.8 5.5         
CTRL UII 10-8 M CTRL UII 10-8 M 






















        
Figure 4.7:  Morphology of 42 MG cells cultured on different crosslinking conditions of HA-ADH hydrogels 
in the absence or the presence of UII (10-8 M). Cells were seeded onto the hydrogels for 4 days in DMEM in 
the absence of FBS. Representative photos of cell cultures were taken using a NIKON inverted microscope. 
Magnification: 20x, Scale bar: 50 µm.  
As discussed earlier, U87MG and 42 MG cells were seeded on HA-ADH scaffolds and 2D culture 
surfaces for 4 days. To ensure that HA-ADH hydrogels at different crosslinking densities in the 
absence or presence of UII demonstrate different cell adhesive properties, the morphology of glioma 
cells seeded on the hydrogels was monitored as function of incubation time. As shown in Figures 4.6 
and 4.7, U87MG and 42 MG cells presented morphology, which was highly dependent on the 
stiffness of the matrix.  After one day of incubation, U87MG and 42 MG cells seeded on the standard 
culture surface obtained their typical elongated morphology with long cell protrusions associated 
with migration [36], whereas both cell lines cultured on the surface of the hydrogels started to adopt 
rounded morphology with loss of cell adhesion. More specifically, cells seeded on the hydrogels of 
low crosslinking density (L1 and L2 conditions) showed rounded morphology and progressive 
clustering of glioma cells forming well-defined spherical shape of neurospheres. In contrast, in the 
case of hydrogels of high crosslinking density (H1 and H2 conditions), cell spreading was relatively 
CTRL UII 10-8 M CTRL UII 10-8 M 


















higher on the surface and cells appeared included in irregular clusters with uneven external rims and 
isolated, possibly due to low porosity and poor diffusion of the cell nutrients across the hydrogel 
network. In addition, it is noteworthy that the presence of UII had negligible effect on the 
morphology, shape and proliferation of glioma cells. These results suggest that glioma cells are 
sensitive to the mechanical properties of the designed hydrogels and their morphology alters 
accordingly to hydrogel’s stiffness and crosslinking density. Recently, Pedron et al found that the 
hydrogel porosity and the matrix mechanical properties significantly impact glioma cell morphology 
[11]. Particularly, they observed that stiffer microenvironments induced cell spreading, while softer 
hydrogels induced low cell spreading, favouring the formation of cell aggregates or neurospheres. 
Similarly, Jiglaire et al observed that U87MG cells cultured on 2D environment after 8 days had 
elongated morphology with small filopodia, while cells seeded on hydrogels obtained rounded 
morphology with less developed lamellipodia or filopodia as shown in Figure 4.8 [37].   
 
                           
Figure 4.8: A. Morphology of U87MG cells seeded on 2D and 3D environment. After 8 days of culture, the 
cells seeded under 3D conditions adopted rounded morphology, while cells on 2D environment adopted 
elongated morphology, B. Confocal microscopy photos indicating U87MG cells with small filopodia on 2D 
condition and rounded cells with lamellipodia or filopodia under 3D conditions. Scale bars represent 10 μm. 
Photos adapted from Jiguet et al [37].    
Moreover, as presented in Figures 4.6 and 4.7, U87MG and 42 MG cells seeded on the standard 
culture surface adopted a flattened and elongated morphology from the first day of culture, leading 
to a typical 2D culture after 4 days of incubation. In contrast, as mentioned earlier, after 1 day of 
culture, cells started to form rounded clusters over time with significantly increased size after 4 days 
of seeding on hydrogels of low crosslinking density, suggestive of proliferation. Interestingly, Pedron 
et al reported that neurospheres of glioma cells were observed on hydrogels containing HA [23]. 
U87MG cells encapsulated within PEG-based hydrogels remained as individuals or as small groups, 
whereas with increasing concentration of methacrylated HA (HAMA) into the hydrogel network, 










Figure 4.9: Morphology of U87MG cells seeded on PEG-based hydrogels with increasing concentration of 
HAMA 2 weeks after seeding. A. In the absence of HAMA, B. In the presence of 0.5 % w/w HAMA and C.
In the presence of 1% w/w HAMA. Progressive clustering of U87MG cells was observed with increasing 
concentration of HAMA. Photos adapted from Conlon et al [23]. 
Furthermore, it can be concluded that U87MG and 42 MG cell motility is higher on softer hydrogels 
such as L1 and L2 due to the looser hydrogel network, leading to the formation of large clusters 
through aggregation but also proliferation. On the other hand, cells seeded on stiffer surfaces, due to 
the denser network, are tightly encapsulated and remain as single cells. Moreover, it is noteworthy 
that slow proliferation rate was observed within cells seeded on L1 and L2 hydrogels compared with 
the cells seeded on the standard culture plate as demonstrated in the graph in Figure 4.10. The cell 
number was calculated based on the standard curve created for U87MG cells (refer to the Appendix).  
 
 
Figure 4.10: Graph summarises the proliferation of U87MG cells seeded on the standard culture surface and 
on the surface of HA-ADH hydrogels over 4 days.  Slower proliferation rate was observed within cells cultured 
on L1 and L2 hydrogels. The data represent the average of triplicate with the corresponding standard deviation.   
This slow rate of proliferation is common as the cells adjust to the porous hydrogel network and due 
to 3D environmental factors such as limited diffusion of nutrients and bigger surface to colonise [38]. 
Additionally, in the literature it has been reported that human GBM cells proliferate in a stiffness-
dependent manner with higher proliferation observed on stiffer surfaces, which partially explains the 
difference on the number of glioma cells seeded on HA-ADH hydrogels. Overall, it can be concluded 
that variations in crosslinking density and the viscoelastic properties of the hydrogels affect cell 

























A B C 
150 
 
4.3.1.2 Viability of glioma cells on HA-ADH hydrogels   
The viability of U87MG and 42 MG cells seeded on the surface of HA-ADH hydrogels at different 
crosslinking densities was determined using MTS assay. MTS assay allows the evaluation of cell 
viability by measuring cells metabolic activity. The method is based on the reduction of the MTS 
tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) by viable cells to form formazan which is directly soluble in the cell 
culture medium as shown in Figure 4.11. This reaction is catalysed by NADPH or NADH produced 
by dehydrogenase enzymes in metabolically active cells. The formazan produced by viable cells is 
quantified by measuring the absorbance at 490 nm.  
 
Figure 4.11: Enzymatic reduction of MTS tetrazolium compound to formazan. The formazan produced by 
viable cells is quantified by measuring the absorbance at 490 nm.    
Briefly, U87MG and 42 MG cells were seeded on HA-ADH hydrogels in the presence or absence of 
UII (10 -8 M) at a density of 5×103 cells per well. The viability of glioma cells was evaluated after 24 
and 48 h of incubation as summarised below in graphs A and B in Figure 4.12. It can be concluded 
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Figure 4.12: Viability of U87MG cells seeded on different crosslinking densities of HA-ADH hydrogels in 
the absence or presence of UII (10-8 M). A. Viability of cells seeded on low crosslinked hydrogels. B. Viability 
of cells on high crosslinking density of hydrogels. The viability of glioma cells was evaluated after 24 and 48 
h of incubation. The data represent the average of n=6 with the corresponding standard deviation.    
 
Glioma cells seeded on HA-ADH hydrogels of low crosslinking density (L1 and L2 conditions) in 
the absence or presence of UII showed viability > 95 % after 24 and 48 h of incubation. On the other 
hand, at higher crosslinking densities of HA-ADH hydrogels (H1 and H2 conditions), cell viability 
was much lower, 62 % and 51 % respectively with cell number reduced even after 24 h seeded 
culture, suggesting cell death. A possible reason for this, is the high crosslinking density of the 
hydrogels which results in low porosity and poor diffusion of the cell nutrients, with adverse effects 
on cell viability. In addition, culture of 42 MG cells on hydrogels in the absence or presence of UII 
resulted in a similar viability profile with U87MG cells as shown in graphs A and B in Figure 4.13. 
These observations support that glioma cells seeded on highly crosslinked hydrogels were either less 
metabolically active, less proliferative or both than those seeded on low crosslinked hydrogels. Th  
results are consistent with the work of Kaufman et al reported that the increased collagen I 
concentration resulted in decreased U87MG glioma viability and metabolic activity due to increased 
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Figure 4.13: Viability of 42 MG cells seeded on different crosslinking densities of HA-ADH hydrogels in the 
presence or absence of UII (10-8 M). A. Cell viability on low crosslinking density of hydrogels. B. Cell viability 
on highly crosslinked hydrogels. The viability of glioma cells was evaluated after 24 and 48 h of incubation. 
The data represent the average of n=6 with the corresponding standard deviation.     
In order to better clarify whether crosslinking density affects GBM cells viability through metabolic 
activity or cell death, qualitative Live/Dead Cell Viability Assay was conducted. Briefly, U87MG 
and 42 MG cells were seeded on the hydrogels at different crosslinking densities as described 
previously and the Live/Dead staining solution was added after 24 h of culture. Viable cells were 
stained green due to their reaction with the Calcein AM and damaged cell cytoplasmic and nuclear 
membranes were stained red because of the reaction with ethidium homodimer. The green and red 
fluorescence images taken from viable and dead cells respectively were merged to one using ImageJ 
as shown in Figure 4.14. The fluorescence microscopy was challenging due to the presence of 
hydrogels leading to loss of constant focal planes, r sulting sometimes in blurry images as depicted 
in Figure 4.14. After 24 h of seeding, glioma cells on the standard culture surface were elongated 
with a spreading shape. U87MG cells seeded on low crosslinking densities of hydrogels (L1 and L2 
conditions) were mostly viable (green) with rounded morphology and progressive formation of 
clusters over time. Cells cultured on highly crosslinked hydrogels (H1 and H2 conditions), started to 
undergo cell death as evidenced by the occurrence of red nuclei. These results are consistent with the 
data obtained from the MTS assay, confirming high cell viability on L1 and L2 hydrogels indicating 
their biocompatibility. In contrast, high crosslinking density demonstrated adverse effect on the 










Figure 4.14: Representative Live/Dead photos of U87MG cells seeded on different crosslinking densities of 
HA-ADH hydrogels. Viable cells were stained green and dead cell nuclei were stained red. L1 and L2 
hydrogels presented good biocompatibility. Magnification: 20×, Scale bar: 50 μm. 
As shown in Figure 4.15, after 24 h of culture 42 MG cells demonstrated consistent results compared 
with U87MG cell culture. In overall, it can be concluded that L1 and L2 hydrogels promoted the 
formation of cell clusters allowing to grow as neurospheres, whereas the highly crosslinked 



























     
Figure 4.15: Representative Live/Dead photos of 42 MG cells seeded on different crosslinking densities of 
HA-ADH hydrogels. Viable cells were stained green while dead cell nuclei were stained red. Magnification: 
20×, Scale bar: 50 μm. 
4.3.1.3 Modified Boyden Chamber invasion and migration assay on HA-ADH hydrogels 
It is generally known that directional cell migration is crucially important in biological processes 
such as wound healing and malignancy and further studies on chemotactic factors should contribute 
to this essential process. Cell migration can be triggered by a variety of molecules that act as 
chemoattractants including peptides and large proteins. Traditionally, cell migration is studied in 
vitro 2D environment, where cells are organised in monolayers such as in wound assays [40], [41]. 
Albeit, this type of setting provides crucial information regarding directional cell migration, it suffers 
from several limitations since cells are not included in a 3D matrix microenvironment. For instance, 
in wound healing assays cells in monolayers contact only the standard coated plastic surface, whereas 
in a 3D environment, cells interact with the matrix which modifies their shape and migration kinetics 
[42]. Additionally, microfluidics devices have been employed to direct cell migration in the presence 
of chemokine gradients but this system is quite expensive and difficult to set up [43]. Chemotactic 
cell migration is often measured using the modified Boyden chamber assay [44]. This assay 


















exploiting the chemokine gradient between upper and lower chambers to address cell invasion and 
migration, is well adapted to study migration in 2D (migration) and 3D (invasion) environment. The 
principle of this assay is based on two chambers containing medium separated by a porous 
membrane. Cells are loaded on the upper chamber and they are allowed to migrate through membrane 
pores (usually 8 μm pore size for adherent cells) toward chemoattractants added in the lower 
chamber. Then, cells that managed to migrate and stayed adhered on the lower side of the porous 
membrane, are fixed, stained and quantified.  
Several in vitro studies have provided relevant insights into the migratory or invasive ability of cancer 
cells within 3D extracellular matrices. Campbell t al investigated the invasion and migration of 
breast cancer cell lines using modified Boyden Chamber assay [45].  Specifically, the upper chamber 
of the Boyden was coated with lyophilised porous 3D collagen-based scaffolds and subsequently 
breast cancer cell lines were seeded on them. The lower chamber was filled with media containing 
gradient FBS in order to stimulate cell migration within the scaffold depth. Cells were attracted to 
invade the scaffold and displayed increased migration in response to the presence of the FBS 
gradient. Similarly, Topman et al studied the directional migration of 3T3L1 (preadipocyte) cells 
seeded on HA-ADH hydrogel-based 3D matrix using cell culture inserts [46]. The bottom of the 
inserts was coated with a thin layer of transparent HA-ADH hydrogel while the lower compartment 
was filled with growth medium to generate a chemotaxis stimulus for directional migration as shown 
in Figure 4.16. 
 
Figure 4.16: Schematic illustration of the experimental set up used by Topman et l for the investigation of 
the directional cell migration in a 3D matrix. The upper chamber was coated with HA-ADH hydrogel and the 
lower chamber was filled with media containing FBS. Adapted from Topman et l [46]. 
Herein, a modified version of the traditional Boyden chamber assay was applied in order to evaluate 
glioma cells ability to invade and migrate through the hydrogel network. Migration is defined as the 
directed movement of cells on a substrate such as ECM fibers or coated culture plates in response to 
specific stimuli such as gradient of chemoattractants, whereas invasion occurs when cells move 
through a 3D matrix. Briefly, glioma cell invasion and migration were investigated using transwell 
cell culture chambers coated with a thin layer of hydrogels as shown in the illustration of F gure 4.17. 
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Low crosslinking densities of hydrogels (L1 and L2 conditions) were chosen for the invasion assay, 
as highly crosslinked hydrogels H1 and H2 did not present good biocompatibility. Different 
thicknesses of hydrogels have been tested and a volume of hydrogel of 100 μL (thickness of 3 mm) 
was applied finally to the upper part of the polycarbonate membranes. U87MG cells were passaged, 
resuspended in DMEM in the absence of FBS and seeded on the hydrogels at a density of 5×104 cells. 
The lower compartment was filled with 600 μL of DMEM in the absence of FBS as control condition 
or with 600 μL of DMEM in the presence of the chemoattractant UII (10-8 M) in order to evaluate 
the invasive and migratory ability of glioma cells.   
 
 
Figure 4.17: Schematic illustration of transwell cell culture chambers. Glioma cells invasion and migration 
were investigated using transwell cell culture chambers coated with a thin layer of hydrogel. Cells migrated 
within 48 h, were fixed, stained and quantified. 
U87MG cells were allowed to invade and migrate through the thin layer of the hydrogel for 48 hours 
at 37 °C. This incubation time was chosen because after 24 h of incubation only few cells invaded 
the hydrogel. After 48 h, cells having migrated were fixed, stained with hematoxylin, photos of the 
membranes were taken and migrated cells were quantified using ImageJ. As summarised in the 
histogram below in Figure 4.18, the addition of UII to the lower migration chamber resulted in a 
significant increase in the number of migrating glioma cells in the absence of the thin layer of 
hydrogel (control condition) and in the presence of the matrix. These results are consistent with the 
previous work of Lecointre t al and Coly et al, in which the presence of UII promoted increase in 
the number of migrating HEK293 cells expressing UT and glioma cells [35], [36]. Moreover, it is 
observed that less U87MG cells migrated towards the hydrogel compared with the control condition 





Figure 4.18: Cell migration was evaluated by counting U87MG cells on the membranes after staining with 
hematoxylin in the absence or presence of UII (10-8 M). A. Histogram shows the quantification of the migrating 
cells exposed to gradient UII after invasion of the thin layer of the hydrogel compared with the control (CTRL). 
The data obtained from one representative experiment in triplicate with the corresponding standard deviation. 
Mann and Whitney test; ** P < 0.01, *P < 0.05. B. Representative photos of the membranes after staining with 
hematoxylin. Magnification: 20×, Scale bar: 50 μm.  
Furthermore, 42 MG cells ability to invade and migrate through the thin layer of the hydrogel was 
evaluated. Similarly, as described above, 42 MG cells were resuspended in DMEM in the absence 
of FBS and seeded on the thin layer of hydrogels at a density of 5×104 cells. The lower compartment 
was filled with 600 μL of DMEM in the absence of FBS and in the presence of UII (10-8 M). 42 MG 
cells were allowed to invade and migrate through the hydrogel matrix for 48 h. Again, cells wer  
fixed, stained and quantified on the porous membranes as described earlier. As shown in the 
histogram in Figure 4.19, 42 MG cells demonstrated migratory behaviour resembling that of U87MG 
cells, highlighting that glioma cells were able to invade the hydrogel network and migrate in response 







Figure 4.19: Cell migration was evaluated by counting 42 MG cells on the membranes after staining with 
hematoxylin in the absence or presence of UII (10-8 M). A. Histogram shows the quantification of the migrating 
cells through the thin layer of the hydrogel compared with the control. Data obtained from one representative 
experiment in triplicate with the corresponding standard deviation. Mann and Whitney test; ** P < 0.01. B. 
Representative photos of the membranes after staining with hematoxylin. Magnification: 20×, Scale bar: 50 
μm. 
4.3.1.4 Immunofluorescence  
Immunofluorescence analysis was performed on U87MG and 42 MG cells cultured on standard 
culture surface and on HA-ADH hydrogels for the expression of the proliferative marker Ki-67 
expressed in nuclei of divided cells. Hydrogels were prepared at the lowest crosslinking density (L1 
condition) in the absence or presence of the chemoattractant UII (10-8 M) to evaluate glioma cell 
cycle in the context of 3D matrix and the chemokine peptide. Briefly, after 2 days of culture, glioma 
cells isolated from 2D standard culture surface or 3D hydrogels were seeded on glass coverslips 
coated with fibronectin for 24 h. Next day, cells were fixed, permeabilised using 0.05 % Triton-1× 
PBS and non-specific sites were blocked using 2 % NDS. After rinsing, cells were immunostained 
with primary antibody directed against Ki-67. Cell nuclei were counterstained with DAPI. Images of 
U87MG and 42 MG cells were taken by confocal fluorescence microscope (Normandie Rouen 







   
Figure 4.20: Representative immunofluorescence images of glioma cells. A. U87MG cells seeded on 2D 
culture surface or on hydrogels were immunostained with antibody against Ki-67. Cell nuclei were 
counterstained with DAPI. B. 42 MG cells seeded on 2D culture surface or on hydrogels were immunostained 
with antibody against Ki-67. Scale bar: 10 μm.    
A 
B 
















































Ki-67 is a marker associated with cell proliferation and it is commonly used in immunofluorescence 
studies as well as for diagnostics [47]. Ten representative images of DAPI and Ki-67 labelled cells 
were taken covering different surface areas. Subsequently, relative quantification of the Ki -67 stained 
cells by measuring the fluorescence intensity of Ki-67 stained cells under the different culture 
conditions was conducted with ImageJ. As summarised in graphs A and B in Figure 4.21, it was 
found approximately fourfold increase in the fluorescence intensity of cells seeded on the standard 
culture surface compared with the cells seeded on the hydrogels, indicating higher cell proliferation 
activity on the 2D culture surface than in 3D. Moreover, it is noteworthy that the presence of the 
chemoattractant UII (10-8 M) did not affect the proliferation rate of glioma cells in both culture 
conditions. 42 MG cells demonstrated similar proliferative activity with U87MG cells with higher 
expression of Ki-67 on cells cultured on the standard 2D culture surface.    
 
 
    
 
Figure 4.21: Ki -67 staining revealed increase in proliferation rate of glioma cells seeded on the standard 2D 
culture surface. A. Quantification of fluorescence intensity of Ki-67 stained U87MG cells. B. Quantification 
of fluorescence intensity of Ki-67 stained 42 MG cells seeded on the standard culture surface compared with 
cells cultured on HA-ADH hydrogels. Background was subtracted from the total fluorescence per cell using 
ImageJ. Bar graph represent the average of n=6 with the corresponding standard deviation. Mann and Whitney 





4.3.1.5 In vitro cytotoxicity of DOX on U87MG cells 
DOX, also known as Adriamycin, is a cytotoxic anthracycline compound isolated from cultures of 
Streptomyces peucetius in 1960s whose structure is shown in Figure 4.22 [48]. This drug is 
commonly used as chemotherapeutic agent for the treatment of various types of human cancer 
including breast, bladder, lung, ovarian, liver cancer, acute lymphocytic leukemia, neuroblastoma 
and Hodgkin's lymphoma [49].     
 
Figure 4.22: Chemical structure of DOX consists of a sugar moiety attached to a tetracyclic ring. It is the lead 
compound of the broad anthracycline family. 
The action mechanism of DOX is based on acting as DNA interchelator which inhibits topoisomerase 
II activity by interchelating between the bases of the DNA double helix, leading to disruption of 
DNA replication and transcription and thus cell death. Another possible mechanism proposes that 
DOX generates free radicals responsible for DNA and cell membrane damage. DOX is mainly 
administered intravenously with inevitable adverse effects. Common side effects involve vomiting, 
hair loss, bone marrow suppression, inflammation of the mouth and heart failure [50], [51]. DOX is 
most commonly used to treat various types of cancer but it is little known for its possible use as 
chemotherapeutic agent in the treatment of brain tumours due to a poor blood-brain barrier 
penetration capacity, despite n vitro efficacy on glioma cell lines [52], [53]. Annovazzi et al reported 
the in vitro cytotoxicity of DOX on different glioma cell lines, by reducing significantly the number 
of viable cells [54]. In addition, in vivo studies on animal models of malignant glioma have suggested 
DOX as an effective anti-glioma agent [55], [56].  Albeit, as mentioned previously the limitations of 
penetrating the BBB effectively, prevents its broad use in the treatment of GBM. Intratumoural 
injections of DOX have prolonged the survival of patients diagnosed with malignant gliomas, 
highlighting its potential as an anticancer drug [57]. To allow penetration of the BBB, several studies 
have investigated the delivery of anticancer drugs using colloidal carriers such as liposomes, 
nanoparticles or hydrogels in order to achieve targeted and effective drug delivery. As extensively 
discussed in Chapter 1, DOX has been loaded on nanoparticles or encapsulated in the liposomes core 
for higher accumulation of the drug close to the tumour site.   
In the present work, we hypothesised that the local delivery of DOX via the hydrogel matrix might 
be beneficial and more effective method of delivery in the treatment of GBM. More specifically, we 
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investigated the cytotoxicity of DOX on U87MG cells in vitro and the cytotoxicity induced by HA-
ADH hydrogels loaded with DOX. The in vitro cytotoxicity on U87MG cells was evaluated by MTS 
assay and qualitatively with Live/Dead assay. Briefly, human U87MG cells were incubated with 
increasing concentrations of DOX (0.01-100 μΜ) for 72 h and the IC50 concentration was determined 
as shown in the graph in Figure 4.23. It was observed that increasing concentration of DOX reduced 
significantly U87MG cell viability. With the range of DOX concentration employed, the IC50 was 
calculated to be ~1 μΜ after 72 h of incubation. The IC50 value was defined as the concentration of 
DOX that caused 50 % inhibition of cell growth after 72 h of treatment. In the literature, IC50 values 
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Figure 4.23: In vitro cytotoxicity of DOX on U87MG cells. % Cell viability of glioma cells after 24, 48 and 
72 h of treatment with increasing concentrations of DOX. The IC50 concentration was determined to be ~1 μΜ. 
Data represent the average of n=4 with the corresponding standard deviation.  
Moreover, the cytotoxicity of DOX on U87MG cells was assessed using Live/Dead assay. Briefly, 
U87MG cells were treated for 48 h with various concentrations of DOX and the Live/Dead staining 
solution was added. As shown in Figure 4.24, inhibition of cell proliferation and higher cytotoxicity 
were observed on cells treated with high concentrations of DOX compared with the control condition, 











Figure 4.24: Representative Live/Dead photos of U87MG cells treated with increasing concentrations of DOX 
after 48 h of treatment. Inhibition of cell proliferation and significant cytotoxicity were observed on higher 
concentrations of DOX. Magnification: 20×, Scale bar: 50 μm. 
4.3.1.6 In vitro cytotoxicity of DOX loaded HA-ADH hydrogels 
To date, there are more than 100 types of chemotherapeutic drugs including cisplatin, paclitaxel, 
carmustine, 5-fluorouracil (5-FU) and doxorubicin. The majority of these drugs are administered via 
intravenous injection to the human body. However, it is challenging to reach therapeutic 
concentrations of the drug in the tumour tissue due to the limitations of the drug delivery methods 
and the presence of the BBB [60]. Recently, hydrogels have gained a lot of attention in drug delivery 
applications due to their unique physical properties. Their porous interconnected structure allows 
loading of various drugs into the gel matrix and subsequent release of the drug through the hydrogel 
network [61]. Loaded drugs can be precisely released from hydrogels in close proximity to the 
tumour sites. Herein, HA-ADH hydrogels loaded with DOX were prepared at different crosslinking 
densities (L1 and L2 conditions) as described in section 4.2.2.4 and their in vit o cytotoxicity on 
U87MG cells was further investigated. The cytotoxicity of the drug-loaded hydrogels was evaluated 
















































by MTS assay and Live/Dead assay. Low crosslinking densities of HA-ADH hydrogels were 
prepared as described earlier into the wells of a 96-well plate and loaded with DOX at concentration 
100 μM. Τhe final concentration of the drug into the hydrogels was 10 μΜ. Hydrogels were washed 
with PBS and with measurement of UV absorbance of the washing solutions, the encapsulation of 
DOX in the hydrogels was confirmed. In addition, hydrogels were prepared in the absence of DOX 
as negative control. U87MG cells were seeded on the blank and DOX-loaded hydrogels and treated 
with solution of free DOX for 24 and 48 h at 37 °C. Subsequently, glioma cell viability was 
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Figure 4.25: % Cell viability of U87MG cells seeded on blank hydrogels and DOX-loaded hydrogels after 24 
and 48 h of incubation. Data represent the average of n=4 with the corresponding standard deviation.  
As shown in Figure 4.25, glioma cells seeded on the L1 and L2 hydrogels in the absence of DOX 
presented good viability > 95 %, indicative of their biocompatibility. In contrast, L1 and L2 
hydrogels loaded with DOX after 24 and 48 h of incubation, demonstrated significant cytotoxicity 
with cell viability lower than 80 % suggesting inhibition of cell growth. In addition, DOX-loaded 
hydrogels presented lower cytotoxic effect than that from the free DOX in the culture medium. Th s 
observation suggests that hydrogels either induced higher glioma cell resistance to DOX treatment, 
and/or less DOX delivery and cell access reducing toxicity. 
Furthermore, Live/Dead assay was performed on U87MG cells treated with solution of free DOX 
and seeded on DOX-loaded hydrogels as shown in Figure 4.26. After 48 h of treatment, Live/Dead 
staining qualitatively revealed that free DOX caused significant cytotoxicity confirmed by substantial 
changes in the morphology of U87MG cells. On the other hand, glioma cells seeded on DOX-loaded 
hydrogels demonstrated higher viability with few cells engaging death. This indicates as mentioned 
earlier more resistance and/or the sustained release of DOX from the hydrogels as discussed in detail 
in Chapter 3. Overall, these results demonstrate that HA-ADH hydrogels could be used for localised 
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therapeutic delivery of DOX for the treatment of GBM, mimicking a better way the brain 
physiopathological conditions.               
    
 
Figure 4.26: Representative Live/Dead photos of U87MG cells seeded on DOX-loaded HA-ADH hydrogels 
after 48 h of incubation. Free DOX caused higher cytotoxicity on glioma cells compared with the sustained 
release of DOX from the hydrogels. Magnification: 20×, Scale bar: 50 μm.    
4.3.1.7 In vitro cytotoxicity of TMZ on U87MG cells 
TMZ, also known as 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, is an 
imidazotetrazine derivative of the alkylating agent dacarbazine and prodrug of the commercially 
available anticancer chemotherapeutic drug Temodar [62]. TMZ belongs to a new class of second 
generation imidazotetrazine prodrugs that undergo conversion to the active alkylating agent (5E)-5-
(methylaminohydrazinylidene)imidazole-4-carboxamide (MTIC) under physiological conditions 
[63] as shown in Figure 4.27.  









































Figure 4.27: Chemical conversion of the prodrug TMZ to the active alkylating agent MTIC under 
physiological conditions. 
TMZ is commonly used as chemotherapeutic drug in the treatment of brain tumours including 
astrocytoma and GBM. In 1999, it was approved by FDA for its use in the treatment of anaplastic 
astrocytoma in adults and in 2005, in the treatment of patients with newly diagnosed GBM [64]. In 
preclinical studies, TMZ due to its lipophilic nature has demonstrated the ability to penetrate CNS 
and cross successfully the BBB [65]. Although, as discussed in Chapter 1, the BBB restricts the 
penetration of nearly all commonly used chemotherapeutic agents, leading to ineffective 
chemotherapy.  
Therefore, TMZ is mainly used in conjunction with radiotherapy for the treatment of GBM. Clinical 
studies from the National Cancer Institute of Canada demonstrated that the median survival rate was 
increased on patients received radiotherapy in combination with TMZ compared with those received 
only radiotherapy [66]. The standard scheme of treatment consists of TMZ at a dose of 75 mg/m2 
and 60 Gy of radiotherapy (2 Gy daily) for 4-6 weeks, followed by a TMZ subsequent dose of 150-
200 mg/m2 for 5 days every 28 days for 6 cycles. It has been observed that adjuvant radiation 
enhances the efficacy of TMZ and improves its antitumour activity in the treatment of brain cancer.  
Its mechanism of action is based on its ability of methylating DNA at the N7 and O6 positions of 
guanine residues or at the O3 position on adenine. The methylation of the O6 on guanine moiety 
results in the insertion of a thymine molecule instead of cytosine during the DNA replication which 
mediates the cytotoxicity of TMZ. However, the cytotoxicity of TMZ against glioma cell lines is still 
controversial. In the literature, several glioma cell lines have been identified as TMZ sensitive or 
TMZ resistant [67]. In the current work, in order to identify if human U87MG cells are sensitive to 
TMZ, in vitro cytotoxicity assay was conducted. Briefly, glioma cells were seeded into the wells of 
a 96-well plate at a density of 5×103 cells per well and allowed to adhere overnight in DMEM as 
described previously. Subsequently, the cells were incubated with increasing concentrations of TMZ 
(50-515 μΜ) for 24, 48 and 72 h. After treatment, the TMZ cytotoxicity was quantified using the 
MTS assay and the relative cell viability was evaluated as summarised in Figure 4.28. After 72 h of 
treatment, TMZ within the range of concentrations used, did not induce substantial cytotoxicity on 
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glioma cells as U87MG cells presented viability > 80 %. Moreover, the cytotoxic effect of TMZ on 


































2 4  h
4 8  h




Figure 4.28: A. Cell viability was measured after 24, 48 and 72 h of incubation with increasing concentrations 
of TMZ (50-515 μM). TMZ did not induce any significant cytotoxicity on U87MG cells. All the results 
presented are the mean of n=6 with the corresponding standard deviation. B. Representative Live/Dead photos 
of U87MG cells treated with increasing concentrations of TMZ after 48 h of incubation. Magnification: 20×, 
Scale bar: 50 μm.     
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As described earlier, U87MG cells were treated with increasing concentrations of TMZ for 48 h and 
the Live/Dead staining solution was added. The Live/Dead assay results were consistent with those 
obtained from MTS assay, confirming the resistance of U87MG cells to TMZ even treated with high 
concentrations of this drug as shown in Figure 4.28.  
In the literature, the IC50 value of TMZ on glioma cells vary. For example, Montaldi et al and 
Hermisson et al found that the IC50 of TMZ on U87MG cells was 7 μΜ and 10 μΜ respectively, 
while Baer et al and Ryu et al reported it as 172 μΜ and < 500 μΜ [68]-[71]. In addition, to date 
several studies have investigated the possible factors that contribute to the TMZ resistance. The O6-
methylguanine methyltransferase (MGMT) which acts to reverse methylation of the O6 position of 
guanine has been associated with the drug-resistance mechanism as shown in Figure 4.29. 
Particularly, it has been reported that cells expressed high levels of MGMT protein, showed TMZ 
resistance [72]. Expression of the Mismatch Repair Protein (MMR) induces TMZ cytotoxicity, while 
in theory defective MMR leads to cell resistance to TMZ. Moreover, Agnihotri et al reported that 
TMZ resistance can be induced not only by the expression of the MGMT protein but also the 
expression of alkylpurine-DNA-N-glycosylase (APNG) protein [73]. This protein mainly regulates 
the repair of O3- methyladenine and N7- methylguanine. Higher expression of APNG protein has 
been correlated with poor survival time on patients diagnosed with GBM. Furthermore, the 
expression of the Base Excision Repair (BER) which is mainly responsible for the repair of N7-
methylguanine and O3-methyladenine, is associated with the resistance to TMZ.   Blough et al found 
that the expression of the gene mutation p53 has also been associated with the TMZ resistance but 
its contribution, is not clear yet [74]. These observations are at least in part explaining the complexity 
of GBM treatment in vivo and the high level of tumour recurrence.       
 
Figure 4.29: Mechanism of TMZ resistance on glioma cells. TMZ modifies DNA at N7 or O6 positions on 
guanine and O3 on adenine by the addition of methyl groups. The methylated moieties can remain mutated, 
repaired by MGMT or removed by BER by the action of a DNA glycosylase such as APNG protein. Expression 
of MMR causes cytotoxicity of TMZ, whereas when MGMT, APNG and BER proteins are expressed, glioma 
cells are resistant to TMZ.  
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Despite the numerous studies in order to identify the cause of GBM resistance to TMZ, multiple 
complex molecular pathways seem to be involved and they will not be discussed further as it is 
beyond the scope of this thesis. Further investigation is required to better understand the mechanisms 
of chemoresistance of GBM cells for the development of new effective treatment.   
4.3.2 Glioma cell culture on HA-BSA hydrogels 
4.3.2.1 Morphology of U87MG cells on HA-BSA hydrogels  
As discussed in Chapter 2, four different crosslinking densities of HA-BSA hydrogels were prepared 
and their ability to promote cell adhesion was investigated. The critical experimental conditions for 
the preparation of HA-BSA hydrogels at different crosslinking densities are provided in Table 4.3. 
Briefly, hydrogels were prepared into the wells of a 96-well plate with a final volume of 50 μL in the 
absence or the presence of the chemoattractant UII. Stock solution of UII of concentration 10-4 M in 
DMEM in the absence of FBS was prepared. Subsequently, HA-BSA hydrogels were loaded with 
UII as described in section 4.2.2.3. In addition, hydrogels were prepared in the absence of UII as 
control condition, in order to check whether the chemoattractant affects the phenotype of GBM cells. 
Table 4.3: Critical experimental conditions for the preparation of HA-BSA hydrogels at different crosslinking 
densities. 
 
U87MG cells were passaged and seeded on the surface of the hydrogels at a density of 5×103 cells 
per well. Glioma cells were seeded for 48 h in DMEM supplemented with 1 % of AA and 1 % of 
sodium pyruvate in the absence of serum at 37 °C. Subsequently, the morphology of U87MG cells 
seeded on HA-BSA hydrogels at different crosslinking densities was monitored as function of 
incubation time.  
As presented in Figure 4.30, U87MG cells showed morphology, which was highly dependent on the 
stiffness of the matrix. Moreover, the presence of UII had negligible effect on the morphology of 
GBM cells. After 24 h of incubation, U87MG cells seeded on the standard 2D culture surface 
obtained their typical elongated morphology, whereas GBM cells seeded on the surface of the 
hydrogels at different crosslinking densities adopted rounded morphology. More specifically, in the 
case of HB16 and HB17 hydrogels, cells obtained rounded morphology and progressive clustering 
of glioma cells was observed over time. In contrast, in the case of HB18 and HB19 hydrogels, single 
cells were predominantly spreading on the surface of the hydrogels in contrast with the clustered 
neurosphere formation on HB16 and HB17 conditions after 48 h of seeding.  
Sample 
abbreviation  




    EDC 
(mg/μmole) 
    BSA 
(mg/nmole)    
   Gelation time  
      (minutes) 
HB16        6.0/3.7    0.5/2.3 2.0/10.4  3.0/45.4             2 
HB17        6.0/3.7   1.25/5.86 5.0/26.1  3.0/45.4             3 
HB18        6.0/3.7   2.5/11.5 10.0/52.2  3.0/45.4             6 





Figure 4.30: Morphology of U87MG cells cultured on different crosslinking conditions of HA-BSA hydrogels 
in the absence or the presence of UII (10-8 M). Cells were seeded on the hydrogels for 24 and 48 h in DMEM 
in the absence of FBS. Representative photos of cell cultures were taken using an EVOS FLoid Cell Imaging 
station. Magnification: 20×, Scale bar: 50 µm.   
4.3.2.2 Viability of U87MG cells on HA-BSA hydrogels 
The effect of crosslinking density of HA-BSA hydrogels on the viability of U87MG cells was 
determined quantitatively using MTS assay and qualitatively using Live/Dead assay. Briefly, 
hydrogels were prepared as described in section 4.2.2.3 into the wells of a 96-well plate. U87MG 
cells were passaged and seeded on the HA-BSA hydrogels at a density of 5×103 cells per well. The 
viability of the cells was evaluated after 24 and 48 h of seeding on the hydrogels in the absence or 
presence of the chemoattractant UII. As summarised in the graphs A and B in Figure 4.31, glioma 
cells presented viability >80 %, indicating the biocompatibility of the hydrogels. More specifically, 
cells seeded on the HB16 and HB17 hydrogels were slightly more metabolically active compared 
with those seeded on the surface of the HB18 and HB19 hydrogels. Similarly, with the seeding of 
glioma cells on HA-ADH hydrogels, the presence of the chemoattractant UII did not present any 
significant effect on the cell viability after 48 h of incubation. 
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Figure 4.31: Viability of U87MG cells seeded on different crosslinking densities of HA-BSA hydrogels in 
absence or presence of UII (10-8 M). A. % Cell viability on HB16 and HB17 hydrogels. B  % Cell viability on 
HB18 and HB19 hydrogels. The viability of glioma cells was evaluated after 24 and 48 h of incubation. The 
presence of UII did not affect the viability of glioma cells. The data represent the average of n=5 with the 
corresponding standard deviation.     
The biocompatibility of the hydrogels was also assessed by Live/Dead assay using U87MG cells. 
Glioma cells were seeded on HA-BSA hydrogels at four different crosslinking densities for 48 h as 
described above. As presented in Figure 4.32, glioma cell growth was not significantly affected at 
the various crosslinking densities, indicating no cytotoxicity and biocompatibility of the hydrogels. 
Consistent with the results from the MTS assay, the majority of cell population remained viable after 
seeding on the hydrogels for 48 h. As shown in Figure 4.32, cells adopted rounded morphology and 
formed clusters when cultured on HB16 and HB17 hydrogels, whereas on HB18 and HB19 
hydrogels, cells remained single and cell spreading was predominant across the culture surface, 
suggesting adhesion to the matrix. These observations reporting that cells tend to obtain rounded 
morphology on soft surfaces and keep their elongated shape on stiffer surfaces, likely allowing 







Figure 4.32: Representative Live/Dead photos of U87MG cells seeded on HA-BSA hydrogels at different 
crosslinking densities for 48 h. Glioma cells remained viable after seeding on hydrogels for 48 h, indicating 
the biocompatibility of the hydrogels. Magnification: 20×, Scale bar: 50 µm.   
4.3.2.3 In vitro cytotoxicity of DOX-loaded HA-BSA hydrogels 
The in vitro cytotoxicity of DOX-loaded hydrogels was determined using MTS and Live/Dead assay. 
Briefly, DOX-loaded hydrogels were prepared into the wells of a 96-well plate as described in section 
4.2.2.5. U87MG cells were passaged and seeded on the drug-loaded hydrogels at a density of 5×103 
cells per well for β4 and 48 h. After treatment, MTS solution (γ0 μL) was added on the hydrogels 
and cells were incubated for 1 h at 37 °C. The absorbance was measured at 490 nm and the % cell 
viability was calculated. Blank HA-BSA hydrogels were also prepared as negative control. As 
demonstrated in Figure 4.33, DOX-loaded HA-BSA hydrogels induced significant cytotoxicity after 
24 and 48 h of incubation. Moreover, it is noteworthy that the cytotoxicity from the drug-loaded 
hydrogels on U87MG cells was lower than the cytotoxicity induced from the free DOX. In addition, 
HB16 and HB17 hydrogels loaded with DOX demonstrated higher cytotoxicity after 48 h of 
incubation, while the highly crosslinked hydrogels did not present significant cytotoxic effect on 
glioma cells.    
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Figure 4.33: A. U87MG cell viability was measured after 24 and 48 h of seeding on DOX-loaded HA-BSA 
hydrogels. All the results presented are the mean of n=6 with the corresponding standard deviation. B. 
Representative Live/Dead photos of U87 MG cells seeded on DOX-loaded hydrogels for 48 h. Magnification: 
20×, Scale bar: 50 μm.     
These results are consistent with the data obtained from DOX release experiments discussed in 
Chapter 3. Higher cumulative DOX release was observed in HB16 and HB17 hydrogels compared 
to highly crosslinked hydrogels, resulting in high in vitro cytotoxicity on U87MG cells. Moreover, 
Live/Dead staining results were consistent with the MTS assay, confirming the higher cytotoxicity 
of the DOX-loaded HB16 and HB17 hydrogels, due to the highest DOX release from these 
crosslinking densities.   







4.3.2.4 Modified Boyden Chamber invasion and migration assay on HA-BSA hydrogels 
Herein, a modified Boyden Chamber assay was applied in order to evaluate the ability of glioma 
cells to invade a 3D ECM and migrate in response to the chemoattractant UII. As described 
previously in section 4.2.2.15, glioma cells were seeded on a thin layer of HA-BSA hydrogels at a 
density of 5×104 cells. HA-BSA hydrogels were prepared at HB16, HB17 and HB18 crosslinking 
densities according to the preparation protocol and a volume of hydrogel 100 μL was applied on the 
upper part of the polycarbonate membrane. 
In this set up, cells were required to invade through the hydrogel into the lower chamber containing 
the chemoattractant as described in section 4.3.1.3  U87MG cells were allowed to invade the thin 
layer of the hydrogel for 48 h. After this incubation time, GBM cells were fixed and stained with 
hematoxylin solution. Quantification of the cells that invaded the hydrogel and migrated in response 
to UII was performed using ImageJ. The reproducibility of the invasion assay was assessed by 
measuring the invasive capability of glioma cells in triplicate (3 transwells). U87MG cells were 
previously shown to be highly invasive and migratory as demonstrated in section 4.3.1.3. Therefore, 
this cell line was chosen and the extent of invasion and migration on HA-BSA hydrogels was further 
investigated. As summarised in Figure 4.34, a higher number of GBM cells invaded and migrated in 
the presence of UII in the absence or presence of the layer of hydrogel. Moreover, it was no ed that 
the crosslinking density of the hydrogels affected at some point the extent of the invasion and 
migration of cells. As the crosslinking density increases, lower number of cells were able to invade 
and migrate through the hydrogel. In overall, these results indicated that hydrogels allowed the 
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Figure 4.34: Modified Boyden Chamber invasion and migration assay on HA-BSA hydrogels A. Histogram 
shows the quantification of U87MG cells that invaded the thin layer of the hydrogel compared with the control. 
The data obtained from one representative experiment in triplicate with the corresponding standard deviation. 
Mann and Whitney test; *P < 0.05. B Representative photos of the membranes after staining with hematoxylin 
solution. Magnification: 20×, Scale bar: 50 μm.  
4.3.3 Glioma cell culture on MC-based hydrogels 
4.3.3.1 In vitro evaluation of biocompatibility of MC-based hydrogels  
MC is a polysaccharide derived from cellulose and its aqueous solutions form thermoreversible 
hydrogels that undergo sol-gel transition upon heating. As described in Chapter 2, the thermal 
gelation properties of MC solutions of various polymer and salt concentrations were investigated and 
their in vitro biocompatibility was evaluated. Briefly, MC solutions of various concentrations in 
sterile PBS were prepared according to the Table 4.4 and as described in section 2.2.2.3.  










U87MG cells were passaged and seeded on the surface of MC-based hydrogels for 24 and 48 h. 
Unfortunately, glioma cells were poorly adherent to the hydrogel surface and formation of cell 
clusters/neurospheres was observed (data are not shown). The % cell viability on the hydrogels after 
24 and 48 h of seeding was determined using MTS assay. As summarised in Figure 4.35, GBM cell 
viability was highly dependent on the polymer concentration. Specifically, as the MC concentration 
       MC  
Concentration 
  (% w/w)                        
     PBS 
Composition 
  Gelation 
Temperature 
   (°C) 
           2                      1×PBS        - 
           4                    1×PBS       42 
           6                       1×PBS       37 
          8                 1×PBS       34 
           2               5×PBS       35 
           4              5×PBS       32 
           6                          5×PBS                   30 
           2           10×PBS       28    




increased, significant decrease in cell viability was observed. In addition, it can be concluded that 
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Figure 4.35: U87MG cell viability on MC-based hydrogels after 24 and 48 h of seeding. The polymer 
concentration and the concentration of salts in PBS showed significant effect on the viability of glioma cells. 
Data represent the average of n=6 with the corresponding standard deviation.  
Increasing concentrations of salts that were present in the PBS solution, resulted in lower cell 
viability after 24 and 48 h of seeding. As discussed in Chapter 2, our goal was to develop 
biocompatible MC-based hydrogels that undergo gelation at body temperature. Therefore, the 
addition of salts to the MC solution contributed to lower gelation temperature. However, the addition 
of salts induced significant increase in osmolality of MC solutions and this was detrimental for 
glioma cell viability as shown in Figure 4.35. This observation agrees with the literature where it is 
reported that increase in osmolality is harmful to cell viability due to the induction of cellular 
dehydration [75]. MC-based hydrogels were not further studied due to their cytotoxicity on glioma 
cells, therefore, blend solutions of XG/MC were prepared and the biocompatibility of the formed 







4.3.3.2 In vitro evaluation of biocompatibility of blend XG/MC hydrogels 
Blend hydrogels have gained a lot of attention in biomedical applications such as drug delivery, cell 
culture and tissue engineering [76]. Blend hydrogels combine the physicochemical and biological 
properties of each component. Chen t al prepared injectable hydrogels from physical blend of 
thiolated hyaluronic acid and collagen I for in vitro construction of engineered cartilage [77]. 
Furthermore, Zheng et al fabricated gelatin-based hydrogels upon blending with gellan at body 
temperature. These hydrogels presented a great potential as injectable wound dressing or scaffold for 
tissue engineering applications [78].     
Herein, as described in chapter 2, injectable blend hydrogels consisted of MC and XG were prepared 
in an effort to improve the biocompatibility of MC-based hydrogels. XG is a non-toxic, hydrophilic, 
biodegradable polymer that has been used in a variety of biomedical applications demonstrating good 
biocompatibility [79]. Taking advantage of this, XG/MC blend solutions were prepared at different 
compositions in 1×PBS (pH 7.4) as summarised in Table 4.5. XG/MC hydrogels were prepared into 
the wells of a 96-well plate and U87MG cells were seeded on the hydrogels at a density of 5×103 
cells per well for 24 and 48 h. Subsequently, MTS solution was added and the % cell viability was 
determined. 









As summarised in Figure 4.36, XG/MC hydrogels at specific ratios of XG/MC presented relatively 
good biocompatibility after 48 h of seeding. In addition, it is noteworthy that increasing concentration 
of MC in the blend hydrogels demonstrated substantial cytotoxicity on U87MG cells. On the other 
hand, blend solutions consisted of higher concentration of XG presented better biocompatibility. 
Moreover, separate solutions of MC and XG were evaluated for their cytotoxicity. Specifically, XG 
did not induce significant cytotoxicity, while solutions of MC at high concentrations (4-8 % w/w) 
demonstrated substantial cytotoxic effect on glioma cells. XG/MC hydrogels that demonstrated 
relatively good biocompatibility, were not studied further due to their poor mechanical properties. 
Sample 
abbreviation 
      XG 
Concentration 
    (% w/w) 
      MC  
Concentration 
  (% w/w)                        
XG1/MC0         1            0                 
XG1/MC3         1            3                   
XG1/MC6         1            6               
XG1/MC8         1            8           
XG2/MC1         2            1            
XG2/MC6         2                                   6                       
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Figure 4.36: Evaluation of viability of U87MG cells seeded on blend XG/MC hydrogels for 24 and 48 h. Data 
represent the average of n=6 with the corresponding standard deviation. 
4.4 Conclusions 
GBM is one of the most devastating and incurable cancer of the last decades. Current methods of 
treatment lack of several limitations as extensively discussed in Chapter 1, rending treatment of GBM 
challenging. Therefore, a great attention has been paid on alternative strategies that focus on targeted 
drug delivery methods. 
To date, various drug delivery systems have been investigated for the treatment of GBM including 
liposomes, nanoparticles and injectable hydrogels. Among them, hydrogels have demonstrated 
promising results due to their unique and tunable physical properties. Moreover, the majority of the 
studies have used hydrogels as anticancer drug delivery systems for the treatment of malignant brain 
tumours. However, these systems present several critical limitations, including the absence of 
molecules that naturally exist in the brain ECM and most importantly they lack from effective 
chemoattractants. Consequently, residual invasive tumour cells remain in the margins of the resection 
cavity, leading to inevitable tumour recurrence.  
Herein, in order to overcome these limitations, we investigated the fabrication of hydrogels mainly 
consisted of HA. Fabricated hydrogels were loaded with human UII as chemoattractant at gradient 
concentration and subsequently with an anticancer drug in order to achieve attraction of GBM cells 
into the hydrogel matrix and cause cell death. Overall, fabricated scaffolds based on HA presented 
good biocompatibility and the preliminary results showed that glioma cells can invade the hydrogel 
matrix and migrate in response to the loaded chemoattractant UII. Hydrogels also loaded with DOX 
induced considerable cytotoxicity on GBM cells. The viability assays performed on GBM culture on 
MC-based hydrogels revealed that these scaffolds do not promote cell adhesion and growth and they 
were not studied further. 
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Chapter 5: Conclusion 
5.1 General Conclusions 
In many countries, cancer ranks the second most common cause of death following cardiovascular 
diseases and it remains as a major health problem around the world. There are different types of 
cancer, the most common types include lung, breast, prostate, colorectal, bladder cancer, melanoma 
and leukaemia. Brain tumours are less common, but there is evidence that the incidence of these 
tumours has been rising. Among malignant brain tumours, GBM is the most common and deadly 
primary tumour, accounting for approximately 50 % of all brain tumours. A  discussed in Chapter 1, 
brain cancer treatment presents several challenges due to the unique sanctuary situation of the brain 
and there is an urgent need for the development of new therapeutic strategies.  
Conventional methods of treatment include surgical resection of the tumour combined with 
concomitant chemotherapy and radiotherapy are mainly unsuccessful and they suffer from several 
limitations. Residual cancer cells that have not been removed and remain in the periphery of the 
tumour site and the existence of brain tumour initiating cells can increase the risk for tumour 
recurrence. The systemic delivery of the drugs at the site of the tumour is mainly ineffective due to 
the presence of BBB and the repeated administration of high doses of the drugs is necessary which 
leads in adverse side effects. Malignant gliomas are often resistant to alkylating agents and this results 
in the formation of recurrences close to the resection borders. In the context of radiotherapy, 
increasing and repeated doses of radiation also lead to severe side effects.  
For the aforementioned limitations of the current chemotherapeutic approaches, there is an urgent 
need to develop more efficient local drug delivery strategies that will enable the targeted drug release 
to the tumour site over a sustained period of time. To date, several pharmaceutical formulations 
including liposomes, nanoparticles and hydrogels have been used as drug delivery systems for the 
treatment of GBM. Among them, hydrogels have gained a lot of attention due to their unique physical 
properties and structural versatility which resembles the ECM of the living tissues. However, the 
majority of the studies have utili sed these systems as injectable anticancer drug loaded carriers in the 
resection cavity. The introduction of this thesis outlined the current limitations of the already 
developed formulations and they are listed below: 
1. Need for the development of relatively easy and cost-effective methods for the formation of 
biocompatible hydrogels 
2. Lack of robust protocols for reproducible hydrogel formation 
3. Lack of molecules that naturally exist in the brain ECM 
4. Absence of effective chemoattractants   
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Each of these points were addressed and discussed throughout this thesis and it is believed that the 
findings presented here will accelerate the potential of these scaffolds in the treatment of GBM. 
Chapter 2 focused on the preparation of hydrogels mainly based on HA, proposing relatively simple, 
reproducible and cost-effective crosslinking methods. Hydrogels were prepared at different 
crosslinking densities and subsequently loaded with the chemoattractant UII in order to identify the 
optimal conditions that will promote invasion and migration of invasive glioma cells towards the 
matrix as illustrated in Figure 5.1. An optimal hydrogel for the treatment of GBM should have some 
critical features that are reported below. 
 
Figure 5.1: Schematic representation of the use of chemoattractant and drug loaded hydrogel for the treatment 
of GBM and the critical features for its successful application.  
Critical features of hydrogels designed for the local treatment of GBM: 
• Biocompatible and injectable in situ 
• Biodegradable and non-immunogenic 
• Adhesion to resection cavity border  
• Mechanical properties compatible with the brain tissue 
• Controlled and sustained release of the loaded drug over time 
• Gradient concentration of the chemoattractant and sustained release from the hydrogel 
The characterisation of the physicochemical and mechanical properties of the fabricated hydrogels 
was imperative in order to ensure that they possess all the aforementioned desirable characteristics. 
The results from the characterisation of hydrogels properties showed that the formulated scaffolds 
had all the desirable characteristics a summarised in Figure 5.2. Hydrogels presented an 
interconnected porous structure and porosity that was highly dependent on the crosslinking density. 
The high porosity of the hydrogels enabled them to swell and the equilibrium swelling degree was 
determined. The in vitro enzymatic degradation experiments revealed that hydrogels can be degraded 
when they are incubated with hyaluronidase. The mechanical characterisation of the hydrogels 
showed that their viscoelastic properties were close to those of the brain tissue, highlighting their 
potential as injectable scaffolds in the brain. The drug release studies performed on hydrogels showed 
that these crosslinked networks can promote sustained release of the drug over a specific period of 
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time, while the release experiments of the FITC- UII loaded hydrogels demonstrated low amount of 
the chemoattractant is released as most of it remains inside the gel, which is desirable for our 
application.    
             
Figure 5.2: Desirable properties of the fabricated hydrogels as injectable scaffolds for the treatment of GBM. 
The biocompatibility of the hydrogels was investigated in Chapter 4. GBM cells were seeded on the 
hydrogels in the absence or presence of the chemoattractant UII and the response of GBM cells was 
evaluated. The viability assays indicated that hydrogels can promote cell growth and the presence of 
the chemoattractant in the matrix can induce invasion and migration of the cells towards the hydrogel 
network. 
5.2 Future work 
It is hoped that this thesis has acknowledged the various limitations of the conventional methods of 
GBM treatment and encouraged the development of alternative strategies using hydrogels. Hydrogels 
have presented promising results and they need to be further investigated. Future work could focus 
on experiments carried out with healthy neural cells in order to ensure the biocompatibility of the 
scaffolds within the healthy brain tissue since the foreseen application of the hydrogel is as an 
injectable material in the resection cavity. Moreover, the response of the hydrogels should be tested 
in vivo conditions including initially mouse models and human models in the future. In vitro 
experiments are indicative of the hydrogel performance but not representative of the in vivo
environment. Particularly, it is expected that the degradation rate of the hydrogels will be different 
in vivo conditions due to the variable enzymatic conditions and different aqueous environment. In 
cancer research, in vitro systems lack the microenvironment, physiological reactions and mainly 
heterogeneity and thus it is too simplistic to predict the response to biomaterials. Therefore, the 
performance of the chemoattractant UII and drug-loaded hydrogels injected in a cavity after tumour 














Furthermore, future work can be focused on the optimisation of the designed formulations. As stated 
previously, the foreseen application of the designed hydrogel is as an injectable biomaterial in the 
cavity after resection of brain tumour. On this account, the injectability of the prepared scaffolds can 
be tested using double barrel syringes. The precursor gelator components can be loaded in the barrels 
and the specific set up can allow the homogeneous mixing and formation of hydrogel in situ. Another 
critical factor that should be studied further is the quantification of the diffusion of drug molecules 
or the FITC-labelled UII within the hydrogel network in order to understand better the release 
kinetics.  
5.3 Personal perspective on the implication of hydrogels for GBM treatment 
The last few years, have witnessed a great interest in the development of alternative therapeutic 
methods for the treatment of GBM. Conventional chemotherapeutic agents fail to present clinical 
relevance in the treatment of brain tumours, due to their high toxicity or chemoresistance, therefore 
emerged research on the design of local drug delivery systems is a good alternative. Several studies 
have focused on the use of hydrogels for this purpose. However, better consideration of these 3D 
networks is necessary to understand why the number of clinical trials performed on hydrogel-based 
systems for the treatment of GBM is so limited. The current chemotherapy regimen includes the 
administration of TMZ or BCNU. Although, BCNU has shown to be effective on GBM cells, the 
first line treatment of GBM is TMZ. On the other hand, GBM cells have shown chemoresistance to 
this drug and many researchers have focused on the administration of alternative anticancer drugs or 
cocktail of drugs. Another critical factor that affects the efficiency of these drug delivery systems is 
the sustained release of the drug from the hydrogel. The drug release is dependent on the hydrogel 
characteristics, structure of the drugs and most importantly on the brain tissue conditions after 
surgery which can influence the drug diffusion behaviour. Recently, computational simulation 
models have been developed to predict the drug release rate and its delivery to the tumour.  
Despite the ongoing research on the development of hydrogels for the treatment of GBM, there is a 
medical demand for more effective therapies to treat this devastating disease. From my perspective, 
hydrogels offer many advantages over other pharmaceutical formulations and these systems can 
address most of the drug delivery challenges, but the extent of their ability to address GBM 
challenges requires more clinical investigation. More knowledge on the long-term stability, safety 
data and performance of injectable hydrogels is required in order to translate these scaffolds from 
the bench to clinical trials for applications in brain tumours.    
ʺImportant thing in science is not so much to obtain new facts as to discover new ways of thinking 
about themʺ. 









                  
Figure 3.44: Amplitude sweep experiments performed on A. L1 and B. H2 crosslinking densities of HA-ADH 
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Figure 3.46: Amplitude sweep experiments performed on A. HB16 and B. HB19 crosslinking densities of HA-
BSA hydrogels. Strain scans were performed within a range from 0.01 to 100 % keeping constant frequency 
at 1 Hz. 




Figure 4.37: A calibration curve was obtained by plotting the semi log relationship between the different 
number of U87MG cells and their corresponding absorbance values. Various numbers of U87MG cells were 
added to the wells of a 96-well plate in fully supplemented DMEM and they were incubated for 1 h at 37 °C. 
Then MTS solution was added and after 1 h of incubation, the absorbance at 490 nm was measured. Each point 
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